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From early neurogenesis to the maintenance of post-mitotic neurons, apoptosis plays a 
pivotal role. Uncontrolled apoptotic events can lead to abnormal neuronal cell loss, which is a 
hallmark of various neurodegenerative diseases including Alzheimer's disease, Parkinson's 
disease or Huntington's disease. As an important protein quality control, the ubiquitin-mediated 
proteasomal degradation is crucially involved in the apoptotic events. E3 ligases are the most 
abundant proteins in the ubiquitin-proteasome system that confer the target specificity and 
catalyze ubiquitination of substrates. Among those, the RING (Really Interesting New Gene)-
type E3 ligases consisting of more than 600 members represent the most numerous components 
in ubiquitination.  
In this study, I show that the brain-dominant protein RNF157, a RING-type E3 ligase, is 
present exclusively in the cytoplasm. In addition, together with our previous finding, my 
functional analyses revealed that RNF157 promotes neuronal survival in hippocampal neurons. 
Further epistasis analyses demonstrated that the newly identified interactor of RNF157, the 
adaptor protein Fe65, operates downstream of RNF157 in regulating neuronal survival. Notably, 
RNF157 ubiquitinates Fe65 via a K63-linked ubiquitin chain and targets Fe65 non-canonically 
for proteasomal degradation, thus inhibiting the pro-apoptotic function of Fe65.  
In addition, I found that nuclear Fe65 is the main contributor in triggering apoptosis in 
hippocampal neurons as compared to cytoplasmic Fe65. Subsequently, I explored if any nuclear 
interactors of Fe65 are involved in the RNF157/Fe65 pathway. While the histone 
acetyltransferase Tip60 does not induce cell death, the novel interactor of Fe65, the RNA-
binding protein Tip110, induces neuronal apoptosis. Epistasis analysis indicates that Tip110 acts 
downstream in the RNF157/Fe65 pathway to regulate neuronal survival.  
Furthermore, I investigated if RNF157 has a role in mouse behavior. Using the RNF157 
knockout mouse model, I found that loss of RNF157 has no impact on the hippocampus-
mediated working and spatial memory. Instead, mice lacking RNF157 exhibit impairments in 
amygdala-mediated fear memory. To sum up, my study discloses a novel RNF157/Fe65/Tip110 
pathway in the control of neuronal survival at the cellular level and the importance of RNF157 in 
cognitive functions. This provides a further insight into the role of E3 ligases in regulating 
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Our brain works wonders so that we can move and perceive the world, experience and 
express our emotions, remember and forget things surrounding us. To achieve this, the 
fascinating network of more than a hundred billion of neurons needs to be precisely controlled. 
From neurogenesis, neuronal differentiation and migration, synaptogenesis to neuronal 
maintenance, even the smallest event requires collaborations of numerous molecules. Any 
mistake can lead to devastating consequences and therefore, we have diverse systems that enable 
quality control at every step. Even after the brain is fully developed, various triggers can 
gradually destroy its homeostasis and lead to unwanted loss of neurons. This in turn results in a 
number of neurodegenerative diseases that can impede our well-being. With this in mind, it is 
essential to investigate the mechanisms underlying cell death. Only then can we understand how 
to retain neuronal viability and prevent those precious cells from being destroyed.  
 
1.1 Cell death during development 
From the embryonic phase throughout the entire life, there is an ongoing controlled loss of 
cells in every organ of our body. The most studied process mediating this event is apoptosis or 
programmed cell death, which is evolutionary conserved from plants to animals. In animals, 
various developmental events are accompanied by apoptosis. One example is the elimination of 
interdigital webs by genes encoding apoptosis activators or pro-apoptotic proteins (Lindsten et 
al., 2000; Yoshida et al., 1998). In mice lacking these genes interdigital webs persist and they 
also develop abnormally enlarged lymphoids (Lindsten et al., 2000). Mutations in apoptosis-
associated genes can furthermore lead to the formation of tumors (Lee and Bernstein, 1995; Yip 
and Reed, 2008). This underscores a fundamental role of the apoptotic machinery in elimination 
of unnecessary or dangerous cells to ensure early organogenesis and to manage homeostasis of 
mature tissues.  
In addition to its role in non-neural organogenesis, apoptosis plays a critical role in the 
establishment and refinement of the nervous system. During early development, a proportion of 
newly born neurons, which were overproduced, undergo apoptosis. The lack of apoptotic signals 




the brain (Kuan et al., 2000). Moreover, the excess of post-mitotic neurons is further reduced by 
the apoptotic process. While deletion of the anti-apoptotic gene Bcl-xL induces massive cell loss 
among post-mitotic neurons, mice lacking its pro-apoptotic inhibitor Bax retain superfluous 
proliferating cells (Motoyama et al., 1995; White et al., 1998). In later stages, once neurons have 
migrated, the access to limited neurotrophic factors is essential for neuronal survival. 
Neurotrophic factors are released from target cells to attract neurons for synaptic contact. If the 
neurons fail to capture survival factors, they will undergo apoptosis (Oppenheim, 1991). Taken 
together, these findings demonstrate the importance of apoptosis throughout neuronal 
development. 
Once the central nervous system is fully formed, mature neurons have very limited capacity 
to proliferate or to regenerate. Hence, abnormal apoptotic events in this system will disrupt 
neuronal networks and lead to severe diseases. In this study, I will first elaborate on the apoptotic 
machinery in neurons and present the key players involved in the regulation of neuronal 
apoptosis as well as their underlying signaling pathways. Further, I will discuss the consequences 
of an imbalance of apoptotic pathways in the nervous system.  
 
1.2 Extrinsic and intrinsic apoptotic pathways 
Various events can trigger apoptosis, including deprivation of neurotrophic factors (Gorin 
and Johnson, 1980), removal of serum or potassium (Atabay et al., 1996; D'Mello et al., 1993), 
as well as DNA damage induced by irradiation or other environmental influence (Roos and 
Kaina, 2013). When a cell undergoes apoptosis, a series of morphological changes can be 
initially observed: cell shrinkage, chromatin condensation (pyknosis), plasma membrane 
blebbing and nuclear fragmentation (karyorrhexis). These are followed by the formation of 
apoptotic bodies containing cell fragments and eventually ingestion and digestion by phagocytes, 
or, in the brain, by microglia (Elmore, 2007; Erwig and Henson, 2008; Witting et al., 2000).  
Two apoptotic pathways manage mainly the incoming apoptotic signals (Fig 1.1). The first 
is the extrinsic pathway, where extracellular ligands bind to and activate their corresponding 
death receptors. Death receptors are normally homotrimers and belong to the superfamily of the 
tumor necrosis factor (TNF) receptors, including CD95 (also known as FAS or Apo1), TNF 
receptor 1 (TNFR1), death receptor 3 (DR3, also called Apo3 or WSL-1), DR4 and DR5 (also 
known as Apo2, TRAIL-R2 or KILLER). Members of this family harbor an extracellular ligand-




to activate the apoptosis-signaling cascade. The ligands that bind to these receptors, belong to the 
TNF superfamily. For example, the CD95 ligand (CD95L) binds to CD95, TNF binds to TNFR1 
and Apo3 ligand (Apo3L) binds to DR3. Upon ligand-binding, the cytosolic death domain of the 
receptor recruits its specific intracellular adaptor protein, such as Fas-associated death domain 
protein (FADD), which in turn connects to the initiators pro-caspase-8 or pro-caspase-10. This 
process forms a death-inducing signaling complex (DISC). If the initiator caspases are not 
present, the binding sites can be occupied by a cellular caspase-8 (FLICE)-like inhibitory protein 
(FLIP), which inhibits the induction of apoptotic signals. Once DISC is formed, it activates 
initiator pro-caspases, which further activate their downstream executioner caspase-3 or caspase-
7 to trigger apoptosis. (Ashkenazi and Dixit, 1998; Portt et al., 2011; Siegel, 2006; Vucic et al., 
2011).  
Apoptosis can also be induced by a signaling cascade inside the cell, namely the intrinsic 
apoptotic pathway. Release of cytochrome c from mitochondria into the cytosol initiates this 
pathway as a response to the cellular stress such as irradiation or growth factor deprivation. 
Cytochrome c binds to the apoptotic protease-activating factor 1 (Apaf1), causing the 
oligomerization of Apaf1 into a wheel-like heptamer called apoptosome. Apaf1 harbors a caspase 
activation and recruitment domain (CARD) that recruits and activates the pro-caspase-9 in the 
apoptosome (Shiozaki et al., 2002; Zou et al., 1997; Zou et al., 1999). The active caspase-9 then 
activates its downstream effector caspases, caspase-3, caspase-6 and caspase-7, to induce 
apoptosis (Li et al., 1997; Slee et al., 1999; Srinivasula et al., 1998; Zou et al., 1999).  
Furthermore, a cross-talk between extrinsic and intrinsic pathways exists. Depending on the 
amount of DISC assembly, extrinsic apoptosis proceeds with two different scenarios. In type I 
cells, sufficient amount of DISC formation leads to direct activation of effector caspases and 
cleavage of the cell, while in type II cells, lower amount of DISC leads to less activated caspase-
8 (Scaffidi et al., 1998). Therefore, the intrinsic pathway is required to amplify the apoptotic 
signals and to execute cell death. Here, caspase-8 first cleaves Bid, a pro-apoptotic protein 
belonging to the Bcl-2 family, resulting in the translocation of the truncated Bid (tBid) from 
cytosol to the mitochondria. This in turn triggers the release of cytochrome c and subsequently 













Fig 1.1 Extrinsic and intrinsic apoptotic pathways 
In the extrinsic pathway, a death receptor (here CD95) binds to its ligand (CD95L) to initiate the formation of the 
death-inducing complex (DISC). This leads to the activation of pro-caspase-8, which directly activates the 
executioner caspase-3 and triggers apoptosis. When the amount of active caspase-8 is not sufficient, the caspase-8 
alternatively cleaves Bid. The truncated Bid (tBid) in turn activates the intrinsic apoptotic pathway. Other intrinsic 
stimuli including DNA damage, cellular stress or deprivation of growth factors can induce the intrinsic 
mitochondria-mediated mechanisms. Upon apoptotic signals, the anti-apoptotic Bcl-2 family proteins are 
inactivated by the pro-apoptotic family members. Meanwhile, Bax or Bak is activated, triggering mitochondrial 
outer membrane permeablization (MOMP) and the resulting release of mitochondrial proteins such as cytochrome c, 
Smac and HtrA2. Cytochrome c then binds to Apaf1, which further recruits caspase-9 to from a complex called 
apoptosome that facilitates the activation of caspase-9. This is followed by the activation of caspase-3, leading to 
apoptosis. FLIP, cellular caspase-8 (FLICE)-like inhibitory protein; FADD, Fas-associated death domain protein; 




1.2.1 The intrinsic apoptotic pathway is regulated by Bcl-2 proteins 
The release of cytochrome c is the consequence of an event called mitochondrial outer 
membrane permeablization (MOMP), which is tightly regulated by the family of Bcl-2 proteins. 
In terms of function, Bcl-2 family members can be divided into either anti-apoptotic or pro-
apoptotic proteins. Besides controlling the exit of cytochrome c from the mitochondria, these 
proteins can bind to each other to counteract each other’s function. In terms of structure, Bcl-2 
proteins possess one or more Bcl-2 Homology domains (BH-1, -2, -3 and -4). Anti-apoptotic 
Bcl-2 members (Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1) as well as some of the pro-apoptotic ones 
(Bax, Bak and Bok) harbor all four BH domains (Kvansakul et al., 2008), whereas the pro-
apoptotic BH3-only members (Bid, Bim, Bad, Puma and etc.) contain a single BH-3 domain 
(Shamas-Din et al., 2011).  
In a healthy cell, Bak is inactive and bound to the outer mitochondrial membrane while Bax 
is predominantly localized to the cytosol. When a cell receives an apoptotic stimulus, the pro-
apoptotic Bax and Bak aggregate at the outer mitochondrial membrane and oligomerize to 
trigger MOMP, thus leading to the efflux of cytochrome c and other pro-apoptotic mitochondrial 
proteins from the mitochondria into the cytosol to regulate downstream apoptotic events (Gross 
et al., 1998; Peixoto et al., 2011; Wei et al., 2001).  
At the same time, the anti-apoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-1, attempt to 
prevent MOMP from taking place. These proteins normally localize to intracellular membrane 
structures such as mitochondria or endoplasmic reticulum (Akao et al., 1994; Hsu et al., 1997; 
Kaufmann et al., 2003; Perciavalle et al., 2012). They are known to prevent the activation of Bax 
or Bak and the resulting MOMP by either sequestering Bax or Bak directly or competing with 
the BH3-only proteins (Billen et al., 2008; Cheng et al., 2001; Willis et al., 2005). In addition, 
Bcl-xL is reported to be involved in the re-translocation of Bax from mitochondria to cytosol 
(Edlich et al., 2011).  
On the other hand, the pro-apoptotic BH3-only members can counteract the anti-apoptotic 
signals. Unlike the activators Bid, Bim or Puma, which directly activate Bax-Bak to trigger the 
release of cytochrome c (Chipuk and Green, 2005; Desagher et al., 1999; Kim et al., 2006; Wei 
et al., 2000), the sensitizer Bad, Bik, Bmf, Hrk or Noxa, sequester the anti-apoptotic Bcl-2 
proteins from Bax, Bak or other activators to recover the apoptotic potential (Certo et al., 2006; 





1.2.2 Other apoptotic mediators  
After induction of MOMP by the Bcl-2 family, other molecules, apart from cytochrome c, 
are released from mitochondria to promote or inhibit apoptosis in a caspase-dependent or -
independent manner. For instance, the second mitochondrial activator of caspases (Smac, also 
known as Diablo) is a pro-apoptotic protein, which inhibits the activity of the inhibitors of 
apoptosis (IAP) family. This inhibition leads to the efflux of cytochrome c and activation of 
effector caspases (Du et al., 2000; Verhagen et al., 2000). A similar pro-apoptotic molecule is 
HtrA2 (also called Omi). During apoptosis, mature HtrA2 translocates into cytosol and binds to 
IAP, thereby eliminating this caspase-inhibition leading to cell death. Besides its caspase-
dependent modulation, HtrA2 also harbors serine protease activity which induces atypical cell 
death. This form of HtrA2-induced apoptosis can not be rescued by inhibition of caspases, 
indicating its role in caspase-independent apoptotic regulation (Hegde et al., 2002; Suzuki et al., 
2001a; Verhagen et al., 2002).  
Additional mitochondrial proteins are involved in caspase-independent apoptotic pathway: 
the apoptosis-inducing factor (AIF) translocates to the nucleus during apoptosis, inducing DNA 
fragmentation and resulting in cell death without caspase-activation (Cregan et al., 2002; Joza et 
al., 2001; Susin et al., 1999). Another similar mitochondria-localized molecule, the endonuclease 
G (EndoG), also moves to the nucleus upon apoptotic signals and triggers caspase-independent 
DNA degradation (Li et al., 2001; van Loo et al., 2001). In addition, DNA fragmentation can also 
be mediated by caspases. The non-mitochondrial protein, caspase-activated DNase (CAD), is 
activated during apoptosis after its inhibitor ICAD is cleaved by caspase-3. The cleavage of 
ICAD appears to happen in the nucleus upon apoptotic stimuli, leading to the release of active 
CAD from ICAD. The active CAD then induces DNA fragmentation and chromatin 
condensation (Durrieu et al., 2000; Enari et al., 1998; Liu et al., 1998; Sakahira et al., 1998). 
In addition to these pro-apoptotic mediators, there are further anti-apoptotic regulators, such 
as ICAD and IAPs. So far, eight IAP members have been identified in humans (Salvesen and 
Duckett, 2002). IAPs such as XIAP, c-IAP-1 or c-IAP2 promote cell survival by directly binding 
to the caspases 3, 6 or 7, preventing improper caspase activation and thereby inhibiting apoptosis 
(Deveraux et al., 1999; Roy et al., 1997). 
Other than the abovementioned core regulators in the apoptotic machinery, there are 
numerous molecules that can affect cell viability. For instance, the neuronal survival pathway 




by neurotrophic factors. This in turn activates the pro-survival transcription factor NFκB and 
results in transcription of survival genes including BcL-xL and IAPs (Brunet et al., 2001). On the 
other hand, DNA damage can activate the pro-apoptotic gene p53. Activated p53 triggers the 
transcription of pro-apoptotic genes such as Fas, Bax or Noxa that induces neuronal apoptosis 
(Nakamura, 2004; Riley et al., 2008).  
Besides the transcriptional regulation of apoptotic genes, cell fate is also controlled by 
various post-transcriptional modifications such as phosphorylation, acetylation, or ubiquitination. 
Prior to activating its effectors, Akt requires the phosphorylation by PI3K (Hemmings and 
Restuccia, 2012). Phosphorylated Akt can then further phosphorylate its downstream effectors 
including the pro-apoptotic protein Bad, thereby inhibiting Bad-induced cell death (Datta et al., 
1997). On the contrary, c-Jun N-terminal kinase (JNK) phosphorylates a pro-apoptotic BH-3 
member, Bim, upon trophic factor deprivation. This further activates Bax-dependent apoptosis 
(Putcha et al., 2003). In addition to phosphorylation, the acetylation of p53 by Tip60 is essential 
for triggering the transcription of Puma, which in turn leads to apoptosis (Tang et al., 2006). 
Lastly, ubiquitination of various apoptotic regulators can control their stability and activity 
(Vucic et al., 2011). For example, the anti-apoptotic Mcl-1 can be ubiquitinated by Mule, leading 
to the elimination of its pro-survival function and thus inducing apoptosis (Zhong et al., 2005). 
On the other hand, the ubiquitination of caspase-8 by HECTD3 decreases the caspase-8 
activation, leading to cell survival (Li et al., 2013). These findings underline the importance of 













1.3 Ubiquitination in neuronal apoptosis 
Ubiquitination is involved in various apoptotic events in different cell types. Among those, 
neuronal apoptosis, due to disturbed ubiquitination, has drawn increasing attention in the last 
decades (Ciechanover and Brundin, 2003; Vucic et al., 2011). In the following paragraph, I will 
address the mechanism of ubiquitination and its implication in regulating apoptosis. 
 
1.3.1 Ubiquitination cascade 
Ubiquitination is characterized by the process where a 76-amino-acid protein, ubiquitin, is 
attached to the substrate. An enzymatic cascade requires an E1 ubiquitin-activating enzyme, an 
E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase to catalyze the covalent attachment 
of ubiquitin onto substrates (Fig 1.2). First of all, the E1 enzyme activates ubiquitin in an ATP-
dependent manner, leading to the formation of a thioester bond between ubiquitin and its active 
cysteine residue. The activated ubiquitin is then transferred to an active cysteine residue of an E2 
enzyme. The E2-ubiquitin conjugate is further recognized by an E3 ligase that binds target 
substrates. There are mainly two types of E3 ligases: the HECT-type and the RING-type E3 
ligases. The HECT-type E3 ligases harbor a homologous to E6AP carboxyl terminus (HECT) 
domain containing a catalytic cysteine that recruits the ubiquitin directly from an E2 and forms 
an E3-ubiquitin thioester intermediate, followed by the transfer of the ubiquitin from the active 
cysteine to one or more lysine residues of the substrate associated with the E3. On the other hand, 
members of the really interesting new gene (RING) E3 family act as scaffolds to bring the E2 
and substrates in close proximity and thus mediate the transfer of ubiquitin from E2 to the 
substrates (Berndsen and Wolberger, 2014; Rotin and Kumar, 2009). While E1, E2 and E3 
enzymes catalyze the ubiquitination, deubiquitinating enzymes (DUBs) can remove the ubiquitin 
from the substrate. The cellular signaling mediated by ubiquitination is therefore dependent on 
the interplay between ubiquitinating versus deubiquitinating enzymes (Reyes-Turcu et al., 2009).   
Once a target substrate is ubiquitinated, the type of ubiquitin chains decides its fate. A 
substrate can be monoubiquitinated, multi-monoubiquitinated or polyubiquitinated. These events 
can take place at the lysine residues (Lys) of ubiquitin, including Lys6, Lys11, Lys27, Lys29, 
Lys33, Lys48 and Lys63. The structure of these chains then determines the physiological 
consequences of target substrates (Fig 1.2b, c). The best-known example is the polyubiquitin 
chain linked via Lys48 that targets substrate proteins for proteasomal degradation. The Lys11-




chains formed via Lys63 regulate NFκB activation, DNA repair as well as lysosomal degradation. 
The monoubiquitination or the multi-monoubiquitination also have an important role in 
mediating protein interaction, localization and substrate activity. Besides these established 
functions of the aforementioned ubiquitin chains, the role of Lys6, Lys27, Lys29 or Lys33-
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Fig 1.2 Overview of ubiquitination cascade 
a) Ubiquitination of target substrates starts with ATP-dependent activation of ubiquitin by an E1 ubiquitin-
activating enzyme, leading to the formation of a thioester bond between the E1 and ubiquitin. The activated 
ubiquitin is then transferred to the active cysteine residue of an E2 ubiquitin-conjugating enzyme. An E3 ubiquitin 
then facilitates the transfer of ubiquitin onto one or more lysine residues of the substrate protein. One type of E3 
ligases harbors a HECT domain (light blue), which recruits ubiquitin from an E2 onto its active cysteine and then 
transfers the ubiquitin to a lysine of a substrate protein. Another type of E3 ligases possesses a RING domain 
(green), which recognizes the E2. By bringing the E2-ubiquitin thioester intermediate close to the substrate, a 
RING E3 facilitates the transfer of ubiquitin from the E2 to the substrate. Modified from Berndsen and Wolberger, 
2014.   
b) Polyubiquitination via Lys48 or Lys11 targets the substrate to the 26S proteasome for degradation, while Lys63 
linked polyubiquitination regulates NF-κB activation, DNA repair and lysosomal degradation. Modified from Ye 
and Rape, 2009.   
c) Monoubiquitination or multi-monoubiquitination leads to functional modification of substrates, affecting protein 





1.3.2 E3 ubiquitin ligases 
In the ubiquitination system, the substrate specificity is conferred by E3 ligases. This 
explains why the E3 ligases outnumber the E1 and E2 enzymes. While the human genome 
encodes two E1 and approx. 30 E2, over 600 E3 enzymes are predicted in a genome-wide 
analysis (Li et al., 2008b). Among those E3 ligases, approx. 30 are HECT-type while the others 
are RING-type E3 ligases. HECT-type E3 ligases are characterized by the conserved HECT 
domain at C-terminus with diverse N-terminal domain structures. These other domains determine 
substrate targeting (Rotin and Kumar, 2009). In mammals, HECT E3 ligases have been shown to 
be involved in cell signaling to control various cellular events such as cell growth, proliferation, 
protein trafficking or DNA damage response. Several HECT E3 ligases also impact on neuronal 
development as well neuronal survival. For example, Nedd4-1 can mono- or diubiquitinate a 
small GTPase, Rap2A, to inhibit its activity, and thus promote the function of its effectors 
leading to dendritic growth (Kawabe et al., 2010). In addition, while Smurf1 downregulates a 
small GTPase, RhoA, to induce axon extension, Smurf2 degrades Rap1B and thus enhances 
neuronal polarization (Bryan et al., 2005; Schwamborn et al., 2007; Wang et al., 2003). Another 
HECT E3, E6AP, promotes cell survival in a neuronal cell line and can ubiquitinate p53 for 
degradation, suggesting that E6AP could protect cells from p53-linked apoptosis (Culmsee and 
Mattson, 2005; Mishra and Jana, 2008).  
With more than 600 members, RING-type E3 ligases represent the largest group of E3 
ligases. Unlike HECT-type E3 ligases forming a thioester intermediate with ubiquitin, RING-
type E3 ligases mediate ubiquitin transfer between the E2 and the substrate. RING-type E3 
ligases consist of a RING finger and often other functional domains. The canonical RING 
domain is characterized by a defined spacing of cysteine residues and a histidine (Cys-X2-Xys-
X9-39-Cys-X1-3-His-X2-3-Cys-X2-Cys-X4-48-Cys-X2-Cys, X can be occupied by any amino acids), 
resulting in a “cross-brace” arrangement stabilized by the binding of two zinc ions to the cysteine 
and histidine residues (Fig 1.3a). In addition, several RING finger variants have been identified; 
either cysteines or histidines change positions, or one of them is exchanged with other zinc 
coordinating residues, such as aspartic acid.  Not all of the variants possess E3 ligase activity. 
For instance, LIM and PHD domains share similar organization of cysteins and histidines, but 
they are not implicated in ubiquitination due to their different folding structures. On the other 
hand, a derivative of the RING finger, U-Box, is structurally similar to the RING finger and can 
mediate ubiquitination although the metal-chelating residues of its RING finger are lacking 






     
b 
         
c 
       
d 
    
 
 
Fig 1.3 The RING E3 ligase and its RING finger motif. 
a) The RING finger domain is organized by cysteine and histidine 
residues with two zinc ions stabilizing its structure. C1 refers to the 
first cysteine coordinates with zinc and so on. H1 is the position where 
histidine is localized. Modified from Deshaies and Joazeiro, 2009.   
b-d) RING E3 ligases can act as a monomer (b), dimer (c) or as a 
multi-subunit complex (d). RING finger domains in RING E3 ligases 
can interact with E2 and bring E2 closer to the substrate. When RING 
E3 executes its function in the form of a dimer, only one of the RING 
domains recruits E2.  The binding of the other RING E3 is to enhance  
or initiate the E3 ligase activity. The multi-subunit is composed of a scaffold protein, a small RING finger protein, 
an adaptor protein as well as a F-box subunit for substrate targeting. There are two main groups of RING multi-
subunit complexes: the SCF and the APC/C E3. In (d), the arrangement of an SCF complex is depicted. Here, 
Cullin-1 serves as the adaptor protein and RBX1 is the RING-containing protein, which binds to E2. An adaptor 
protein is Skp1, which interacts with an F-box protein conferring the substrate specificity. Modified from 
Lipkowitz and Weissman, 2011. 
 
While HECT-type E3 ligases form monomers only, RING-type E3 ligases can act as 
monomers, dimers or as a multi-subunit complex (Fig 1.3b, c, d, respectively). The dimerization 
is achieved by binding of two identical RING-type E3 ligases at the RING domains or between a 
RING E3 and its interactor. Mostly, only one of the RING domains of these dimers acts as the 
functional recruiter of an E2. The homodimerization of the RNF4 E3 ligase via the RING 
domain is essential for its activity (Liew et al., 2010). The most complex RING-type E3 ligases 
are multi-subunit E3 ligases. A multimeric E3 ligase consists of a small RING finger protein, a 
scaffold protein, several adaptor proteins and a substrate recognition subunit. Among these 
complexes, the Skp1, Cullin, F-box containing complex (SCF complex) and the anaphase-




consists of a RING domain containing protein Rbx1, the scaffold protein Cullin-1, the adaptor 
protein Skp1 and diverse F-box domain proteins, which confer the substrate specificity. The 
APC/C E3 ligase is more complex and formed by the RING finger protein APC11, the cullin-
related scaffold protein APC2, and a co-activator Cdc20 or Cdh1 as well as at least 11 other 
subunits. The function of co-activators of the APC/C complex resembles the F-box proteins of 
the SCF complex, namely to control substrate recognition. In addition, other post-transcriptional 
modifications, such as phosphorylation or sumoylation, further regulate substrate targeting as 
well as the activity of RING-type E3 ligases (Deshaies and Joazeiro, 2009; Lipkowitz and 
Weissman, 2011; Nakayama and Nakayama, 2006). Due to their abundance, RING E3 ligases are 
involved in almost every physiological event, from regulating cell cycle and maintaining 
genomic integrity to signaling transduction. Therefore, imbalance of ubiquitination causes 
various diseases. In neurons, RING-type E3 ligases have also shown their capacity in modulating 
neuronal migration, neurite outgrowth as well as the neuron viability (Kawabe and Brose, 2011; 
Weissman et al., 2011). Collectively, E3 ligases are essential to achieve proper cell development 
and integrity. 
 
1.3.3 RING-type E3 ligases in apoptosis and neurodegerative diseases 
RING-type E3 ligases are directly involved in major apoptotic pathways. Several members 
of the anti-apoptotic IAP family as mentioned in chapter 1.1.2 harbor a RING domain in addition 
to the BIR domains. Take XIAP for example, while the binding of caspase-3 and -7 to BIR1-2 
domains of XIAP can already inhibit the activation of caspases, the ubiquitination of mature 
caspase-9, active caspase-3 as well as Smac mediated by XIAP targets these substrates for 
degradation and therefore inhibits apoptosis (Deveraux et al., 1999; Morizane et al., 2005; 
Suzuki et al., 2001b). Other IAPs, such as c-IAP1 and c-IAP2, are also reported to mediate the 
ubiquitination of Smac, whose subsequent degradation leads to cell survival (Hu and Yang, 
2003).  
Furthermore, upon apoptotic stimuli, IAPs display autoubiquitination activity. Truncated c-
IAP1, harboring a mutation in the RING domain, is more resistant to autoubiquitination as 
compared to wild type c-IAP1. The XIAP without RING domain is also less ubiquitinated and 
thus acts in a protective manner in cells. Since autoubiquitination probably also lowers the 
cellular apoptotic threshold during apoptosis (Yang et al., 2000), IAPs play an important role in 




In addition to the direct role of IAPs in apoptosis, numerous RING E3 ligases mediate 
neuronal viability by providing a suitable cellular environment for the survival of post-mitotic 
neurons. For example, besides its role in mitosis, the cell cycle regulator Cdh1-APC ligase has 
been shown to protect post-mitotic neurons from cell cycle re-entry by degrading cyclin B1 and 
thus inhibiting apoptosis (Almeida et al., 2005; Kruman et al., 2004). Another multi-subunit 
RING E3, the Fbw7-SCF ubiquitinates phosphorylated c-Jun and targets it for degradation, 
which results in the disruption of the JNK-mediated neuronal apoptosis (Nateri et al., 2004). 
Furthermore, an SCF-like E3 complex composed of Cullin-1, the RING-containing protein 
parkin, as well as an F-box/WD repeat protein hSel-10 targets cyclin E for ubiquitination-
mediated degradation (Staropoli et al., 2003). Deletion of parkin results in accumulation of 
cyclin E in post-mitotic cultured neurons. Treatment of parkin deficient cultured neurons with 
the excitotoxin kainate leads to accumulation of cyclin E followed by apoptosis. In contrast, 
overexpression of parkin protects neurons from cell death (Staropoli et al., 2003). This suggests a 
role of parkin in maintaining neuronal survival.  
Aside from multi-subunit E3 ligases, various single-subunit E3 ligases are also involved in 
regulating neuronal apoptosis. For instance, Phr1 ubiquitinates dual leucine zipper-bearing 
kinase (DLK) for degradation and promotes cell survival (Huntwork-Rodriguez et al., 2013). 
This survival phenotype can be, however, altered by JNK-mediated phosphorylation of DLK. 
The phosphorylation of DLK prevents it from being ubiquitinated and degraded, which then 
inhibits neuronal viability (Huntwork-Rodriguez et al., 2013). Furthermore, Mdm2 is known to 
ubiquitinate pro-apoptotic protein p53, which by itself induces apoptosis in neurons. The 
ubiquitination of p53 via Mdm2 probably leads to the export of p53 from the nucleus to the 
cytoplasm, where it is degraded by the proteasome and prevents cell death (Fang et al., 2000; 
Haupt et al., 1997; Jesenberger and Jentsch, 2002; Jordan et al., 1997; Tao and Levine, 1999).  
There are also E3 ligases that can directly mediate the intrinsic apoptotic pathway, such as 
the Trim17 E3 ligase, which belongs to the TRIM/RBCC protein family (Reymond et al., 2001). 
It acts upstream of mitochondria to enhance neuronal apoptosis (Lassot et al., 2010). While 
overexpression of Trim17 triggers Bax-dependent apoptosis, knockdown of Trim17 inhibits cell 
death in cultured neurons. Moreover, deletion of its RING domain abolishes its apoptotic 
phenotype, indicating that the ligase activity is essential to trigger cell death (Lassot et al., 2010). 
A subsequent study demonstrates that the Trim17 ubiquitinates an anti-apoptotic Bcl-2 member, 
Mcl-2, for degradation (Magiera et al., 2013). Taken together, the E3 ligase Trim17 promotes the 




1.3.4 RING E3 ligases in neurodevelopment and neurodegenerative diseases 
One of the major functions of ubiquitination is to target the substrate for degradation. 
Ubiquitination-mediated proteasomal protein turnover serves as protein quality control, which 
protects the cell from misfolded proteins or toxic aggregates. Disrupted ubiquitination in neurons 
can thus lead to abnormal accumulation of these toxic protein species, which are hallmarks of 
various neurological disorders.  
For instance, giant axonal neuropathy (GAN), an early-onset recessive neurological disease, 
is attributed to mutations in the GAN gene (Kuhlenbaumer et al., 2002). GAN encodes gigaxonin, 
which is a potential adaptor protein of a multi-subunit E3 ligase together with cullin-3 
(Furukawa et al., 2003). Recently, a study has shown that loss of GAN potentiates irregular 
aggregates of vimentin intermediate filaments (VIF) in GAN-/- mouse embryonic fibroblasts as 
well as in the cells from patients carrying GAN mutations. Other intermediate filaments (IF) 
such as neurofilament proteins have also been found to accumulate in patients (Mahammad et al., 
2013). These aggregates in the nervous system are believed to induce progressive muscle 
weakness, disrupted tendon reflexes and disabled walking. As the disease develops further, the 
central nervous system is affected and patients suffer from dementia, seizures and require life 
support including artificial nutrition and mechanical ventilation until they die prematurely at 
around 30 years of age. Although it is clear that a dysfunctional gigaxonin-containing E3 ligase 
leads to GAN by inducing abnormal aggregation of IFs (Mahammad et al., 2013), it is not known 
which apoptotic pathway is involved. 
Another example is Alzheimer’s disease (AD), which is the most common 
neurodegenerative disease, representing 50-70% of all dementia cases. It is characterized by age-
dependent decline of memory and progressive deterioration of cognitive functions.  
Histopathological analyses of AD brains reveal brain atrophy in various cognition-related areas, 
which is a consequence of extensive loss of neuronal cells as well as synaptic connections. The 
hallmarks of AD brains are β-Amyloid plaques and neurofibrillary tangles (NFTs). Emerging 
evidence shows the presence of ubiquitin in the plaques as well as NFTs, indicating a potential 
role of ubiquitination during the development of AD (Atkin and Paulson, 2014; Götz and Ittner, 
2008).  
β-Amyloid plaques are mainly composed of Aβ, a peptide derived from amyloid precursor 
protein (APP). The cleavage of APP through β-secretase and the subsequent γ-secretase leads to 




neuroprotective, Aβ42, the major component of plaques, is more neurotoxic (Götz and Ittner, 
2008; Gregory and Halliday, 2005). Both of Aβ species can induce apoptosis. While 
microinjection of Aβ40 into mouse cortex leads to caspase-3-mediated cell loss (Takuma et al., 
2004), intrahippocampal Aβ42 injection in mice also induces caspase-3-associated neuronal loss 
and related memory deficits (Brouillette et al., 2012), suggesting a link between Aβ and caspase-
dependent cell death. The production of Aβ can be modified by E3 ligases, such as HRD1, a 
ligase for endoplasmic reticulum-associated degradation (ERAD). It is one of several E3 ligases 
that are involved in different stages of APP processing as well as Aβ formation. A reduced level 
of HRD1 is found in the cortices of AD patients. Overexpression of HRD1 promotes the 
ubiquitination and degradation of APP, which in turn reduces Aβ production. Accordingly, 
suppression of HRD1 potentiates APP accumulation as well as Aβ formation, indicating its role 
in processing of APP (Kaneko et al., 2010). Additionally, a ubiquitin ligase adaptor protein 
Fbxo2 also has a potential role in regulating APP through ERAD (Atkin et al., 2014). 
Overexpression of Fbxo2 in a heterologous cells system reduces the APP level, while mice 
lacking Fbxo2 show an age-dependent upregulation of APP in the brain, indicating that Fbxo2 
could be involved in the ubiquitination of APP, which results in APP degradation (Atkin et al., 
2014). 
The other pathological hallmark of AD, the NFTs, consists of hyperphosphorylated tau. Tau 
is a microtubule-associated protein, which could regulate cytoskeleton by the binding with actin 
or tubulin. It is a phosphoprotein with 84 putative phosphorylation sites. Under normal condition, 
phosphorylated tau is believed to stabilize microtubules, while in the pathological condition, the 
hyperphosphorylation of tau detaches from microtubule, thereby facilitating the formation of 
NFTs (Götz and Ittner, 2008; Morris et al., 2011). Upon caspase-3 activation, tau can be cleaved 
by active caspase-3. Cleaved tau in turn induces cell death. Although the downstream cascade is 
not yet elucidated, these studies indicate the toxicity of truncated tau (Chung et al., 2001; Idan-
Feldman et al., 2012). An U-box containing E3 ligase, CHIP, forms a complex with Hsp70, 
resulting in ubiquitination of phosphorylated tau. In addition, overexpression of CHIP can rescue 
tau-induced cell death, indicating the CHIP/Hsp70 complex can ubiquitinate tau to attenuate the 
cellular toxicity (Shimura et al., 2004).  
The second most common neurodegenerative disease is Parkinson’s disease (PD), 
characterized by impaired motor functions including tremor, bradykinesia, rigidity, and postural 
instability. Patients can also suffer from mood disorder, sleep abnormalities or cognitive decline. 




the substantia nigra. The cause for the cell loss is yet unclear, but various studies indicate a role 
of α-synuclein in regulating neuronal apoptosis in PD (Yasuda et al., 2013). PD patients also 
show intraneuronal aggregation so-called Lewy bodies, which are mainly composed of 
misfolded α-synuclein. Additionally, mutations in the SCNA gene are involved in familial PD 
(Andalib et al., 2014; Yasuda et al., 2013). Due to the importance of α-synuclein, numerous 
RING-type E3 ligases that modulate α-synuclein are identified. For example, Siah-1 mediates α-
synuclein ubiquitination, which promotes the aggregation of α-synuclein as well as cell 
apoptosis (Lee et al., 2008a).  Furthermore, besides its role in AD, the U-box E3 ligase CHIP is 
also found in Lewy bodies of PD patients. Overexpression of CHIP can reduce α-synuclein 
accumulation and enhance α-synuclein degradation through either proteasomal or lysosomal 
protein turnover routes, thus protecting cells from α-synuclein triggered cell death (Shin et al., 
2005).  
Moreover, a dysfunction of the E3 ligase parkin is identified in various cases of autosomal 
recessive PD (Kitada et al., 1998). Parkin can ubiquitinate the pro-apoptotic Bax (Johnson et al., 
2012). Instead of degradation, ubiquitination of Bax prevents its stress-induced translocation to 
mitochondria, thus inhibiting the downstream apoptotic pathway. The disease-related mutation of 
parkin renders it unable to keep Bax away from mitochondria, leading to enhanced apoptosis 
(Johnson et al., 2012).   
In addition to aforementioned diseases, RING-type E3 ligases are further involved in the 
amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) as well as spongiform 
degenerative diseases (Dantuma and Bott, 2014). Patients with familial ALS carry various 
mutations in the SOD1 gene. Notably, transgenic mice with mutant SOD1 exhibit similar 
ubiquitin-positive cytoplasmic protein inclusions as shown in patients, although these aggregates 
are not necessarily SOD1-positive (Watanabe et al., 2001). Mutant SOD1 contributes to caspase-
1 and -3-mediated motor neuron apoptosis (Pasinelli et al., 2000). Furthermore, mutant SOD1 
associates stronger with anti-apoptotic Bcl-2 as compared to wild type SOD1, and thus leads to 
potential inhibition of Bcl-2 function (Pasinelli et al., 2004). SOD1-induced apoptosis can be 
rescued by Hsp70, which forms a complex with the E3 ligase CHIP. CHIP does not ubiquitinate 
mutant SOD1 directly, although only mutant SOD1 interacts with the CHIP/Hsp70 complex. 
Instead, CHIP mediates ubiquitination of Hsp70. Ubiquitinated Hsp70 then recruits mutant 
SOD1 and probably translocates together with SOD1 to the proteasome for degradation 




In HD, intranuclear aggregates in neurons as well as dystrophic neuritis are found in patients. 
Both of the abnormal features are ubiquitin-positive and truncated huntingtin (Htt)-positive, 
indicating a possible role of the ubiquitin proteasome system in the progress of HD (Becher et al., 
1998; DiFiglia et al., 1997).  While mutant Htt in the nucleus triggers apoptosis, wild type Htt 
acts downstream of Bcl-2 and upstream of caspase-3 to protect neurons from cell death 
(Rigamonti et al., 2000; Saudou et al., 1998). An E3 ligase, TRAF6, binds to mutant Htt, which 
induces atypical ubiquitination of mutant Htt via Lys6, Lys27 and Lys29-linked chains (Zucchelli 
et al., 2011). The functional outcome of this ubiquitination, however remains unclear. 
Last but not least, recent studies implicate ubiquitin in the spongiform neurodegenerative 
diseases (Whatley et al., 2008). The hallmark of spongiform degeneration is widespread neuronal 
or glial cell loss characterized by numerous vacuoles in the central nervous system. Creutzfeldt-
Jakob disease is the best-known one in human and corresponds to scrapie in sheep and bovine 
spongiform encephalopathy in cow, which are all characterized by progressive motor 
disturbances and cognitive dysfunctions. The cause of this disease is considered to be the 
conformational change of a wild type cellular prion protein (Prpc) into a pathological isoform, in 
scrapie called PrpSc. The affected brain tissue reveals ubiquitin-positive staining in and around 
the spongiform structure as well as surrounding the prion plaques. Moreover, various studies also 
report dysfunction of the proteasome and the resulting alterations in ubiquitination in prion 
diseases (Whatley et al., 2008). However, the E3 ligases involved in disease progression are not 
yet identified.  
In addition to prion proteins, spongiform neurodegeneration can be directly triggered by loss 
of an E3 ligase. Mice carrying a point mutation in the RING E3 ligase mahogunin 1 (Mgrn1) 
gene, which disrupts the transcription of Mgrn1, exhibit progressive widespread spongiform 
neurodegeneration in the central nervous system (He et al., 2003). The pathological mechanism 
underlying Mgrn1-deletion is different from the progress of prion diseases but rather a 
consequence of mitochondrial dysfunction (Silvius et al., 2013). Moreover, Mgrn1 
monoubiquitinates TSG101 to regulate the TSG101-mediated endo-lysosomal trafficking of 
ubiquitinated cargos, although a direct link to neuronal death is still missing (Jiao et al., 2009). 
Recently, Mgrn1 was reported to be upregulated with Hsp70 in misfolded inclusion bodies upon 
cellular stress (Chhangani and Mishra, 2013). Overexpression of Mgrn1 restores viability of 
stressed cells and can enhance degradation of misfolded proteins, while knockdown of Mgrn1 
facilitates the release of cytochrome c followed by apoptosis in cells exposed to stress. 




Mishra, 2013). Although it remains unclear if Hsp70 is a substrate of Mgrn1, this study further 
supports the notion that Mgrn1 is necessary for cellular homeostasis (Chhangani and Mishra, 
2013).  
Interestingly, a homologue of Mgrn1, RNF157 (Mgrn2) was introduced in Jiao’s study. 
Mgrn1 and RNF157 share 69% homology in sequence with a highly comparable N-terminus 
containing the RING domain (Jiao et al., 2009). While Mgrn1 is expressed throughout the body 
from brain to periphery tissues including heart, kidney, liver, lung and spleen, RNF157 appears 
to be predominantly present in the brain (Expression Atlas, EMBL-EBI). Therefore, we 
hypothesized that RNF157 could have a similar role as Mgrn1 in mammals. Since the function of 
RNF157 was elusive, we set out to investigate its role in the central nervous system. 
 
1.3.5 RING E3 ligase RNF157 in neuronal apoptosis 
In the pioneering study, A. Matz has demonstrated a brain-dominant protein expression of 
RNF157, which is consistent with the finding that RNF157 mRNA is robustly expressed in the 
brain, while only to a smaller extent in lung, heart and kidney (Matz et al., in press). In addition, 
RNF157 protein is stably expressed in cultured cerebellar granule neurons as well as in cortical 
neurons. Using whole tissue lysate, she also confirmed that throughout brain development from 
embryonic day (E) 18 to postnatal (P) 60, protein expression of RNF157 is downregulated in the 
cortex, upregulated in cerebellum and unchanged in hippocampus. Intriguingly, RNF157 was 
found to promote cell survival in primary cerebellar granule neurons. While knockdown of 
RNF157 triggers neuronal apoptosis, overexpression of RNF157 protects neurons from cell 
death induced by serum deprivation (Matz et al., in press). Moreover, the mutant RNF157 
lacking the catalytic RING domain fails to rescue neurons from death, suggesting that RNF157 
promotes neuronal survival in a ligase-activity-dependent manner (Matz et al., in press). 
 
1.3.5.1 Fe65, an adaptor protein, interacts with RNF157 
The story took an interesting turn when an interaction partner of RNF157, Fe65, was 
identified in our previous yeast two-hybrid screening (Matz et al., in press). Fe65 is a member of 
the Fe65s family including Fe65L1 and Fe65L2. While Fe65L1 and Fe65L2 are widely 
expressed, Fe65 reveals a brain-enriched expression pattern (Guenette et al., 1996a; Sabo et al., 




domain and two phospho-tyrosine binding (PTB) domains (Fig 1.4a). The mapping analyses 
demonstrated that Fe65 associates with N-terminal region of RNF157 excluding the RING 
domain, and RNF157 binds to the c-terminal PTB2 domain of Fe65 (Fig 1.4b) (Matz et al., in 
press). Fe65s act as adaptor or scaffold proteins to form protein complexes. Depending on the 
binding partners of Fe65s, they are involved in various cellular events such as APP trafficking 
and processing, cell motility, synaptic transmission and nuclear signaling (Borquez and 
Gonzalez-Billault, 2012; Matz et al., in press; McLoughlin and Miller, 2008) 
 
a 
                 
b 
                   
 
Fig 1.4 Fe65s and its interaction with RNF157. 
a) Domain structure of human Fe65s. Modified from McLoughlin and Miller, 2008.  
b) Fe65 binds to the N-terminus of RNF157 exclusive of the RING domain, and RNF157 associates with the 
PTB2 domain of Fe65. 
 
1.3.5.1.1 Fe65 in APP processing 
Fe65s drew a lot of attention owing to the interaction with APP, which implicates a role in 
Alzheimer’s disease. All Fe65 members of the family can bind to APP (Kimberly et al., 2001; 
McLoughlin and Miller, 1996; Tanahashi and Tabira, 1999). The interaction between the PTB2 
domain of Fe65 and the YENPTY motif in the intracellular domain of APP (AICD) is of 
particular interest. This binding stabilizes AICD and colocalizes Fe65 and AICD in the nucleus 
(Kimberly et al., 2001). Furthermore, mutations in the YENPTY motif in APP block its 
endocytic trafficking and decreases Aβ formation (Perez et al., 1999). Therefore, it is possible 




production. Furthermore, while APP binds to the PTB2 domain of Fe65, the low-density 
lipoprotein receptor-related protein (LRP) can bind to Fe65’s PTB1 domain (Trommsdorff et al., 
1998).  This leads to the formation of a trimeric complex consisting of Fe65, APP and LRP, 
which is also involved in regulating APP processing (Pietrzik et al., 2004). Overexpression of 
LRP enhances Fe65-mediated APP processing (Pietrzik et al., 2004), whereas Dab1, another 
adaptor protein with a PTB domain, can bind to LRP to counteract the impact of Fe65 or LRP on 
APP cleavage (Kwon et al., 2010). In addition, Dab1 competes with Fe65 for the binding to APP, 
resulting in the release of Fe65 from APP and thus facilitating the nuclear translocation of Fe65 
as well as suppressing the Fe65-mediated APP processing (Kwon et al., 2010). Besides the 
binding to LRP, Fe65 can also bind to the apoE receptor ApoEr2 and may in turn form a complex 
with APP to modulate APP processing (Hoe et al., 2006). While ApoEr2 or Fe65 by itself can 
enhance APP processing, the Fe65/ApoEr2 complex further increases the amount of membrane-
bound c-terminal APP fragment (Hoe et al., 2006; Hoe et al., 2005). These findings support the 
notion that Fe65, together with its interacting proteins, is essential for the cleavage of APP.  
 
1.3.5.1.2 Fe65 acts at cytoskeleton and synapse 
Moreover, Fe65 binds to tau via its PTB1 domain. This complex colocalizes with APP in 
primary neurons, implicating a role of Fe65 in the regulation of the cytoskeleton (Barbato et al., 
2005). In addition, Mena, an Abl-associated signaling protein involved in regulating actin 
dynamics, interacts with Fe65 through its WW domain (Ermekova et al., 1997). It associates 
with APP and Fe65 simultaneously and colocalizes with actin, Fe65 and APP in lamellipodia 
(Sabo et al., 2001). Since overexpression of APP and Fe65 accelerates cell migration (Sabo et al., 
2001), it is speculated that the APP/Fe65/Mena complex acts at the cytoskeleton to regulate 
movement. Furthermore, Fe65 is present at synapses and binds to P2X2 subunits (Masin et al., 
2006). P2X2 is a ligand-gated ion channel activated by extracellular ATP and is involved in 
synaptic transmission. Overexpression of Fe65 hinders the permeability change of P2X2 
receptors (Masin et al., 2006), suggesting a role of Fe65 in synaptic transmission.  
 
1.3.5.1.3 Fe65 in gene transcription and nuclear signaling 
In addition to the aforementioned functions, nuclear Fe65 acts with various proteins in the 




factor (LSF) via its PTB1 domain, Fe65 blocks LSF-mediated transactivation of the thymidylate 
synthase gene. Interestingly, overexpression of APP counteracts this inhibition (Bruni et al., 
2002). Moreover, as already mentioned, Fe65 can translocate into the nucleus upon binding to 
AICD. Once Fe65 and AICD have entered the nucleus either separately or together, Fe65 binds 
to the histone acetyltransferase (HAT) Tip60 to initiate the transcription of target genes (Cao and 
Südhof, 2001; Kimberly et al., 2001). However, the transcription can be suppressed by Dexras1, 
a Ras family small G protein (Lau et al., 2008). Dexras1 binds to Fe65 at its PTB2 domain. 
Hence, it competes with APP for the association with Fe65. Once APP-Fe65 binding is disrupted, 
the APP-Fe65-mediated transcription is subsequently blocked (Lau et al., 2008).  
Fe65 is also involved in DNA damage response. When DNA damage occurs, Tip60 forms a 
complex with TRRAP, a cofactor of HAT complexes, to acetylate histone H4 at DNA double 
strand breaks and in turn, promote DNA repair (Murr et al., 2006). Upon DNA damage, deletion 
of Fe65 suppresses the recruitment of Tip60-TRRAP to the damage site and therefore hinders 
DNA repair. Interestingly, APP is required for Fe65-mediated DNA repair (Stante et al., 2009). 
Knockdown of APP restricts Fe65-induced recruitment of Tip60-TRRAP and thus decreases 
DNA repair efficiency. A similar series of studies using sorbitol to induce DNA damage supports 
this finding (Cao and Südhof, 2001; Nakaya et al., 2008, 2009; Tang et al., 2006). Under osmotic 
stress induced by sorbitol, Fe65 enters the nucleus mediated by APP and AICD. Nuclear Fe65 in 
turn prevents p53 from proteasomal degradation, perhaps regulated by the binding between Fe65 
and Tip60 as well as the Tip60-induced acetylation of p53. The stabilized p53 then facilitates the 
phosphorylation of the histone H2AX (γH2AX) and triggers either DNA repair or apoptosis. 
Taken together, these findings support that APP-regulated Fe65 translocation into nucleus is 
required for the nuclear signal transduction in response to DNA damage. 
 
1.3.5.1.4 Fe65 transgenic animal models 
To study the role of Fe65 in vivo, various transgenic models have been generated. Ablation 
of feh-1 gene, the only orthologue of Fe65 in Caenorhabditis elegans, leads to arrest during the 
late embryonic period or at the first larval stage L1, suggesting that Fe65 is required for proper 
development of C. elegans (Zambrano et al., 2002). The single Fe65 knockout mouse are grossly 
normal but with subtle impairments. Deletion of Fe65 affects neurogenesis and these mice 
exhibit reversal learning deficits in Morris water maze at 14 months of age, indicating a role of 




demonstrates that mice lacking either Fe65 or Fe65L1 appear to be apparently normal, while the 
Fe65/Fe65L1 double knockout mice have severe neurodevelopmental defects including 
disorganized cortices and hippocampi resulting from aberrant midline crossing and abnormal 
axonal projections (Guenette et al., 2006). Furthermore, mouse embryonic fibroblasts isolated 
from Fe65-/- are more sensitive to irradiation, accelerating rapid upregulation of p53 and γH2AX 
(Minopoli et al., 2007). These findings suggest that Fe65 is crucial for proper neurodevelopment 
as well as DNA damage response in vivo. 
  
1.3.5.1.5 The role of Fe65 in apoptosis 
So far, studies concerning the role of Fe65 in cell viability demonstrate that overexpression 
of Fe65 either does not induce cell death in HEK293T and SH-SY5Y cells, or augments 
apoptosis in CHO, HEK293T as well as Neuro 2A cells (Chow et al., 2012; Kim et al., 2007b; 
Lee et al., 2009a; Vazquez et al., 2009). The discrepancy could be attributed to different 
experimental procedures. On the other hand, knockdown of Fe65 is shown to partially attenuate 
H2O2-induced apoptosis in HEK293T cells (Kim et al., 2012). These findings suggest a potential 
pro-apoptotic function of Fe65. However, the role of Fe65 in neuronal apoptosis was not well 
investigated.  
The study by Matz and colleagues demonstrated that overexpression of Fe65 triggers 
apoptosis in cerebellar granule neurons, while knockdown of Fe65 prevented neurons from 
serum-deprivation-induced cell death (Matz et al., in press). Further survival analyses using Fe65 
deletion mutants revealed that the PTB2 domain of Fe65 was localized to the nucleus and was 
most potent in initiating apoptosis. Having established that Fe65 interacted with RNF157 and 
served as an apoptotic inducer in cerebellar granule neurons, subsequent epistasis analyses were 
carried out. The result exhibited that Fe65 acted downstream of RNF157 to regulate apoptosis in 








1.4 Aim of the study 
The aim of my study was to expand the understanding of how the RING-type E3 ligase 
RNF157 and its interactor Fe65 work in the brain. Using the RNF157 knockout mouse model, I 
first elucidated the spatial distribution of RNF157 in vitro and in vivo. Next, I characterized the 
function of RNF157 as well as the role of its interactor Fe65 in hippocampal neurons. 
Furthermore, I sought to identify possible molecules that are involved in the RNF157/Fe65 
survival pathway. In addition to the establishment of an RNF157-dependent linear survival 
pathway in vitro, I aimed at understanding the functional implication of RNF157 in vivo. I 
therefore conducted a comprehensive behavioral test battery in the RNF157 knockout mice. 
Utilizing biochemical and immunochemical methods as well as behavioral analysis, my study 
provides a comprehensive view of the role of RNF157 in neuronal viability and cognition in the 
central nervous system. 
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2 Materials and methods 
 
2.1 Chemicals and kits 
Unless mentioned in the text, chemicals and reagents used in this study were purchased from 
AppliChem (Darmstadt, Germany), Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), 
Becton Dickinson and Company (Heidelberg, Germany), Sigma-Aldrich (Steinheim, Germany) 
or Invitrogen (Darmstadt, Germany). 
Human Fetal Brain Mate & Plate® Library was from Clontech Laboratories, Inc. (Mountain 
View, USA). NucleoSpin® Plasmid QuickPure kit, NucleoSpin® Gel and PCR Clean-up kit, and 
NucleoBond® Xtra Midi EF kit were from Macherey-Nagel (Düren, Germany). 
 
2.2 General Equipment 
The following equipment was used in the experiments: plastic wares such as 1.5 ml micro-
centrifuge tubes, pipette tips, reaction tubes (15 or 50 ml) or culture dishes were from Eppendorf 
(Hamburg, Germany), Sarstedt AG (Nürnbrecht, Germany), Gilson (Middleton ,USA) or  Bio-
One (Frickenhausen, Germany), centrifuges from Eppendorf, rocker and shaker from Heidolph 
(Schwabach , Germany), thermocycler from Biometra (Göttingen, Germany), heat block from 
Grant Instruments (Shepreth, UK), and spectrophotometer from GE Healthcare (Freiburg, 
Germany). Microscopic images were taken with an SP2 confocal microscope from Leica (Solms, 
Germany) or with an inverted light microscope (Exlipse TS100) from Nikon (Tokyo, Japan). 
Dissection microscope (SMZ645) was from Nikon. 
 
2.3 Enzymes 
Enzymes used in this study are listed below: 
Enzyme Supplier 
Pfu DNA polymerase Fermentas 
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Restriction Enzymes New England Biolabs 
Alkaline phosphatase, calf intestinal (CIP) New England Biolabs 
T4 DNA Ligase Fermentas 
T4 DNA Polymerase Fermentas 
T4 Polynucleotide Kinase New England Biolabs 
GoTaq® DNA polymerase Fermentas 
PCR SuperMix Invitrogen 
 
2.4 Buffers and solutions 
The buffers and solutions listed bellow were frequently used in various experiments: 
TX-100 lysis buffer: 150 mM NaCl, 50 mM Tris HCl pH 7.5, 1 mM EDTA, 1% Triton X-100 
 
Running buffer: 25 mM Tris, 250 mM glycine, 0.1% SDS 
 
Transfer buffer: 190 mM glycine, 24 mM Tris, 0.0375% SDS, 20% methanol 
 
Lower buffer: 1.5 M Tris pH 8.8, 0.4% SDS 
 
Upper buffer: 0.5 M Tris pH 6.8, 0.4% SDS 
 
4x SDS sample buffer: 25 ml Upper Buffer, 20 ml Glycerol, 4 g SDS, 2 ml 2-Mercaptoethanol, 
2 g Bromphenolblue (stored in 1 ml aliquots at -20°C) 
 
PBS:  136 mM NaCl, 2.68 mM KCl, 4.29 mM Na2HPO4 x 7H2O, 1.47 mM KH2PO4 
 
PBST: PBS, 0.1% Tween 20 
 
2xYT media (1L): 16 g tryptone, 10 g yeast extract, 5 g NaCl 
 
Annealing buffer: 100 mM potassium acetate, 30 mM Hepes, 2 mM magnesium acetate 
 
8% PFA: 375 ml sterile H2O at 60°C, 40 g of PFA, 50 ml 10x PBS and 40 g sucrose; fill up with 
sterile H2O to final volume of 500 ml, pH 7.4 
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Co-IP buffer: 150 mM NaCl, 20 mM Tris pH 7.4, 1 mM EDTA, 1% Nonidet P-40, 10% 
Glycerol 
RIPA buffer: 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP40, 0.5% Sodium deoxycholate, 
0.1% SDS, 5 mM EDTA 
 
Buffer A: 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EGTA, 0.1 mM EDTA 
   
Buffer A+: Buffer A, 0.1% Nonidet P-40 
 
Buffer C: 20 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA 
 
Mounting medium: 6 g of 85% glycerol, 2.4 g Mowiol 4-88 (Calbiochem), 6 ml H2O, 12 ml 
0.2 M Tris-HCl pH 8.5 and 2.5% DABCO 
 
Cbc medium: BME [+] Earle´s [-] L-Glutamine, 10% Calf serum (heat inactivated, Hyclone), 
1% PSG and 25 mM KCl 
 
BME112 medium: 35 mM Glucose, 10 µg/ml Insulin, 1% PSG in BME [+] Earle´s [-] L-
Glutamine 
 
2x HBSS: 4 g NaCl, 117.5 mg KCl, 95 mg Na2HPO4x7H2O, 675 mg glucose, 2.5 g Hepes-free 
acid in 250 ml H2O, pH 7.05 or pH 7.08 
 
HHGN: 1x HBSS-Hank's buffered salt solution [-] Calcium [-] magnesium, 2.5 mM Hepes pH 
7.3-7.5, 350 mM glucose and 0.04 M NaHCO3 
 
DnB: 500 μl DNase (2 μg/μl), 10 ml BME [+] Earle´s [-] L-Glutamine 
 
TDn: 250 μl DNase (2 μg/μl), 5 ml HHGN, 50 mg Trypsin (Worthington) 
 
Hippocampal neuron plating medium: DMEM [+] 4.5 g/l glucose [+] glutamine [+] pyruvate, 
10% FBS (Biochrom), 1% PSG, 0.0125 mM glutamate 
 
Neuron growth medium: Neurobasal medium, 2% B27 supplement, 1% PSG 
 
HEK 293T medium: DMEM [+] 4.5 g/l glucose [-] glutamine [-] pyruvate (GIBCO®, Life 
TechnologiesTM, Catalog no. 11960) with 10% FBS and 1% GlutaMAX® 
 
Bacterial lysis buffer: 10 mM Tris/HCl pH 7.9, 10% Glycerol, 0.5 M NaCl, 0.1% Nonidet P-40 
and 5 mM 2-Mercaptoethanol  
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Tail Lysis buffer: 10 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS; add fresh 200 mM NaCl, 200 
µg/ml Proteinase K 
Blocking buffer: BME [+] Earle´s [-] L-Glutamine with 10 % HS 
 
DAPI: 1 µg/µl stock, dilute 1:8000 in H2O 
 
Hoechst: 1μg/μl in PBS, 0.1 % Triton X-100 
 
X-Gal staining solution: 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM 
MgCI2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 (NP-40) in PBS, with freshly 




2.5 Expression plasmids and primers 
Expression constructs generated in the lab: 
Vector plasmid Constructed by Primers 
pBluescript-U6-RNF157 RNAi III A. Matz 14907/14908 
pCMV-myc-RNF157 A. Matz 15828/15829 
pCMV-myc-RNF157-Res A. Matz 22180/22181 
pCMV-myc-RNF157 ΔRING A. Matz 
15828/17434/ 
17435/15829 
pCMV-myc-Fe65aa1-325 J. Stegmüller 17802/17803 
pCMV-myc-Fe65aa326-524 J. Stegmüller 17804/17805 
pCMV-myc-Fe65aa525-711 J. Stegmüller 17806/17807 
pCMV-myc-Fe65aa1-524 J. Stegmüller 17802/17805 
pCMV-myc-Fe65aa326-711 J. Stegmüller 17804/17807 
pCMV-myc-Fe65 A. Matz 17802/17807 
pCMV-myc-NLS-FE65 J. Stegmüller  
pCMV-myc-NES-FE65 J. Stegmüller  
pBluescript-U6-Fe65 RNAi III A. Matz 19778/19779 
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pEGFP-C2-RNF157 A. Matz 14864/14763 
pCMV-myc-Fe65 ∆PTB1 S. Lee 
17802/29386/ 
29385/17807 
pCMV-myc-Fe65 ∆PTB2 S. Lee  
17802/29384/ 
29383/17807 
pCMV-myc-Fe65 ∆B12 S. Lee 
17802/30092/ 
30027/17807 
pET3a-RNF157 immunogen S. Lee 26304/26305 
pBluescript-U6-Tip110 RNAi #1 S. Lee 31811/31812 
pBluescript-U6-Tip110 RNAi #2 S. Lee 31813/31814 
pBluescript-U6-Tip110 RNAi #3 S. Lee 31815/31816 
pBluescript-U6-Tip110 RNAi #5 S. Lee 31819/31820 
 
 


















Plasmids Obtained from 
pcDNA3.1-myc-Fe65 U. Konietzko 
pcDNA3.1-Flag-Fe65 T. Suzuki 
pcDNA3-human APP A. Matz 
pcDNA3-swedish mutant APP A. Matz 
pBICEP-CMV2-Tip60 A. Repouskou 
pCS2-myc M. Rape 
pCS2-myc-Tip110 M. Rape 
pCS2-HA M. Rape 
pCS2-HA-Tip110 M. Rape 
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Sequence of the primers used for cloning:  
 
Primer Sequence 5’-3’ 
14763 GGCGTCGACCAGACAGCCAAAGGATCCCATACG 
14864 GGCAAGCTTCATGGGAGGAGAGAAGTTTGACTGC 
14907 GGACAATAAGCTGTGCTCTGAAGTTAACGCAGAGCACAGCTTATTGTC CCTTTTG 
















19778 AAGCTGACCCAGATGCTCAAAAGTTAACGTTGAGCATCTGGGTCAGCT TCTTTTG 
19779 AATTCAAAAGAAGCTGACCCAGATGCTCAACGTTAACTTTTGAGCATC TGGGTCAGCTT 
22180 GTCGCGAGCGTGAAAGCACTGGATAACAAACTCTGTTCGGAGGTCTGC TTACCCGGTACCTGGCAAC 
22181 GTTGCCAGGTACCGGGTAAGCAGACCTCCGAACAGAGTTTGTTATCCA GTGCTTTCACGCTCGCGAC 
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31811 AAGAGCTCTGGCTGGAGTGGAAGTTAACGCCACTCCAGCCAGAGCTCT TCTTTTG 
 
 





Primary and secondary antibodies used for immunoblotting and immunostaining in this 
study: 
Primary antibody Host species Company 
Working Dilution 
WB ICC/IHC 
α RNF157 Rabbit Sigma-Aldrich 1:300  
α 14-3-3β Mouse Santa Cruz 1:1000  
α Sp1 Rabbit Santa Cruz 1:500  
α SnoN Rabbit Santa Cruz 1:500  
RNF157 Genotyping Primer 
Primer Sequence 5’-3’ Description 
28743 GAGAAAAGCAAGAGAAAGAGAAAAGC WT FWD 
28744 AGGCCATCTAAATACACGCACG WT REV 
25171 CTTGCAAAATGGCGTTACTTAAGC Mut FWD 
25172 GCGCTGACATCCTGTGTTC Mut REV 
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α γ-Tubulin Mouse  1:5000  
α α-Tubulin Mouse  1:5000  
α myc Mouse Santa Cruz 1:1000 1:250 
α β-galactosidase Mouse Santa Cruz 1:500 1:100 
α GFP Rabbit Invitrogen 1:1000 1:1000 
α GFP Mouse Santa Cruz 1:1000  
α Fe65 Rabbit Santa Cruz 1:1000  
α Fe65 Goat Santa Cruz 1:500  
α Flag Mouse Sigma Aldrich 1:1000 1:250 
α Ubiquitin Rabbit Dako 1:500  
α HA Rabbit Abcam 1:1000 1:200 
α HA Mouse Santa Cruz 1:500  
α TuJ1 Mouse Promega  1:250 

















α mouse IgG Goat HRP Dianova 1:10000  
α rabbit IgG Goat HRP Dianova 1:10000  
α mouse IgG Goat Cy2/ Alexi 488 Dianova  1:1000 
α rabbit IgG Goat Cy2/ Alexa 488 Dianova  1:1000 
α mouse IgG Goat Cy3/ Alexa 555 Dianova  1:1000 
α rabbit IgG Goat Cy3/ Alexa 555 Dianova  1:1000 
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2.7 Expression plasmid construction and cloning 
2.7.1 General molecular cloning 
To clone a desired cDNA sequence into an expression vector, the amplification setup is 
listed as in the table below. The annealing temperature was set 5°C below the melting 
temperature of the primers.  For the PCR program, the elongation time at 72°C was set according 
to the length of the template (1 min/500 bp of template). 
PCR reaction setup 
1 µl template DNA (10 ng/µl) 
1 µl forward primer (10 pmol/µl) 
1 µl reverse primer (10 pmol/µl) 
0.4 µl dNTPs (25 mM) 
0.5 µl Pfu DNA polymerase (2.5 units/ µl) 
5 µl 10X reaction buffer (+MgSO4) 
41.1 µl H2O 
 
PCR Program 
Denaturation 95°C 3 min  
Denaturation 95°C 30 sec 
30 cycles Annealing X°C 30 sec 
Elongation 72°C X min 
Final elongation 72°C 5 min  
 
To assess size and quality of the PCR product, the product was subjected to electrophoresis 
in a 0.8-2% agarose gel according to the expected size. DNA fragments of correct size were 
excised from the gel, extracted with NucleoSpin® Gel and PCR Clean-up kit and eluted in 40 µl 
H2O. 
The purified PCR product (insert) and the target expression vector (2 μg) were digested with 
the corresponding restriction enzymes for 1-2 hour at 37°C in a volume of 50 μl. Directly after 
digestion, the insert was purified using NucleoSpin® Gel and PCR Clean-up kit and eluted in 20 
μl H2O. The digested vector was further treated with 10 units of calf intestinal alkaline 
phosphatase (CIP) for 30 min at 37°C to remove the 5´ phosphate groups of DNA and thus 
prevent self-religation. After CIP treatment, the vector was separated electrophoretically in an 
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agarose gel to verify the DNA linearization. The linearized fragment was subsequently extracted 
with NucleoSpin® Gel and PCR Clean-up kit and in 40 µl H2O.  
For the ligation of the digested insert and vector, the reaction setup is listed in the table 
below:    
Ligation reaction setup 
6 µl insert 
1 µl vector 
1 µl ATP (10 mM) 
1 µl 10X T4 ligation buffer 
1 µl T4 DNA ligase 
Overnight in icy water (10°C) 
 
The next day, the entire ligation reaction was transferred into 100 µl of chemically 
competent DH5α E. coli cells. The bacteria were then incubated on ice for 20 min, heat shocked 
at 37°C for 1 min and cooled down on ice for 1 min. Afterwards, 300 µl antibiotic-free 2xYT 
media (room temperature) was added into the reaction followed by 30 min of shaking at 37°C. 
Next, bacteria were spun down at 4000 rpm for 3 min and plated on a pre-warmed 2xYT agar 
plate with a suitable antibiotic according to the resistance gene encoded in the vector. The plate 
was kept at 37°C overnight.  
To assess if the ligation was successful, colonies on the plate were transferred into 2 ml 
2xYT media supplemented with the corresponding antibiotic. The cultures were incubated 
overnight at 37°C. Next, the plasmid DNA from each culture was extracted using the 
NucleoSpin® Plasmid Quick Pure kit. The plasmids were then digested with the appropriate 
enzymes to determine the positive clones. Afterwards, the sequence of the DNA from positive 
clones was analyzed by the AGCTLab at the MPI of Experimental Medicine.  
 
2.7.2 Construction of vector-based RNA interference 
In this study, the RNA interferences (RNAi) were constructed in the pBlueScript vector 
containing the RNA polymerase III U6 promoter.  The rules listed below were use to design the 
primers for generating RNAi:  
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1. 5’ primer starts with AA, AG or GG 
2. Followed by 18 nucleotides (target sequence), alternative loop sequence AAGTTAACG 
harboring an HpaI site and the antiparallel target sequence 
3. End with CTTTG (stop signal for the RNA polymerase III and a part of EcoRI site) 
4. The target sequence should have 45-60% GC content 
5. Avoid AUG and AAAA 
6. Confirm that the sequence is specific for the target DNA 
7. The 3’ primer is complementary to the 5’ primer with TTAA added to the end 
To generate the RNAi, 2 µl of 5’ sense and 3’ antisense primer (50 pmol/µl) were 
resuspended in 46 µl of annealing buffer, incubated at 95°C for 4 min, 72°C for 10 min and 
slowly cooled down (0.1°C/sec) to room temperature. 20 µl of the annealed reaction mix was 
phosphorylated using polynucleotide kinase (PNK) at 37°C for 30 min. In the meanwhile, the 
pBlueScript-U6 vector was first digested with ApaI and then blunted with T4 DNA polymerase 
to remove the sticky ends of the vector. Further, the vector was digested with EcoRI and 
dephosphorylated by CIP. The annealed oligonucleotides (insert) and the vector were ligated 
overnight in ice-cold water and transformed into DH5α E. coli cells as described in Section 2.7.1. 
Positive clones were tested using HpaI restriction enzyme since the HpaI site was designed into 
the primers. The sequence was analyzed by the AGCTLab. 
 
2.8 Cell culture and transfection 
All the experimental procedure concerning cell culture was done in a biological safety 
cabinet (HERAsafe®, Kendro). Cultured cells were kept in appropriate media according to the 
cell types. All the heterologous cells were grown in an incubator (Hera cell 150, Kendro) 
supplemented with 5% CO2 at 37°C, while the primary cells were in another incubator to avoid 
contamination.  
 
2.8.1 Culture of HEK293T cells 
HEK293T cells were maintained in a 10-cm dish with HEK293T medium in the CO2-
Incubator. Cell splitting was performed when the cells reached 90% confluence. First, the cells 
were washed once with PBS and incubated with 2ml of 1x TE at 37°C for 2 min. Next, 8 ml of 
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HEK293T medium was added into the plate and mixed with the cells by pipetting up and down. 
The cell suspension was then spun down at 800 rpm for 5 min at 4°C, resuspended in 5 ml 
medium and plated in 6-well, 12-well or 10-cm plates according to the experiment design.  For 
maintenance of the cell line, 500 µl of cell suspension was added into 10 ml medium and plated 
in a 10-cm dish. 
 
2.8.2 Transfection of HEK293T cells 
HEK293T cells were split into a 6-well plate one day before transfection. When the cells 
grew to approx. 70-80% confluency, 10ng - 2µg plasmid DNA was diluted into 90 µl sterile H2O. 
Next, the DNA solution was mixed properly with 10 µl of 2.5 M CaCl2 and then with 100 µl of 
2× HBSS. The mixture was incubated for 5 min at RT and added gently to the cells. 
 
2.8.3 Culture of primary cerebellar granule neurons 
Isolated cerebella from postnatal day 6 (P6) Wistar rats or from P5 RNF157 transgenic mice 
were collected in HHGN medium on ice. Using fine forceps, the meninges were then removed 
under a dissection microscope. After 3 HHGN washes, the cerebella were incubated with 5 ml of 
TDn for 10 min at 37°C and another 10 min at room temperature. Next, the cerebella were 
washed 3 times with HHGN medium and triturated in 4 ml of DnB till the suspension reached 
homogeneity.  After 5 min incubation on ice, the supernatant was transferred into a fresh falcon. 
The remaining tissue was triturated with another 4 ml of DnB and combined with the separated 
supernatant. The cell suspension was centrifuged at 800 rpm for 5 min at 4°C and the pellet was 
resuspended in 20 ml of Cbc medium. The number of cells was estimated in a hemocytometer. 
Prior to plating, the plates or coverslips were coated with 15 µg/ml of poly-ornithine for at least 
30 min at 37°C and washed twice with sterile H2O. 20 x 106 cells were then seeded in a 24-well 
plate, 30 x 106 cells in a 6-well plate and 50x106 cells in a 10-cm dish. At the next day, day in 
vitro (DIV) 1, neurons were treated with an anti-mitotic agent, 10 µM nucleoside cytosine 
arabinoside (AraC), to inhibit the proliferation of non-neuronal cells. If neurons were kept longer 
in culture, 35 mM glucose was supplemented to the medium every third day. 
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2.8.4 Culture of primary cortical neurons 
Cortices were isolated from E18 Wistar rat embryos in 1 x HBSS medium (BME [-] calcium 
[-] magnesium, Gibco®) under a dissection microscope and transferred to a falcon filled with 
HBSS medium on ice. After 3 HBSS washes, the cortices were incubated with 5 ml of TDn for 
10 min at 37°C and another 10 min at room temperature. Next, the tissues were washed 3 times 
with HBSS medium and triturated in 5 ml of neuron growth medium with 250 µl freshly added 
DNase (2 mg/ml). The cell suspension was centrifuged at 800 rpm for 5 min at 4°C the pellet 
was resuspended in 20 ml of neuron growth medium. Cells were counted in a hemocytometer. 
Prior to plating, the plates or coverslips were coated with 15 µg/ml of poly-ornithine for at least 
30 min at 37°C and washed twice with sterile H2O. 1.2-2 x 106 cells were seeded in a 24-well 
plate, 8 x 106 cells in a 6-well plate and 10 x 106 cells in a 10-cm dish.  
 
2.8.5 Culture of primary hippocampal neurons 
Hippocampi were isolated from E18 Wistar rat embryos in HBSS medium (BME [-] calcium 
[-] magnesium, Gibco®) and transferred to a falcon filled with HBSS medium on ice. After 3 
HBSS washes, the volume was reduced to 1.8 ml and 200 µl of 0.05% Trypsin-EDTA (Gibco®) 
was added. The hippocampi were incubated for 10 min at 37°C. Followed by another 3 HBSS 
washes, the hippocampi were triturated in 1 ml of hippocampal neuron plating medium with 50 
µl DNase (2 mg/ml).  The cell suspension was centrifuged at 800 rpm for 5 min at 4°C the pellet 
was resuspended in 5 ml of hippocampal neuron plating medium. Cells were counted in a 
hemocytometer. Prior to plating, the plates or coverslips were coated with 0.00083% poly-L-
Lysine for at least 30 min at 37°C and washed twice with sterile H2O. 1.2-2 x 106 cells were 
seeded in a 24-well plate and 8 x 106 cells in a 6-well plate. In the next day, the plating medium 
was replaced by neuron growth medium. 
 
2.8.6 Transfection of primary neurons and nucleofection 
Primary cerebellar granule neurons, hippocampal neurons and cortical neurons in 24-well 
plates were transfected at the indicated points in time. First, the conditioned culture medium was 
collected and kept at 37°C.  Neurons were washed twice with prewarmed DMEM ([+] 4.5 g/l 
glucose [-] glutamate [-] pyruvate for transfection) and starved for 30-45 min in 500 µl DMEM 
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at 37°C. Meanwhile, the plasmid DNA was diluted in sterile H2O to a volume of 18 µl. Then, the 
DNA solution was mixed properly with 2 µl of 2.5 M CaCl2 and then with 20 µl of 2× HBSS. 
The mixture was incubated for at least 5 min at RT and added gently to the cells after cell 
starvation. The neurons were incubated at 37°C for 5-18 min according to the experimental setup. 
Finally, neurons were washed twice with DMEM and the collected conditioned medium returned. 
For nucleofection, 4-8 × 106 dissociated cortical neurons were resuspended in 100 μl of 
DMEM ([+] 4.5 g/l glucose [-] glutamate [-] pyruvate) and mixed with 8 μg of the indicated 
RNAi plamids, together with the GFP plasmid and the anti-apoptotic Bcl-xL plasmid. The cell 
suspension was pulsed using the program O-005 in the nucleofector (Amaxa, Lonza). Neurons 
were then immediately transferred into pre-warmed DMEM supplemented with 10% FCS in 6-
well plates. After 4 hours, the medium was exchanged with neuron growth medium.   
 
2.9 Immunocytochemistry 
The cells for morphological analysis were washed twice with PBS and fixed with 4% PFA 
for 10 min, while the neurons for survival assay were directly fixed by adding 8% PFA to the 
medium. After 2 more PBS washes, cells were permeabilized with 0.4% Triton X-100 in PBS for 
10 min. Cells were then washed twice with PBS followed by blocked in blocking buffer (BME + 
10% horse serum) for 30 min.  Next, primary antibody diluted in blocking buffer was applied to 
cells for either 1 hour at RT or overnight at 4°C. Afterwards, the cells were washed twice with 
blocking buffer before the secondary antibody, the fluorophore-coupled antibody was diluted in 
blocking buffer and added to the cells. After 45 min of incubation, cells were washed twice with 
PBS and incubated with a DNA dye (bisbenzimide Hoechst 33258 or 4’6-diamidino-2-
phenylindole - DAPI) for 5-10 min. After 2 PBS washes, coverslips were mounted upside down 
with Mowiol mounting medium on microscope slides (Marienfeld) and kept at 4°C till analysis. 
 
2.9.1 Survival assays in neurons  
Procedures for survival assays were modified from a previously described method (Becker 
and Bonni, 2004). Briefly, neurons were prepared as mentioned in 2.8.3 and 2.8.5 and seeded in 
a 24-well plate. At DIV2, neurons were transfected with the indicated expression plasmids 
together with a plasmid encoding β-galactosidase using the calcium phosphate transfection 
method as in 2.8.6. For gain-of-function experiments, neurons were cultured for 6 days, while 7 
days for loss-of-function or epistasis analyses. Next, neurons were subjected to 
immunocytochemistry using the monoclonal β-galactosidase antibody and abovementioned 
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DNA dyes. Neuronal survival and death were examined in β-galactosidase expressing neurons 
based on the integrity of neurites and the morphology of the nucleus. Analyses were performed 
in a blinded manner (n ≈ 100 cells per condition) using a fluorescence microscope. 
 
2.10 X-Gal staining of mouse brain sections 
For the sagittal brain sections, mice were first perfused with 4% PFA and the brains were put 
into 4% PFA, gently shake at 4°C for 3 hours as post-fixation. Afterwards, the brains were rinsed 
twice with PBS and kept in PBS supplemented with 0.02% NaN3 at 4°C till cutting. Dissection 
was performed using a vibratom (VT1000S, Leica).  The brains were cut into 40 µm sections and 
stored in PBS with NaN3. 
For staining, sections were incubated with X-Gal staining solution under lightproof 
conditions overnight at 37%. The next day, the sections were washed twice with PBS, collected 
on a slide and stored at 4%. The images were obtained using an inverted light microscope. 
 
2.11 Biochemical methods 
2.11.1 Tissue lysate preparation 
Mice or rats were sacrificed by either decapitation or CO2 inhalation. Tissues were isolated 
and placed rapidly into ice-cold TX-100 lysis buffer with freshly added protease inhibitor cock-
tail (1 mM DTT, 3 µg/ml aprotinin, 1 µg/ml leupeptin and 1 µg/ml pepstatin). Subsequently, the 
mixture was homogenized using 2 ml Dounce or Ultra Turrax (IKA®) homogenizer. After 30 
min of incubation on ice, samples were spun down at 14000 rpm for 10 min at 4°C and the su-
pernatants were collected into a fresh eppendorf tube. If not immediately used for further exper-
iments, the lysates were flash frozen in liquid nitrogen and kept at -80°C. 
 
2.11.2 Cell lysate preparation 
To collect the lysate from cultured HEK 293T or primary neurons, cultured medium was 
first aspirated off from the plates and the cells were washed once with PBS on the ice. Next. TX-
100 lysis buffer with freshly added protease inhibitor cocktail (1 mM DTT, 3 µg/ml aprotinin, 1 
µg/ml leupeptin and 1 µg/ml pepstatin) was added to the wells. Adherent cells were then 
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removed from the plates using a cell scraper and collected in an eppendorf tube. Samples were 
incubated on ice for 30 min and centrifuged at 14000 rpm for 10 min at 4°C. The supernatants 
were collected into a fresh tube and kept at 4°C for the further experiments. 
 
2.11.3 Bradford protein assay 
To determine the concentration of protein in tissue or cell lysates, Bradford Reagent (Bio-
Rad®) was used. The Reagent was diluted 5x in PBS.  For the standard curve, 2, 4, and 7 µg of 
bovine serum albumin (BSA) was added into 1 ml Bio-Rad®/PBS solution. For the protein 
concentration, 2 µl of lysates from proteins of interest were suspended in 1 ml Bio-Rad®/PBS 
solution. The absorbance shift based on the protein binding to Coomassie Brilliant Blue G-250 
was determined by a photometer (Amersham Biosciences, Ultro spec 3100 pro) at the 
wavelength of 595 nm. Lastly, the protein concentration was calculated according to the BSA 
standard curve.     
 
2.11.4 Co-Immonoprecipitation (CoIP) 
Transfected HEK 293T were washed once with PBS and lyzed in ice-cold CoIP buffer with 
freshly added protease inhibitor cocktail (1 mM DTT, 3 µg/ml aprotinin, 1 µg/ml leupeptin and 1 
µg/ml pepstatin) on ice. Samples were incubated on ice for 30 min and centrifuged at 14000 rpm 
for 10 min at 4°C. After measuring the protein concentration, 100 µg of the samples were set 
aside as input control. Then, at least 1 mg of protein was incubated with 1µg of antibody for 3 
hours at 4°C on the rotator. Meanwhile, protein A-sepharose beads (Protein A-Sepharose™ Fast 
Flow, GE Healthcare), which bind to rabbit and mouse IgGs, were washed 3 times with CoIP 
buffer and stored in equal amount of CoIP buffer (i.e. 300µl buffer for 300 µl beads) till needed. 
After 3 hours, 30 μl of washed beads was added to every sample and rotated for another hour at 
4°C. Next, samples were spun down at 10000 rpm for 1 min and the supernatants were discarded. 
The beads were washed twice with either RIPA or TX-100 lysis buffer and once with PBS. 
Finally, the PBS was removed leaving ~10 µl of the liquid upon the beads. The samples were 
then boiled at 95°C for 5 min with 20 µl of 4x SDS sample buffer. The boiled CoIP samples and 
input controls were further subjected to SDS-PAGE and western-blot analysis.  
 
 39 
Materials and methods 
 
2.11.5 Subcellular fractionation 
Primary neurons were grown in a 10-cm plate. Neurons were first washed once with PBS 
and lyzed in 250µl of buffer A with freshly supplemented protease inhibitors (5-10 µg/ml 
aprotinin, 1 mM PMSF and 5-10 mM N-Ethylmaleimide (NEM). If mouse brains were used, 
brain tissues were lyzed directly in Buffer A with protease inhibitors. Next, samples were kept 15 
min on ice and subjected to a mechanical disruption using a 2 ml Dounce homogenizer.  
When lysates reached homogeneity, samples were centrifuged at 2000 rpm for 5 min at 4°C. 
The postnuclear supernatant (PNS) was collected in a new eppendorf tube as the cytoplasmic 
fraction. The remaining nuclear pellets were then washed three times with Buffer A+ and 
resuspended in 50 µl Buffer C followed by 30 min of rotation at 4°C. In the last step, the nuclei 
were centrifuged at 14000 rpm for 20 min at 4°C and the supernatant was collected as nuclear 
fraction (NF).  
For the tissue lysate, samples were centrifuged at 2000 rpm for 5 min at 4°C. The superna-
tant (S1) was collected in a new eppendorf tube and spun down again for 5 min at 4°C. The su-
pernatant from S1 was then the PNS. The pellets from S1 were washed 6 times with Buffer A+, 
resuspended in 100 µl Buffer C and rotated for 30 min at 4°C. Finally, the pellets were spun 
down at 14000 rpm for 20 min at 4°C and the supernatant was harvested as nuclear fraction (NF). 
For further fractionation, the PNS I was ultracentrifuged for 40 min at 4°C at 21000g, the result-
ing pellet I and PNS II were collected. PNS II was then ultracentrifuged for 2.5 hours at 4°C at 
257000g resulting in pellet II and the cytoplasmic fraction. After measuring the protein concen-
tration, equal amount of PNS and NF was subjected to SDS-PAGE and western-blot analysis. 
 
2.11.6 Ubiquitination assay 
Ubiquitination assays were performed under denaturing conditions according to the protocol 
of Lu and colleagues with some modifications to avoid the detection of non-specific 
ubiquitination (Lu et al., 2007). Briefly, transfected HEK 293T cells were lysed in RIPA buffer 
without SDS (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP40, 0.5 % sodium deoxycholate, 5 
mM EDTA, protease inhibitors and 10 mM NEM). Next, 1 mg of total protein was incubated in 
1% SDS for 5 min at 4°C, boiled for 12.5 min at 95 °C, diluted 10x in lysis buffer (50 mM 
HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1% Triton X-100) to adjust the 
concentration of SDS to 0.1% and immunoprecipitated with an antibody or with antibody-
conjugated beads overnight at 4°C. For non-conjugated antibodies, the antibody-antigen complex 
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was immunoprecipitated for 45 min at 4°C using Protein A-Sepharose. Precipitated proteins 
bound to the beads were washed twice with lysis buffer, twice with HNTG buffer (20 mm 
HEPES, pH 7.5, 150 mm NaCl, 0.1% Triton X-100, 10% Glycerol) and eluted by boiling the 
beads in SDS sample buffer. Lysates were analyzed by SDS-PAGE and subsequent 
immunoblotting analysis.  
 
 2.11.7 SDS-PAGE and western blot 
 For SDS-PAGE, the polyacrylamide gels were prepared in the gel casting system (Mini-
PROTEAN Tetra Electrophoresis System, Bio-Rad®). A gel consists of a lower separating gel (8-
15% of acrylamide according to experimental design) and an upper stacking gel (3.9%). The 
most commonly used gels contained 8%, 10 or 12% and the reagents needed are listed below: 
 
The reagents for a separating gel were first mixed, loaded into the gel system and covered by 
a layer of isopropanol. After 45 min of polymerization, isopropanol was washed out with H2O 
and the stacking gel was added to the top followed by the insert of a 10-well comb. The upper 
gel was polymerized after about 40 min. 
Lysates containing 30-80 µg of proteins were diluted in 4× SDS sample buffer and boiled for 
5 min at 95°C. After loading into the gel, the proteins were separated by eletrophoresis at 35 mA 
per gel. Subsequently, the proteins were transferred onto a nitrocellulose membrane using a Mini 
Trans-Blot® cell (Bio-Rad®) at 250-300 mA for 90 min. After transfer, the membrane was 
blocked in PBST supplemented with 4% milk powder (Frema Reform) for 30 min at RT and 
washed 3 times for 10 min in PBST. Next, a primary antibody prepared in 3% BSA or 4% milk 
powder with 0.02% NaN3 in PBST was added to the membrane and incubated for 1 hour at RT 
or overnight at 4°C. Afterwards, the membrane was washed 3 times with PBST for 10 min and 
 Separating Gel (ml) Stacking Gel 
% Acrylamide 8% 10% 12% 3.9% 
30% Acrylamide 2 2.5 3 0.65 ml 
Lower buffer 1.875 1.875 1.875 1.25 ml Upper buffer 
H2O 3.625 3.125 2.625 3.05 ml 
APS 30 µl 
TEMED 3 µl 
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incubated with a secondary antibody diluted in PBST with 4% milk powder for 30-45 min at RT. 
The secondary antibody was coupled with horseradish peroxidase (HRP). Lastly, the membrane 
was washed 3 times with PBST for 10 min and incubated shortly in enhanced chemiluminescent 
(ECL) horseradish peroxidase substrates (Thermo Fisher Scientific). An X-ray film was then 
exposed to the membrane and developed in an automatic film processor (Kodak imaging station). 
 
2.11.8 Protein expression and purification   
The cDNA of interest was first cloned into pET3a expression vector. Then, the plasmid was 
transformed into BL21 E. coli cells on a 2xYT agar plate. A single colony was used for a 20 ml 
overnight pre-culture in 2xYT medium supplemented with ampicillin at 37°C. Next day, 
appropriate amount of the pre-culture was diluted in 250 ml of 2xYT supplemented with 
ampicillin until the OD600 was 0.1. Then, the culture was incubated on a shaker for 2.5 ~ 3 hours 
at 37°C and 1 mM IPTG was added to the culture when the OD600 reached 0.5 ~ 0.6. Afterwards, 
the culture was shaken for another 3 ~ 3.5 hours at 30°C, distributed into 50-ml falcons and spun 
down at 3500 rpm for 10 min at 4°C. The pellets were lyzed in ice-cold bacterial lysis buffer 
with freshly added protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin and 0.5 mM PMSF). 
Next, the samples were sonicated at 4°C using 30% of the power and for 3 times (30 sec each 
sonication with 30 sec intersection interval). After sonication, the samples were centrifuged at 
15000 g for 30 min at 4°C. The supernatant was collected into a new falcon with 1 mM 
immidazol, 1 mM PMSF and 500 µl Ni-sepharose beads and rotated overnight at 4°C. 
Next day, the sample was spun down at 4000 rpm for 5 min at 4°C and the supernatant was 
collected as flow through (FT). 10 ml BC100 buffer supplemented with 20 mM immidazol and 
0.5 mM PMSF was added to the beads and the sample was rotated for 30 min at 4°C. Then, the 
sample was again centrifuged at 4000 rpm for 5 min at 4°C and the supernatant was kept as wash 
I (WI). The procedure was repeated with 5 ml BC100 buffer supplemented with 40 mM 
immidazol and 0.5 mM PMSF for wash II (WII).  Finally, 400 µl BC100 buffer together with 
200 mM immidazol and 0.5 mM PMSF was added to the beads. After 30 min rotation at 4°C, the 
sample was spun down at 4000 rpm for 5 min at 4°C and the supernatant was the purified protein.  
To verify the purification, the samples from FT, WI, WII, beads and purified protein were 
analyzed by SDS-PAGE and western blot. 
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2.12 Generation of RNF157 transgenic mouse 
The RNF157 knockout ES cells generated by Texas A&M Institute for Genomic Medicine 
(TIGM, USA) were from a C57/BL6 mouse and injected into a blastocyst from a FVB/N mouse. 
In these ES cells, a gene trap cassette containing a β-galactosidase reporter gene and a neomycin 
resistance gene was inserted into the second intron of the RNF157 gene, so that the fusion 
mRNA only encodes the first 2 exons and thus the transcription of RNF157 is disrupted. The 
chimeric animals were crossed with wild type C57/BL6 mice to achieve a germline transmission.  
 
2.12.1 Isolation of genomic DNA  
Tail tips from RNF157 transgenic mice were incubated with tail lysis buffer (200µl / tail tip) 
for 3 hours or overnight at 55°C. After flicking the samples to resuspend the DNA, the samples 
were spun down at 13000 rpm for 5 min at RT. The supernatant was transferred to fresh tubes 
and 500µl of 100% EtOH was added to precipitate the DNA. Following centrifugation at 13000 
rpm for 10 min, the supernatant was discarded, the precipitated DNA was washed with 70% 
EtOH and resuspended in 50-100 µl of H2O.  
 
2.12.2 Genotyping of RNF157 mice 
Two PCR reactions were set up for each sample, one using wild-type primer pairs (primer 
28743/28744) and the other using mutant pairs (primer 25171/25172). The PCR reactions were 
set up with the GoTaq® DNA polymerase as following: 
 
PCR reaction setup 
0.5 µl genomic DNA (10 ng/µl) 
1 µl forward primer (10 pmol/µl) 
1 µl reverse primer (10 pmol/µl) 
0.4 µl dNTPs (2.5 mM) 
0.1 µl GoTaq® DNA polymerase  
5 µl 5X GoTaq® buffer 
17 µl H2O 
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2.13 Behavioral analyses  
After weaning and during the period of behavioral testing, mice were housed in groups of 4 
or 5 in standard plastic cages (26.5 × 20 × 14 cm) under a standard 12-hour light/dark cycle with 
food and water ad libitum, unless mentioned elsewhere. The temperature in the behavioral 
facility was kept at 21 ± 2˚C. All experiments were conducted in a blinded manner during the 
light phase of the day.  
The experiment started when the animals were 9 ± 1 weeks old. All the tests were carried 
out in an order oriented toward increasing invasiveness as described before (Bodda et al., 2013): 
elevated plus maze for examining anxiety, open field for spontaneous activity, hole board for 
exploratory behavior, grip strength and rotarod for motor force, balance and coordination, marble 
burying for stereotypic, obsessive-compulsive behaviors, visual cliff for vision, the startle 
response to randomly presented acoustic stimuli ranging from 65 dB to 120 dB for hearing, pre-
pulse inhibition of the startle response for sensorimotor gating, social interaction for sociability, 
buried food finding for olfaction, hot plate test for sensitivity of pain, fear conditioning for 
associative memory and Morris water maze for spatial learning and working memory.   
 
2.13.1 Elevated plus-maze   
To explore anxiety in mice, the elevated plus-maze was used. The maze was made of gray 
Perspex with a 5 × 5 cm central platform and 2 open, 2 enclosed 30 × 5 × 15 cm arms. Individual 
mice were placed on the central platform, facing an open arm of the plus-maze inside a room 
with light intensity of 120 lx. Exploratory behavior was monitored by an overhead video camera 
RNF157 genotyping PCR 
Denaturation 95 °C 3 min  
Denaturation 95 °C 30 sec 
30 cycles Annealing 48 °C 30 sec 
Elongation 72 °C 25 sec 
Final Elongation 72 °C 5 min  
 44 
Materials and methods 
 
connected to a PC with “Viewer 2” software (Biobserve GmbH, Bonn, Germany) to record the 
time each animal spent in open or closed arms. The proportion of time spent in open arms was 
used as readout of anxiety or anxiolytic-like behavior. 
 
2.13.2 Open field 
Locomotor activity was assessed using the open field test. In this test, a grey Perspex arena 
(120 cm in diameter, 25 cm high) was placed inside a room with light intensity of 120 lx. The 
mouse was released from the center of the arena and allowed to explore the open field for 7 min. 
The behavior was recorded by video camera linked to a PC equipped with “Viewer 2” software. 
The velocity, distance traveled and time spent in central, intermediate or peripheral zones of the 
open field were recorded.  
 
2.13.3 Hole board 
The hole board test was used to assess exploratory activity. The apparatus comprised a 50 
cm × 50 cm × 36 cm transparent Perspex chamber with a non-transparent floor raised 3 cm 
above the bottom of the chamber with 16 holes of 2.2 cm diameter in a grid-pattern. The test was 
applied in a room with low illumination (5 lx). Individual mice were placed into the center and 
allowed to explore the chamber for 5 min. The number of explored holes (nose pokes) was 
monitored by 2 layers of infrared photo beams connected to a computer with AKS software (TSE 
Systems GmbH, Bad Homburg, Germany).  
 
2.13.4 Pre-pulse inhibition 
In order to test the sensorimotor gating, the mice were placed individually in small metal 
cages (90 × 40 × 40 mm) to restrict major movements and exploratory behavior. The cages were 
equipped with a movable platform attached to a sensor that records vertical movements of the 
platform. The individual cages were placed into sound-attenuating isolation cabinets (TSE 
Systems GmbH). Startle reflexes were evoked by acoustic stimuli delivered from a loudspeaker 
that was suspended above the cage and connected to an acoustic generator. The startle reaction to 
an acoustic stimulus evokes a movement of the platform. The transient force resulting from this 
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startle amplitude after pre-pulse and pulse 
startle amplitude after pulse only 
× 100 % pre-pulse inhibition =  100 – 
movement of the platform was recorded with a computer during a recording window of 260 ms 
(beginning with the onset of pre-pulse) and saved for further evaluation. From the onset of the 
acoustic stimulus, the mice’s reaction was recorded. Each experimental session started with a 2 
min habituation to 65 dB background white noise, which was presented throughout the session, 
and followed by a 1-min baseline recording. Next, 6 pulse-alone trials with startle stimuli of 120 
dB intensity and 40 ms duration were played in order to decrease influence of within-session 
habituation. These measurements were not included in the analysis. To assess pre-pulse 
inhibition, the 120 dB/ 40 ms startle pulse was applied either alone or preceded by 20 ms 70 dB, 
75 dB, or 80 dB pre-pulses. Between each pre-pulse and pulse stimulus, a 100 ms background 
white noise was presented. All trials were presented in a pseudorandom order with inter-trial-
intervals varying from 8 to 22 sec. The amplitude of the startle response (in arbitrary units) was 
defined as the difference between the maximum reaction detected during a recording window 
and the reaction measured right before the stimulus started. Amplitudes for stimulus alone trials 
and stimulus preceded by a pre-pulse were averaged for each mouse separately. Pre-pulse 
inhibition was calculated as the percentage of the startle response as below:  
 
 
2.13.5 Rotarod test 
Rotarod is a test for motor coordination. In this test, a rotarod apparatus consisting of a 
rotating drum, automatic timers and falling sensors was used (MED Associates Inc., Vermont, 
USA). During test, the drum is accelerated from 4 to 40 rpm over the course of 5 min. After each 
mouse was placed on the drum, acceleration was started. The latency a mouse stayed on the 
drum till falling was recorded. Motor learning was measured by repeating the test 24 hours later.  
 
2.13.6 Grip Strength  
To assess the forelimb grip strength, a grip strength meter (TSE Systems GmbH) was used. 
Mice were held by their tail and lifted to enable then grasp a wire grid using their forepaws. The 
mice were then gently pulled backward facing the surface of the table until they released the grid. 
The peak force applied by the forelimbs of the mouse was recorded. Each mouse was tested three 
times, and the average of these three measurements was used for further statistical analysis. 
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2.13.7 Hearing  
In order to restrict mouse movement, individual mice were placed into small metal cages (90 
× 40 × 40 mm), which were attached with a movable platform connected to a sensor that records 
vertical movements of the mice. Then, the cages were placed in sound-attenuating cabinets 
individually (TSE Systems GmbH). Mice were exposed to acoustic stimuli delivered from a 
loudspeaker, which were controlled by an acoustic generator. The startle response evoked by an 
acoustic stimulus was recorded with a computer for further analysis. The recording period was 
defined from the onset of the acoustic stimulus. Each session started with a 2 min habituation to 
65 dB background white noise that lasted throughout the session, which was followed by a 
baseline recording for 1 min. Afterwards, stimuli with different intensity were presented and 
each stimulus lasted for 40 ms. The intensity of stimuli ranged from 65 dB to 120 dB, increased 
with 3 dB per step. All intensity was presented 10 times in a pseudorandom manner with an 
inter-stimulus-interval of 8 to 22 sec. The amplitude of the startle response (in arbitrary units) to 
each stimulus was defined as the difference between the maximum movement detected and the 
movement measured immediately before the stimulus onset. Amplitudes of responses toward 
each stimulus with same intensity were averaged for individual mice.  
 
2.13.8 Marble burying  
This test was applied to investigate stereotypes and obsessive-compulsive behavior in mice. 
A plastic cage (34.5 × 56.5 × 18 cm) filled with 5cm deep wood-chip bedding was placed in a 
room with dim light (6 lx). 24 glass marbles were positioned on top of the bedding. The marbles 
were placed in 6 rows with 4 marbles per row at a distance of 4 cm. Each mouse was released 
into the cage and could freely manipulate the marbles for 30 min. Number of buried marbles (to 
2/3 their depth) was counted.  
 
2.13.9 Visual cliff  
To assess more profound visual deficiencies, e.g. contrast perception, a transparent Perspex 
board (63 × 29 cm) attached to a grey Perspex shelf (31.5 × 29 × 54 cm) as depicted below was 
used: 
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The transparent board was positioned in the way that half of the board was placed on the 
shelf with white paper below (“ground” side), and the other half was 54 cm above the floor 
(“air” side). Some objects were placed around the apparatus as visual cues for depth perception. 
Mice were placed in the middle of the “ground” area, and their activity was monitored for 5 min 
by a computer and the video-tracking system “Viewer 2” (Biobserve GmbH,). The time spent in 
each area was recorded and the percentage of time in the “ground” and the “air” areas was used 
for statistical analysis. The light intensity in the room was 120 lx.   
 
2.13.10 Novel object recognition 
This test was designed to assess an animal’s spatial and non-spatial working memory, 
following the modified protocol as described previously (Roullet et al., 1996).  The apparatus 
used was a grey Perspex arena (60 cm in diameter, 40 cm high) positioned in the middle of a 
room with illumination at 120 lx. The ground of the arena was divided into different sectors and 
covered by a layer of glass as illustrated below. As the only visual cue in the uniformed 













  ground air 
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Every mouse underwent 7 sessions. After released from position “S”, animals were allowed 
to explore the area for 7 min with the 3 min inter-session interval. In the session 1, individual 
mice were placed into the empty arena for habituation. From session 2 to 4, four different white 
Perspex objects were placed in a square arrangement at position A, B, C and D. During session 5 
and 6, the object at position D was moved to the position E for assessing the spatial memory. In 
the final session 7, the white object at position B was replaced by a new black object for 
examining the non-spatial memory. The activity and time mice spent on exploring individual 




Two days before habituation, 2 pieces of chocolate cookies per animal per day were placed 
into the cages. For habituation to testing environment, mice were placed into the test cages (29.5 
× 18.5 × 13 cm) with a visible piece of cookie inside per trial. The cookie was placed randomly 






In every trial, mice were released in the center of the cage and allowed to explore the 
environment for 10 min. All mice underwent 4 trials per day with an inter-trial interval of approx. 
50 min. After two days of habituation, mice were food deprived overnight while water was 
available ad libitum and 2 small pieces of cookie were placed within the homecage. 
On day 5 the test took place. Individual mice were placed into test cages with a chocolate 
cookie hidden 1 cm under the standard bedding at position A, B, C or D. Mice were allowed to 
look for the hidden cookie for 5 min per trial. Each animal was tested twice with an inter-trial 
interval of approx. 100 min. The latency from the time when the animals were released in the 
cage until they found the cookie was recorded. The average time of two trials was the measure of 
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the integrity of the olfactory system. 
In order to control for other sensory, motor or motivational deficiencies that might influence 
the food-finding latency, the test was repeated as described above with a piece of cookie clearly 
visibly placed on the bedding. A fresh cage and bedding was used for each trial, and all mice 
were subjected to identical testing procedures.  
 
2.13.12 Morris water maze 
Spatial learning and memory was assessed in a water maze as described previously (Morris, 
1984; Radyushkin et al., 2010). Firstly, a circular tank (diameter 1.2 m, depth 0.4 m) was filled 
with opaque water (25 ± 1°C, depth 0.3 m). The swim patterns of mice were monitored by the 
video-tracking system “Viewer 3” (Biobserve GmbH). The escape latency, swim speed, path 
length and trajectory of swimming were recorded for each mouse. During the first 2 days, mice 
were trained to find a hidden escape platform (10 × 10 cm) submerged 1 cm below the water 
surface tagged with a 15-cm high black flag. The platform was located pseudo-randomly in 
different locations across trials. Mice underwent two days of training in the visible condition, 
followed by hidden platform training (acquisition) where the flag was removed. For 8 days, mice 
were trained to find a hidden platform that was placed at the center of one of the four quadrants 
of the tank. Throughout the acquisition, the platform for each mouse was fixed. Mice had to 
orientate themselves using spatial cues that were placed on the walls of the testing room. Every 
day, each mouse performed four trials with an inter-trial interval of 5 min. Mice were released 
into the pool facing the sidewall at one of four start locations and allowed to search for the 
platform until they found it, or for a maximum of 90 sec. Any mouse that failed to find the 
platform within 90 sec was guided to the platform and remained on the platform for 20 sec 
before being removed from the pool. The next day after the hidden platform training, a probe 
trial was conducted to determine if mice developed a spatial preference to the location where the 
platform was. After removal of the platform, mice were allowed to swim freely for 90 sec. The 
percentage of time spent in each quadrant of the pool as well as the number of times the mice 
crossed the former position of the hidden platform were recorded. When no genotype differences 
were observed, mice were subjected to the reversal spatial learning after the probe trial. The 
reversal learning was applied following the same procedure as the spatial training but the 
platform was placed on the opposite quadrant of the previous location used in the hidden 
platform acquisition. The reversal learning lasted for four days followed by a probe trial.   
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2.13.13 Hot plate test 
To measure pain perception, the hot plate test was applied. Mice were placed onto a metal 
plate (Ugo Basile, Italy) that was preheated up to 55°C. The latency to show hind paw licking or 
jumping was recorded. Mice were removed from the plate immediately after appearance of the 
response or after 40 sec stayed on the plate to protect mice from injury. 
 
2.13.14 Cued and contextual fear conditioning 
The fear conditioning test was applied to assess the mice’s associative memory. Mice were 
first trained within the same session for both contextual and cued fear conditioning. During the 
training session, mice were placed in the conditioning chamber (context) for 120 sec to assess 
the baseline level of activity. This period was followed by a 10 sec, 5 kHz, 85 dB tone (condi-
tioned stimulus, CS). Immediately after the tone, a 2 sec, 0.4 mA foot shock (unconditioned 
stimulus, US) was applied. This CS-US pairing was repeated 13 sec later. The individual mice 
remained in the chamber for an additional 23 sec following the second CS-US pairing. 24 hours 
after training, mice were positioned into the same context (the same chamber) and monitored 
over 2 min for freezing to examine the contextual memory. The cued memory test was then per-
formed 27 hours after training in a new chamber. First, freezing response in the new context was 
monitored over a 2 min pre-cue period with no tone followed by a 2 min cued period when the 
tone (cue) was presented. Duration of freezing behavior, defined as the absolute lack of move-
ment (excluding respiratory movements), was recorded by a video camera connected to a PC 






3.1 Characterization of the expression and function of RNF157 
The balance between cell survival and cell death is essential for the development and 
maintenance of a functional neuronal network. Therefore, the molecules that mediate neuronal 
apoptosis draw much attention. Accumulating evidence suggests a role of the ubiquitin-
proteasome system (UPS) in controlling apoptosis. Since E3 ligases function as quality control in 
UPS, we attempted to investigate the role of E3 ligases in neuronal apoptosis. Here, the brain-
dominant E3 ligase RNF157 was in focus. Our previous gain- and loss-of-function analyses 
indicated that the brain-dominant E3 ligase RNF157 promotes survival in cerebellar granule 
neurons. Subsequent experiments showed that Fe65 acts downstream in the RNF157-mediated 
survival pathway (Matz et al., in press). Following these results, I used both in vitro and in vivo 
techniques to expand the understanding of RNF157 as a regulator of neuronal survival. 
 
3.1.1 RNF157 is present in neuronal and non-neuronal cell types in the brain 
Previous analyses in our lab showed the E3 ligase RNF157 is predominately expressed in 
the postnatal and adult brain, with abundant expression in e.g. cerebellar granule neurons and 
cortical neurons (Matz et al., in press). Here, I carried out further analyses of RNF157 expression 
in other cell types. 
 Started out by validating the specificity of a new RNF157 antibody, I generated a 
recombinant rat RNF157 protein (Fig 3.1a) that contains amino acids 562 to 617 of the RNF157 
protein. Importantly, this recombinant protein was anticipated to be recognized by the RNF157 
antibody. Next, I used lysates of cultured cortical, hippocampal and cerebellar granule neurons 
and subjected them to immunoblotting with RNF157 antibody. While I found a band at 110 kDa 
in the RNF157 antibody condition, the preabsorption with recombinant RNF157 protein led to 
the disappearance of this band (Fig 3.1b), indicating the specificity of the RNF157 antibody. It is 
also noteworthy to mention that the calculated molecular weight of RNF157 (70 kDa, 644 amino 
acids) differed from the 110 kDa owing to the acidic nature of RNF157, which results in slow 
migratory behavior (Matagne et al., 1991). Furthermore, lysates from astrocytes and 




antibody (Fig 3.1c). Interestingly, RNF157 could also be detected in these non-neuronal cell 
types. Taken together, RNF157 is expressed in astrocytes and oligodendrocytes in addition to its 
robust expression in cultured cortical, hippocampal and cerebellar granule neurons. 
 
 
3.1.2 RNF157 is strongly expressed in various brain regions  
Following the expression analysis in cell lysates, I went on to examine the spatial 
distribution of RNF157. In order to analyze the expression pattern and function of RNF157 in 
vivo, we generated a conventional mouse, in which a gene trap containing β-Geo gene was 
inserted into the second intron of Rnf157 gene to disrupt the transcription of RNF157 (Fig 3.2a). 
Instead, the β-Geo gene results in the expression of β-galactosidase driven by the endogenous 
RNF157 promoter. For genotyping, two sets of primers were designed to specifically detect the 
wild type or the mutant allele as described in chapter 2.12.2. The result of a representative 
genotyping PCR is illustrated in Fig 3.2b.  
Next, I verified if the gene trap successfully deleted the expression of full length RNF157. 
Lysates of cortices and hippocampi isolated from wild type, heterozygous and homozygous 
postnatal day 5 (P5) RNF157 transgenic mice were subjected to immunoblotting with the β-Gal 
antibody and the RNF157 antibody. β-Gal was expressed in the RNF157+/- and the amount 










Fig 3.1 RNF157 is expressed in different cell types in the brain.  
a) Immunoblotting of recombinant RNF157 protein using Flag or RNF157 
antibodies.  
b) Cultured cortical (CTN), hippocampal (HTN) and cerebellar granule 
neurons (CGN) were lyzed and subjected to immunoblotting with RNF157 
antibody, RNF157 antibody preabsorbed with antigen or γ-Tubulin antibody. 
γ-Tubulin served as loading control. 
c) Lysates from cultured hippocampal (HTN), cerebellar granule neurons 
(CGN), astrocytes and oligodendrocyte precursor cells (OPC) were 





observed in the RNF157-/- brain while only half of the amount was expressed in RNF157+/- mice 
as compared to the wild type (RNF157+/+) (Fig 3.2c). The mice with homozygous deletion of the 
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In addition, I subjected sagittal brain sections of P28 RNF157-/- mouse and its wild type 
littermate to X-Gal staining (Fig 3.2d). While the staining of the section of the wild type mouse 
gave expectedly no results, I found strong enzymatic β-galactosidase activity throughout the 
whole brain of the RNF157-/- mouse. I observed a particularly strong expression observed in the 
cortex, hippocampus, midbrain, thalamus and hypothalamus, while the signal in the cerebellum 
was more restricted to Purkinje cell layer with a low expression level in the molecular and 
granule cell layer. In summary, these results confirmed that indeed RNF157 is expressed in 
various cell types in the brain.  
 
3.1.3 RNF157 localizes to cytoplasm 
To refine our previous findings in which we described that RNF157 is a component of the 
postnuclear fraction in a subcellular fractionation experiment (Matz et al., in press), I carried out 
a more elaborate method to support a potential cytoplasmic localization. Together with N. 
Schwedhelm-Domeyer, I purified the cytoplasm from P5 wild type mouse cortex by applying 
two steps of ultracentrifugation at 21000 g and 257000 g to remove the plasma membrane and 
the heavy membrane. The collected fractions were subjected to immunoblotting analysis with the 
RNF157 antibody. The nuclear marker SnoN, the plasma membrane marker N-Cadherin and the 
cytoplasmic marker pan 14-3-3 were included as quality control for the fractions. The result 
revealed that RNF157 is a cytoplasmic protein (Fig 3.3). 
 
 
Fig 3.2 RNF157 is expressed in the brain.    
a) Schematic representation of RNF157 genomic structure and the location of the gene trap cassette encoding the 
β-galactosidase (β-Gal). 
b) Genomic DNA was isolated from mouse tail biopsies and subjected to PCR amplification. The upper band at 
498 bp represents the wild type fragment while the lower band at 280 bp indicates the mutant fragment. 
c) Lysates of cortices and hippocampi isolated from P5 mice were immunoblotted using the β-galactosidase or 
the RNF157 antibody. 14-3-3β served as loading control. The asterisk indicates a non-specific band.  
d) X-Gal staining of a sagittal brain section of a 28-day-old RNF157 homozygous mouse. Blue spots indicate the 
activity of RNF157 promoter. Inset is the X-Gal staining of a section from a wild type mouse, where no X-Gal 
signals can be detected. CTX, cortex; HP, hippocampus; MB, midbrain; CB, cerebellum; CP, caudate putamen; 
TM, thalamus; AN, anterior olfactory nucleus; VS, ventral striatum; HT, hypothalamus; P, pons; M, medulla. 






3.1.4 Altered major pathways regulating cell survival due to deletion of RNF157 
Having established the subcellular localization of RNF157, I determined the functional 
consequence of loss-of-RNF157 for neuronal survival in vivo. Although the RNF157-/- mice are 
viable, a dysregulation of cell survival/apoptosis pathways could not be excluded. One of the 
critical regulators of neuronal survival is the serine-threonine kinase Akt, which has been 
implicated in various survival pathways and whose active phosphorylated form was reported to 
be neuroprotective (Datta et al., 1999; Lu and Xu, 2006b).  Another important regulator of cell 
survival, the extracellular-signal-regulated kinase, Erk, has been shown to have pro-survival as 
well as pro-apoptotic functions in various conditions (Lu and Xu, 2006b). Hence, I went on to 
investigate the level of total Akt, total Erk, activated Akt and activated Erk in the RNF157-/- mice. 
P5 cortical and hippocampal tissues from RNF157-/- animals and their control littermates 
were subjected to immunoblotting with Erk, phosphorylated Erk (pErk), Akt and phosphorylated 
Akt (pAkt) antibodies. I found that the total amount and the active forms of these kinases were 
unchanged at P5 (Fig 3.4a, b). Next, cerebella, hippocampi and cortices of 10-week-old mice 
were lysed and immunoblotted with the abovementioned antibodies. Surprisingly, while the total 
amount of Akt and Erk remained unaltered in the 10-week-old mice, a clear reduction of pAkt 
and pErk was detected (Fig 3.4c). These results indicated that although loss-of-RNF157 did not 
have an immediate effect upon neuronal survival in vivo, but it induced an age-dependent 
alteration of the major survival/apoptotic regulators. Taken together, these data support the 
notion that RNF157 is involved in maintaining neuronal health. 
  
 
Fig 3.3 RNF157 is present in the cytoplasm.  
Lysates of P5 mouse cortex was subjected to 
subcellular fractionation analysis. The nuclear 
fraction (NF) was first separated. The remaining 
post-nuclear supernatant (PNS) containing 
plasma membrane, heavy membrane and 
cytoplasm was further ultra-centrifuged. The 
resulting fractions PNS I, Pellet I, PNS II, Pellet 
II and cytoplasm were immunoblotted with 
RNF157, SnoN (nuclear fraction marker), N-
Cadherin (plasma membrane marker) and pan 14-
3-3 antibodies (cytoplasmic marker). Lysates of 
wild type and RNF157-/- mouse cortices served 







3.1.5 Functional analysis of RNF157 in hippocampal neurons 
Having confirmed a potential role of RNF157 in neuronal viability in vivo, I set out to 
analyze the function of RNF157 in hippocampal neurons. A previous study in our lab described 
that RNF157 regulates neuronal survival using cerebellar granule neurons as a model system 
(Matz et al., in press). Since RNF157 exhibited a robust expression in hippocampal neurons, I 
asked if the pro-survival RNF157 pathway also operates in hippocampal neurons. To answer this 
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Fig 3.4 Loss of RNF157 led to age-
dependent downregulation of active Akt 
and active Erk.    
a) Cortical and b) hippocampal lysates of P5 
wild type, RNF157 heterozygous or 
homozygous mice were immunoblotted using 
the total Akt, total Erk, phosphorylated Akt 
(pAkt), phosphorylated Erk (pErk) and 14-3-
3β antibodies. The latter served as loading 
control. 
c) Tissue lysates of 10-week-old mouse 
cerebella, cortices and hippocampi were 
subjected to immunoblot analysis with the 
total Akt, total Erk, phosphorylated Akt 
(pAkt), phosphorylated Erk (pErk) and 14-3-
3β antibodies. The latter serves as loading 






question, I first examined the efficacy of the RNF157 RNAi construct in neurons for the further 
experiments. 
Since RNF157 RNAi construct #3 was most efficient in knocking down exogenous RNF157 
in HEK293T (Matz et al., in press), I have used this plasmid throughout the study and referred to 
it as RNF157 RNAi. To examine endogenous knockdown of RNF157 in neurons, I nucleofected 
isolated cortical neurons with U6 control vector or with RNF157 RNAi plasmid together with 
the Bcl-xL and GFP expression plasmids. At day in vitro (DIV) 5, neurons were lysed and 
subjected to immunoblotting with RNF157 and γ-Tubulin antibodies (Fig 3.5a). The result 
indicates that expression of the RNF157 RNAi plasmid induces efficient endogenous knockdown 
of RNF157 in cortical neurons.  
It has been demonstrated that loss-of-RNF157 in cerebellar granule neurons as well as 
hippocampal neurons leads to cell death (Matz et al., in press). To exclude that the RNF157 
RNAi-induced apoptosis in hippocampal neurons is an off-target effect, I carried out rescue 
experiments using the RNF157-Rescue (RNF157-Res) construct previously generated in the lab. 
RNF157-Res harbors 6 silent mutations in the RNF157 RNAi targeting region and thus is 
resistant to knockdown. Cultured hippocampal neurons were transfected at DIV2 with the 
control vector, RNF157 RNAi, RNF157-Res plasmid, or both of the RNF157 RNAi and 
RNF157-Res expression plasmids together with the β-Gal construct. After 5 days, hippocampal 
neurons were subjected to immunocytochemistry and analyzed. Here, I found that while RNF157 
knockdown led to a significant increase in cell death, expression of RNF157-Res in the 
background of RNF157 knockdown significantly protected hippocampal neurons from apoptosis 
(Fig 3.5b). Together with our previous finding, my result suggests that RNF157 serves as a pro-
















Fig 3.5 Knockdown of endogenous RNF157 leads to increased apoptosis in hippocampal neurons.  
a) Lysates of cortical neurons, nucleofected with U6 control plasmid or RNF157 RNAi plasmid, were 
immunoblotted with RNF157 and γ-Tubulin antibodies. The latter served as loading control.  
b) Hippocampal neurons transfected at DIV2 with control vector, the RNF157 RNAi, the RNF157-Res plasmid, 
or both the RNF157 RNAi and RNF157-Res plasmids together with β-gal expression plasmid, were fixed after 5 
days and analyzed. A total of 1099 neurons from 4 independent experiments were included in the analysis 
(ANOVA, *** p<0.001, mean +s.e.m.). 
 
3.2 Fe65, a novel interactor of RNF157, regulates neuronal survival in 
different neuronal types  
Previously, Fe65 has been identified as an interactor of RNF157 and overexpression of Fe65 
promotes cell death in cerebellar granule neurons (Matz et al., in press). I reasoned that Fe65 
could have the same role in controlling neuronal survival in hippocampal neurons. Moreover, 
Fe65 was reported to be present in the nuclear and cytoplasmic extracts of PC12 cells (Minopoli 
et al., 2001) and previous data in the lab showed that the nuclear Fe65 (NLS-Fe65, NLS refers to 
nuclear localization signal) but not the cytoplasmic Fe65 (NES-Fe65, NES is nuclear export 
signal) contributes to the apoptotic phenotype in cerebellar granule neurons (Matz et al., in press). 
Therefore, I first asked if Fe65 localizes to nucleus and cytoplasm in neurons. Furthermore, I 
addressed if Fe65 is pro-apoptotic in the hippocampal neurons and if the localization of Fe65 is 
essential for its role in apoptosis.  
 
3.2.1 Fe65 localizes to the nucleus and cytoplasm of cerebellar granule neurons 
and cortical neurons 
 To confirm the nuclear and cytoplasmic localization of Fe65 in neurons, cultured cerebellar 
granule neurons and cortical neurons were subjected to subcellular fractionation experiments and 
immunoblotted with the Fe65, SnoN, Sp1 or 14-3-3β antibodies. While SnoN and Sp1 are 
nuclear proteins, 14-3-3β is found in the cytoplasm. The results revealed that in neurons, Fe65 is 
present in the nucleus as well as in the cytoplasm (Fig 3.6a, b).  
Since the Fe65 antibody failed to work in immunocytochemistry, I overexpressed myc-Fe65 
in HEK293T cells and stained the cells with myc antibody together with the DNA dye DAPI. 
The analysis of confocal images also supported the fractionation studies that Fe65 is localized to 







3.2.2 Nuclear Fe65 is the main contributor to cell apoptosis in hippocampal 
neurons  
Next, I analyzed the role of Fe65 and the relevance of its localization in neuronal survival in 
hippocampal neurons. I transfected cultured hippocampal neurons at DIV2 with control vector, 
wild type Fe65, NES-Fe65 or NLS-Fe65 plasmids together with the β-Gal plasmid. At DIV 6, 
neurons were fixed and subjected to viability analysis. As previously reported by A. Matz, wild 
type Fe65 and NLS-Fe65 were equally potent in triggering neuronal apoptosis. Interestingly, I 
found that overexpression of NES-Fe65 also led to a significant increase in apoptosis. The 
stimulation however was not as potent as wild type Fe65 or NLS-Fe65 (Fig. 3.7).  This result 
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Fig 3.6 Fe65 localizes to the nucleus and cytoplasm in neurons as well as HEK293T cells.  
a), b) Cerebellar granule neurons (CGNs) and cortical neurons were subjected to subcellular fractionation 
experiments and then immunoblotted with Fe65 antibody. SnoN and SP1 antibodies were used as quality control 
for postnuclear supernatant (PNS) while 14-3-3β served as control for nuclear fraction (NF). The analysis of 
cerebellar granule neurons was done by M. Kannan. 
c) HEK293T cells were transfected with myc-Fe65 and subjected to immunochemistry analysis with the myc 





Fig 3.7 Nuclear Fe65 is the main contributor in triggering 
neuronal apoptosis in hippocampal neurons. 
Hippocampal neurons transfected at DIV2 with control vector, wild 
type Fe65, NES-Fe65 or NLS-Fe65 plasmids together with β-Gal 
expression plasmid were fixed at DIV6 and subjected to 
quantification of apoptotic neurons. A total of 1361 neurons from 4 
independent experiments was included in the analysis (ANOVA, 




3.2.3 Fe65 acts downstream of RNF157 to regulate neuronal survival  
Since Fe65 is an interactor of RNF157, we then asked if they act in a linear pathway to 
control neuronal survival. Prior to epistasis analysis, I first verified the endogenous knockdown 
of Fe65 by the Fe65 RNAi plasmid. I nucleofected isolated cortical neurons with either U6 
control vector or Fe65 RNAi together with the Bcl-xL and GFP expression plasmids. Neurons 
were lysed 5 days later and subjected to immunoblotting with Fe65 and γ-Tubulin antibodies 
(Fig 3.8a). The result showed that the Fe65 RNAi triggered efficient endogenous knockdown of 
Fe65 in cortical neurons. 
 
 
Using the Fe65 RNAi, epistasis analysis was performed by A. Matz. Here, hippocampal 
neurons were transfected with control vectors, RNF157 RNAi, Fe65 RNAi or both RNF157 
RNAi and Fe65 RNAi together with β-Gal expression plasmid at DIV2. After 4 days, neurons 
were fixed and the apoptotic rate was analyzed. The neurons transfected with RNF157 RNAi 
showed a strong increase in apoptosis as compared to the control condition, the Fe65 knockdown 
or the RNF157/Fe65 double knockdown (Fig 3.8b, c). This result suggested that Fe65 
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Fig 3.8 Fe65 acts downstream of RNF157 in a linear pathway to regulate neuronal survival.  
a) Lysates from cortical neurons electroporated with U6 control vector or Fe65 RNAi plasmid were 
immunoblotted with Fe65 and γ-Tubulin antibodies. The latter served as loading control.  
b) Hippocampal neurons were transfected at DIV2 with plasmids encoding control vectors, control vector with 
RNF157 RNAi, Fe65 RNAi with control vector, or Fe65 RNAi and RNF157 RNAi together with β-Gal plasmid. 
Four days later, neurons were subjected to immunocytochemistry with the β-Gal antibody and the DNA dye 
DAPI and the apoptotic rate was quantified. A total of 1305 neurons in 3 independent experiments was analyzed. 
This experiment was done by A. Matz. (ANOVA, *** p<0.001, mean+s.e.m.). 
c) Representative images of neurons in Fig 3.7b. Insets depict the nuclei of transfected neurons. The arrow 




knockdown protects neurons from RNF157-knockdown induced neuronal death and indicated 
that Fe65 acts downstream of RNF157 in the control of neuronal survival.  
 
3.2.4 RNF157 ubiquitinates Fe65 with lysine 63-linked ubiquitin chain 
Having established that RNF157 acts together with Fe65 in a linear pathway in the control 
of neuronal survival, we set out to examine if Fe65 is a substrate of RNF157. First we analyzed 
if RNF157 has ligase activity and could autoubiquitinate itself. Since the RING domain is 
necessary to recruit the E2-ubiquitin conjugate, we generated a deletion mutant of RNF157 
lacking the RING domain, which was anticipated to be ligase-dead. Then, the autoubiquitination 
assay was carried out by N. Schwedhelm-Domeyer, where she transfected HEK293T cells 
transiently with the myc-RNF157 or the myc-RNF157 ∆RING construct together with HA-
ubiquitin plasmid. Next, the lysates were collected, denatured and immunoprecipitated with myc 
antibody followed by immunoblotting with HA antibody for ubiquitin. The result indicated a 
clear autoubiquitination response upon overexpression of wild type RNF157 but not RNF157 
∆RING (Fig 3.9a). 
Additionally, I also tested if Fe65 responds to a deubiquitinase (DUB) inhibitor, N-
ethylmaleimide (NEM). The addition of NEM blocks DUB activity (Kapuria et al., 2010) and 
thus the attached ubiquitin on a substrate would be preserved. If a protein is ubiquitinated, a 
mobility shift using SDS-PAGE analysis should be observed with NEM treatment. Here, mouse 
cortical tissue was treated with either vehicle or 5 mM NEM during lysis and subjected to 
immunoblotting with Fe65 and γ-Tubulin antibodies. A clear shift could be detected in the 
condition with NEM (Fig 3.9b), indicating that Fe65 can be indeed ubiquitinated.  
Then we went on to determine if Fe65 is a substrate of RNF157. The ubiquitination assay 
was conducted by A. Matz to analyze if RNF157 ubiquitinates Fe65 and if the ubiquitination is 
ligase-activity-dependent. Moreover, the type of ubiquitin chain which was transferred to Fe65 
was also investigated. For this experiment, Flag-Fe65 was expressed in HEK293T cells together 
with either myc-RNF157 or the myc-RNF157 ∆RING and with HA-tagged wild type ubiquitin 
or ubiquitin mutants K48R or K63R which are not able to form lysine (K)48 or K63-linked 
ubiquitin chain, respectively. Cell lysates were denatured, immunoprecipitated with Flag-
sepharose beads and immunoblotted with the HA antibody. The results showed that while wild 




these results also demonstrated that RNF157 ubiquitinated Fe65 via K63-linked chain as the 
ubiquitin-smear disappeared in the condition with K63R ubiquitin, where the formation of K63-
chain was abolished (Fig 3.9c). 
 
Taken together, these experiments indicated that Fe65 is ubiquitinated by RNF157, which 
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 Fig 3.9 RNF157 is a RING E3 ligase and 
ubiquitinates Fe65.  
a) HEK293T cells, transfected with myc-
RNF157 or myc-RNF157 ∆RING plasmid 
together with HA-ubiquitin plasmid, were 
lysed and subjected to a denaturing protocol, 
immunoprecipitated with myc antibody 
followed by immunoblotting with HA 
antibody. Courtesy of N. Schwedhelm-
Domeyer 
b) Mouse cortical tissues were lysed with 
additional control or 5mM NEM. Lysates 
were immunoblotted with Fe65 and γ-
Tubulin antibodies.  
c) Lysates of HEK293T cells, transfected 
with myc-RNF157 or myc-RNF157 ∆RING 
construct together with Flag-Fe65 and HA-
tagged ubiquitin or indicated ubiquitin 
mutants, were denatured and subjected to 
immunoprecipitation with Flag-sepharose 
beads followed by immunoblotting with HA 






3.2.5 Ubiquitination of Fe65 via RNF157 leads to Fe65 degradation 
Having identified Fe65 as a substrate of RNF157, I examined the consequence of the 
ubiquitination. Growing evidence has suggested the role of K63-linked ubiquitination in 
functional modification as well as lysosome-mediated degradation (Lim and Lim, 2011). 
However, the possibility that K63-linked ubiquitination leads to proteasomal degradation cannot 
be excluded (Saeki et al., 2009). Therefore, I first examined if ubiquitination of Fe65 leads to its 
degradation in vivo. I collected the cortical and hippocampal tissues from P5, 6 weeks and 10 
weeks old RNF157+/+ and RNF157-/- mice. Tissues were lysed and subjected to immunoblotting 
with the Fe65 antibody. While I found a slight upregulation of Fe65 in the brain of P5 RNF157-/- 
mice, I detected a significant increase at the age of 6 weeks and 10 weeks, indicating an age-
dependent upregulation of Fe65 (Fig 3.10a, b). Moreover, to establish that the upregulation of 
Fe65 is a consequence of post-translational modifications, we further analyzed the mRNA level 
in the RNF157-/- mice by quantitative PCR. First, I designed the primers for Fe65. Then total 
RNA was isolated from cortices of P5 and 10-week-old wild type and RNF157-/- littermates (3 
pairs). The quantitative PCR was carried out by N. Schwedhelm-Domeyer and we found that 
Fe65 mRNA expression remained unaffected in the RNF157-/- brain (Fig 3.10c). 
As mentioned in chapter 3.2.2, the localization of Fe65 influences neuronal apoptosis. 
Hence, I went on to examine if the accumulation of Fe65 is restricted to a certain compartment in 
the cell using subcellular fractionation analysis. Cortical tissues isolated from 6-week-old 
RNF157+/+ and RNF157-/- mice were separated into the nuclear fraction (NF) and the postnuclear 
supernatant (PNS). Interestingly, I found that Fe65 was upregulated both in the PNS and NF (Fig 
3.10d). On comparing the cytoplasmic Fe65, which also contained phosphorylated versions of 
Fe65, nuclear Fe65 appeared to be unphosphorylated. An additional Fe65 antibody/antigen 
competition experiment confirmed the specificity of these Fe65 bands (Fig 3.10e). Taken 
together, these results suggested that RNF157 is required for the ubiquitination of Fe65 and loss-




























3.2.6 The degradation of Fe65 is mediated by the proteasome 
Due to the slow accumulation of Fe65, I asked how Fe65 is degraded. Proteins are degraded 
via two major pathways: by either lysosomes or proteasomes (Ciechanover, 2013; Korolchuk et 
al., 2010). Therefore, I first tested if treatment of neurons with lysosomal inhibitors alters the 
protein level of Fe65. 24 hours before lysis, cultured cortical neurons were treated with either 
leupeptin or NH4Cl. The lysates were immunoblotted with Fe65, APP (positive control for 
lysosomal inhibition) and β-Actin antibodies (Fig 3.11a, b). While APP accumulated in the 
neurons treated with lysosomal inhibitors, Fe65 level appeared to be stable. This indicates that 
Fe65 is not degraded by the lysosomal pathway.  
On the other hand, cultured hippocampal neurons were treated with the proteasomal 
inhibitor, lactacystin, and subjected to immunoblotting analysis with Fe65, SnoN (positive 
control for proteasomal inhibition) and γ-Tubulin antibodies. Aside from the mobility shift of 
Fe65 upon lactacystin treatment, I also observed an increase of Fe65 levels (Fig 3.11c), which 
could mean that Fe65 level is regulated by the proteasome. My results indicated that Fe65 is 







Fig 3.10 Loss of RNF157 led to slow accumulation of Fe65.    
a) Cortical and b) hippocampal lysates of P5, 6-week-old as well as 10-
week-old wild type or RNF157 knockout mice were immunoblotted using 
the Fe65 antibody. γ-Tubulin served as loading control. The lower panel 
indicates the quantification of the Fe65 level normalized to the loading 
control. (Student’s t-test, n.s.=non-significant, *=p<0.05, **=p<0.01) 
c) Quantitative PCR of Fe65 mRNA expression in P5 and 10-week-old 
cortices of wild type and RNF157-/- mice. Three independent littermates 
were analyzed (Student’s t-test, n.s.=non-significant). 
d) 6-week-old wild type and  RNF157-/- cortices were subjected to subcellular fractionation followed by 
immunoblotting with the Fe65, SnoN and pan 14-3-3 antibodies. SnoN served as quality control for nuclear 
fraction and pan 14-3-3 for postnuclear supernatant. 
e) Subcellular fractions of 21 weeks cortical tissue were immunoblotted with the rabbit Fe65 antibody, that was 
used throughout the paper, the goat Fe65 antibody and the goat Fe65 antibody pre-absorbed with the Fe65 
antigen, SnoN and α-Tubulin antibodies. The latter two served as quality control for nuclear fraction and 





3.3 Potential players involved in the RNF157/Fe65 survival pathway 
To enhance our understanding of RNF157 and its interactor Fe65 in neuronal survival, we 
set out to identify further components, which might act in this pathway. In the following, I 
analyzed the expression and function of three Fe65-interacting proteins and examined if they 
operate together with RNF157 and Fe65 in the control of neuronal survival. 
 
3.3.1 RNF157 competes APP for the binding with Fe65  
One of the previously characterized interaction partners of Fe65 is the amyloid precursor 
protein (APP) (Borg et al., 1996; Fiore et al., 1995; Guenette et al., 1996b). Various studies 
implicated APP and in particular its cleavage products in the development of Alzheimer’s disease 
(Hardy and Selkoe, 2002). The interaction between Fe65 and APP was found to affect the 
production of Aβ (Ando et al., 2001; Sabo et al., 1999). Since RNF157 interacts with Fe65 
through the PTB2 domain where APP interacts with Fe65, I first examined if RNF157 has an 
impact on the APP/Fe65 interaction. To address this question, I expressed wild type human APP 
(hAPP) and control vector or myc-Fe65 expressing plasmid together with increasing amounts of 
the GFP-RNF157 plasmid in HEK293T for immunoprecipitation analysis. Lysates of HEK293T 
were immunoprecipitated with the myc antibody and subjected to immunoblotting with the APP 
a 
        
b 
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Fig 3.11 Ubiquitination of Fe65 could result in its proteasomal degradation, not lysosomal degradation.  
a) Lysates of cortical neurons, treated with either vehicle or 100 µM leupeptin for 24 hours, were 
immunoblotted with Fe65, APP and β-Actin antibodies. The latter served as loading control. 
b) Lysates of cortical neurons, treated with either vehicle or indicated concentration of NH4Cl for 24 hours, 
were subjected to immunoblotting with Fe65, APP and β-Actin antibodies. The latter served as loading control. 
c) Hippocampal neurons treated with vehicle or 40 µM lactacystin for 8 hours were lysed, followed by 





antibody. Interestingly, I found that the interaction between APP and Fe65 decreased when the 
amount of RNF157 increased (Fig 3.12a). In addition to wild type APP, I also examined if 
RNF157 has similar effect on the interaction of Fe65 and the APP carrying the Swedish mutation 
(swAPP), since swAPP is more prone to Aβ production (Citron et al., 1994; Macq et al., 1998). I 
found that RNF157 outcompeted swAPP for its binding to Fe65 (Fig 3.12b). 
 
 
With these results in mind, I reasoned that RNF157 could influence the Aβ production by 
decreasing the binding affinity between Fe65 and APP. Since reports concerning the effect of 
Fe65 on Aβ production were controversial and the analyses were done using different 
experimental setups (Ando et al., 2001; Guenette et al., 2006; Sabo et al., 1999; Santiard-Baron 
et al., 2005), I set out to determine if Fe65 stimulates or inhibits the cleavage of APP. In addition, 
to study the impact of RNF157 on the production of Aβ since it competes APP for the binding 
with Fe65, I included RNF157 in the experiment. Here, I overexpressed either control plasmid, 
myc-Fe65, myc-RNF157, together with hAPP or swAPP in N2A cells and subjected the medium 
to an ELISA assay to examine the Aβ42 production. The results revealed that Fe65 appeared to 
promote the Aβ42 production through the cleavage of hAPP and swAPP, although the difference 
was not significant (Fig 3.13). Moreover, the influence of RNF157 on Aβ42 was not consistent 
(Fig 3.13). Taken together, RNF157 can compete the binding of Fe65 with APP and the 





Fig 3.12 RNF157 competes APP for the interaction with Fe65. 
Lysates of HEK293T cells, transfected with control vector, the myc-Fe65 plasmids, increasing amount of GFP-
RNF157 plasmid together with either a) hAPP or b) swAPP, were immunoprecipitated with the myc antibody and 










Fig 3.13 Fe65 might facilitate the 
production of Aβ 42 in N2A cells. 
N2A cells were transfected with 
control vector, myc-Fe65, myc-
RNF157, hAPP or swAPP plasmids 
and the medium was subjected to 
ELISA assay to determine the Aβ 
level. Blank refers to the condition of 
untransfected cells. 
 
3.3.2 Tip60, interacts with Fe65 at PTB2 domain, does not promote apoptosis 
Another interesting interaction partner of Fe65, which could be a potential player in this 
pathway, is Tip60. It was first identified as a HIV-1 Tat interaction protein which possesses 
histone acetyltransferase activity (Kamine et al., 1996; Kimura and Horikoshi, 1998; Yamamoto 
and Horikoshi, 1997). A previous study reported that a complex consisting of Fe65, Tip60 and 
amyloid precursor protein intercellular domain (AICD) can translocate into the nucleus to 
regulate gene transcription (Cao and Südhof, 2001). In addition, Tip60 was also shown to 
acetylate p53 and thus control the cell cycle arrest as well as apoptosis (Legube et al., 2004; 
Tyteca et al., 2006). Therefore, I examined if Tip60 is a potential player in RNF157/Fe65 













Then, I determined if Fe65 interacted with Tip60 through its PTB1 domain as reported (Cao 
and Südhof, 2001). Using the Fe65 mutant constructs generated in the lab (Fig 3.14b), I carried 
out the mapping analyses. To my surprise, Tip60 did not interact with the PTB1 domain and the 
interaction was robust whenever the PTB2 domain was included in the expressing constructs 
(Fig 3.14c). 
In further mapping analysis, I determined if deletion of either the PTB1, PTB2 domain or 
the amino acids between PTB1 and PTB2 domain abolished the interaction of Fe65 and Tip60. 
Hence, I generated three Fe65 mutant constructs, in which either the PTB1, PTB2 domain or the 
connection between PTB1 and PTB2 domain was removed (Fig 3.15a). As expected, 
immunoprecipitation analysis revealed that Tip60 still could bind to the Fe65 ∆PTB1 mutant 
although the interaction appeared to be weaker, this could be due to the lesser expression of 
Tip60. On the other hand, the interaction between Tip60 and Fe65 ∆PTB2 was not disturbed (Fig 
3.15b). Additionally, the Fe65 ∆B12 mutant still interacted with Tip60 (Fig 3.15b). These results 
indicate that the conformation of Fe65 or amino acid stretches adjacent to the PTB domains 





Fig 3.14 Tip60 interacts with Fe65 
at the region containing PTB2 
domain of Fe65. 
a) HEK293T cells, transfected with 
control vector, together with the 
myc-Fe65 or the Flag-Tip60 
plasmid or with both of the myc-
Fe65 and the Flag-Tip60 plasmids, 
were lysed, subjected to immuno-
precipitation with the myc antibody 
followed by immunoblotting with 
the Flag antibody.  
b) Domain structure of Fe65 
mutants. 
c) Lysates of HEK293T cells, 
transfected with control vector, the 
indicated myc-Fe65 constructs and 
the Flag-Tip60 plasmid, were 
immunoprecipitated with the myc 
antibody and subjected to immuno-
blotting with the Flag antibody. The 
arrowhead indicates the specific 
band and the asterisk indicates the 















Fig 3.15 Tip60 interacts with Fe65 at the 
region containing PTB2 domain of Fe65. 
a) Domain structure of Fe65 deletion 
mutants.  
b) Lysates of HEK293T cells, transfected 
with control vector, the indicating myc-Fe65 
plasmids and the Flag-Tip60 plasmid, were 
immunoprecipitated with the myc antibody 
and subjected to immunoblotting with the 
Flag antibody. The arrowhead indicates the 
specific band and the asterisk indicates the 





3.3.2.1 Overexpression of Tip60 does not trigger apoptosis 
In addition to biochemical analysis of the interaction of Fe65 and Tip60, I examined the role 
of Tip60 in neuronal survival. Here, I overexpressed Tip60 in cerebellar granule neurons for 
gain-of-function analysis. The results showed that Tip60 did not induce neuronal apoptosis (Fig 
3.16a).  Since Tip60 was reported to form a complex together with AICD and Fe65 to regulate 
gene transcription (Cao and Südhof, 2001), I examined if Tip60 would further enhance neuronal 
apoptosis upon Fe65 overexpression. Therefore, I transfected Tip60 together with Fe65 in 
cerebellar granule neurons to determine the apoptotic rate. As demonstrated before, Fe65 
induced neuronal apoptosis as compared to the control condition (Fig 3.16b). However, cell 
death was not increased when I co-expressed Tip60 on top of Fe65 expression. To sum up, Tip60 
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Fig 3.16 Tip60, an interactor of 
Fe65, does not promote neuronal 
death in cerebellar granule 
neurons.   
a) Cerebellar granule neurons were 
transfected at DIV2 with either the 
empty vector or the Tip60 plasmid 
together with β-Gal plasmid and 
subjected to immunohistochemistry at 
DIV6 with β-Gal antibody. A total of 
2434 neurons from 6 independent  
experiments was analyzed (Mann-Whitney U-test, n.s.= non-significant, mean +s.e.m.). 
b) Cerebellar granule neurons, transfected at DIV2 with either the control plasmid, Fe65 expressing plasmid or 
Fe65 and Tip60 plasmids together with β-Gal plasmid, were subjected to immunohistochemistry at DIV6 with β-
Gal antibody. A total of 1376 neurons from 4 independent experiments was analyzed (ANOVA, ** p<0.01, n.s.= 




3.3.3 Tip110, a novel interactor of Fe65, localizes to nucleus  
Since Tip60 is not pro-apoptotic in cerebellar granule neurons, we tried to identify another 
potential player in RNF157/Fe65 pathway. Since nuclear Fe65 potently induced neuronal 
apoptosis in neurons, I reasoned that the proteins interacting with nuclear Fe65 could have an 
impact on neuronal death. A yeast-two hybrid screen was therefore conducted by A. Matz using a 
human fetal brain cDNA library to search for nuclear interactors of Fe65. Here, we identified 
Tip110, a nuclear RNA-binding protein (Gu et al., 1998), as a potential interactor of Fe65. 
Tip110 is an HIV-1 Tat interacting protein (Liu et al., 2002) and has been implicated in RNA 
processing (Song et al., 2010), hematopoiesis (Liu et al., 2011), regulation of embryonic stem 
cells (Liu et al., 2012) as well as HIV-1-mediated gene transcription initiation and elongation 
(Liu et al., 2002; Zhao et al., 2014).  However, the role of Tip110 in neuronal survival has not yet 
been investigated. 
Therefore, I first confirmed the interaction of Fe65 and Tip110 in HEK293T cells (Fig 
3.17a). HEK293T cells were transfected with either the HA-Tip110 plasmid or the Flag-Fe65 
construct, or both of the HA-Tip110 and the Flag-Fe65 plasmids. Cell lysates were subjected to 
coimmunoprecipitation with the Flag antibody and immunoblotting with the HA antibody. I 
found that Tip110 interacted with Fe65. Next, I asked if Tip110 localizes to nucleus also in 




hippocampal neurons and observed an expected nuclear localization (Fig 3.17b), as already 
shown in HeLa cells (Gu et al., 1998). 
 
 
3.3.3.1 Tip110 promotes neuronal apoptosis  
Having established the interaction and localization of Tip110, I further asked if Tip110 has a 
role in mediating neuronal apoptosis. First of all, we conducted the gain-of-function analyses in 
cerebellar granule neurons as well as in the hippocampal neurons. Here, Tip110 was 
overexpressed together with β-Gal plasmid in the cultured neurons at DIV2. Neurons were fixed 
and analyzed at DIV6. Interestingly, overexpression of Tip110 induced cell death up to 2 folds as 
compared to the control cerebellar granule neurons (Fig 3.18a). In hippocampal neurons, Tip110 
induced an even stronger apoptotic phenotype (Fig 3.18b, c). These results indicated that Tip110 
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Fig 3.17 Tip110 interacts with Fe65 and localizes to the nucleus. 
a) Lysates of HEK293T cells, transfected with control vector, together with the Flag-Fe65 or the HA-Tip110 
plasmid or with both of the Flag-Fe65 and the HA-Tip110 plasmids, were immunoprecipitated with the Flag 
antibody and subjected to immunoblotting with the myc antibody.  
b) Hippocampal neurons were transfected with the HA-Tip110 plasmid and subjected to immunohistochemistry 






3.3.3.2 Tip110 acts together with Fe65 and RNF157 in controlling neuronal survival 
To establish Tip110 as a component in the RNF157/Fe65 pathway, I first generated Tip110 
RNAi constructs and verified their efficacy in HEK293T cells expressing the HA-Tip110 
plasmid (Fig 3.19a). Among the four RNAi constructs only Tip110 RNAi #3 was efficient in 
knocking down Tip110 and was used in the following experiments.  
To investigate if Fe65 regulates neuronal apoptosis together with Tip110, I carried out 
epistasis experiments. Here, I overexpressed Fe65, knocked down Tip110, or expressed both the 
Fe65 expression plasmid and Tip110 RNAi plasmid together with the β-Gal plasmid in 
hippocampal neurons at DIV2. After 5 days, hippocampal neurons were immunostained with the 
β-Gal antibody and the DNA dye DAPI and analyzed. Interestingly, I found that while 
knockdown of Tip110 did not show any effect on neurons, it neutralized the apoptosis induced 
by Fe65 (Fig 3.19b, c). These experiments suggested that Tip110 is required for nuclear Fe65 to 
induce apoptosis. In further epistasis analysis, I examined if Tip110 knockdown could rescue the 
strong apoptosis induced by RNF157 knockdown. Here, I knocked down Tip110, RNF157 or 








   
Fig 3.18 Tip110 induces neuronal apoptosis in cerebellar granule and in hippocampal neurons.   
a) Cerebellar granule neurons (CGNs) transfected at DIV2 with the empty vector or the Tip110 expression 
plasmid together with the β-Gal plasmid were subjected to immunocytochemistry with the β-Gal antibody and 
the DNA dye bisbenzimide at DIV6. A total of 541 neurons from 3 independent experiments were analyzed 
(Student’s t-test, ***p<0.001, mean +s.e.m.). Courtesy of A. Matz. 
b) Hippocampal neurons were transfected at DIV2 with control plasmid or the Tip110 expression plasmid 
together with the β-Gal plasmid and analyzed at DIV6. A total of 429 neurons from 3 independent experiments 
were included in the analysis (Student’s t-test, *** p<0.001, mean +s.e.m.). 
c) Representative images of neurons in 3.8b. Arrowhead indicates the nucleus of transfected neurons. Insets 




neurons at DIV2. Neurons were subjected to immunochemistry and analyzed at DIV7. I found 
that knockdown of Tip110 led to a partial rescue of the RNF157 RNAi-induced cell death (Fig 
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Fig 3.19 Knockdown of Tip110 rescued neuronal apoptosis 
induced by Fe65 and ameliorated the cell death upon RNF157 
knockdown in HPNs.   
a) Lysates of HEK293T cells, transfected with the HA-Tip110 
plasmid together with empty vector and different Tip110 RNAi 
constructs, were subjected to immunoblotting with the HA and the 
14-3-3β antibodies. The latter was a loading control. 
b) Hippocampal neurons were transfected at DIV2 with control 
vectors, the Fe65 plasmid, the Tip110 RNAi construct or both the 
Fe65 expression and the Tip110 RNAi plasmids and fixed at DIV7. 
A total of 1447 neurons in 4 independent experiments were 
analyzed (ANOVA, *** p<0.001, mean +s.e.m.).  
c) Representative images of neurons in 3.19b. Insets depict higher magnification of nuclei. Scale bar = 20 μm. 
d) Hippocampal neurons were transfected at DIV2 with control vectors, the Tip110 RNAi plasmid, the RNF157 
RNAi plasmid or both the Tip110 RNAi and the RNF157 RNAi plasmids and fixed at DIV7. A total of 1410 





3.4 Behavioral phenotyping of RNF157 knockout mice 
According to our in vitro analyses, RNF157 has a role in neuronal survival. Therefore, loss 
of RNF157, which induced neuronal death, might result in neurodegeneration in mice. To 
determine the functional and cognitive outcome of the loss of RNF157 in vivo, I first examined 
the general health and activity of male wild type (n=11), heterozygous (n=22) and homozygous 
(n=18) mice using the basic behavior assessment battery to rule out the influence of physical 
deficits on cognitive test. Then, I finalized the phenotyping with the cognitive tests to investigate 
learning and memory.  
 
3.4.1 General behavioral characterization of RNF157 mice 
3.4.1.1 Loss of RNF157 does not affect appearance and body weight   
 During the behavioral tests, the general health and the weight of all mice were monitored. A 
previous study described that a mutation in the gene encoding the RNF157 homologue MGRN1 
induces the alteration in mouse coat color (Phan et al., 2002). However, RNF157-/- mice did not 
exhibit differences in their fur color or posture. The weight of all mice was comparable 
throughout the testing period (Fig 3.20).  
 
3.4.1.2 Anxiety and locomotor activity is unaltered in RNF157-/- mice    
First of all, both anxiety and activity of animals were assessed. Before animals got used to 
the testing environment, the anxiety was investigated using elevated plus maze. The plus maze 
consists of two open arms and two enclosed arms. By using anxiolytic or anxiogenic drugs, this 
 
Fig 3.20 Body weight of RNF157 transgenic mice were similar in all genotypes.    




widely used test has been proven to be a valid measure for anxiety. Untreated rodents tend to 
avoid the open space while the ones receiving anxiogenic substances stay even longer in the 
closed arms (Pellow et al., 1985; Pellow and File, 1986; Treit et al., 1993). During the test, the 
maze was lifted and the mice were allowed to explore the whole maze freely. The distance mice 
traveled and time they spent in each area (open arms, closed arms and center) were recorded. I 
found all tested mice exhibited natural avoidance of the elevated, open area and spent most of the 
time in the closed arm (Fig 3.16a; p < 0.001). They also travelled farthest in the closed arm (Fig 
3.16b; p < 0.001). However, there was no difference between genotypes in time spent (Fig 3.21a) 
and distance travelled (Fig 3.21b). 
 




Fig 3.21 RNF157 transgenic mice exhibit normal anxiety levels in the elevated plus maze test.  
a) The distance animals travelled b) the time mice spent in the closed arm, center and the open arm in the 
elevated plus maze were not different between genotypes. 
 
In the open field test, all genotypes travelled significantly farther and spent significantly 
more time in the peripheral area as compared to the intermediate and the center zones (Fig 3.22a, 
b; p < 0.001). Mice also exhibited the tendency to remain close to the walls and to avoid the 
central area. This behavior is referred to as thigmotaxis, which could be used as another readout 
for anxiety in rodents (Simon et al., 1994; Treit and Fundytus, 1988). Although the wild type 
mice appeared to travel more in the peripheral area than the RNF157+/- and RNF157-/- mice (Fig 
3.22a), no overall difference could be observed in distance travelled and time spent in each zone 
(Fig 3.22b). The average velocity was also comparable between the different genotypes (Fig 















Fig 3.22 RNF157 transgenic mice showed similar 
locomotor activity. 
a) The distance mice travelled b) the time mice spent in the 
closed arm, center and the open arm in the open field were 
similar for all genotypes. 
c) No difference was shown in the average velocity with 
which animals were traveling in the open field. 
 
3.4.1.3 RNF157-/- mice show intact motor function   
 The general motor function including balance and coordination was assessed using the 
rotarod test. The duration that mice can stay on the accelerating rotarod is recorded. On the first 
test day, I observed a difference in the genotypes (Fig 3.23a; p < 0.05). Post-hoc analysis 
revealed that RNF157-/- mice performed significantly worse as compared to wild type littermates 
(Fig 3.23a; p < 0.01). However, all mice improved the performance when tested 24 hours later. 
To verify this result, a three-trial rotarod test was conducted, for which the mice were tested 3 
times in a day, 1 hour between each trial. No difference was found in all the trials and all mice 
exhibited intact motor learning (Fig 3.23b).  
In addition, the muscular strength was measured using grip strength meter. The strength that 
animals apply to hold the grip was measured. The measurement showed that all mice possessed 
similar grip force (Fig 3.23c). These results indicated that the deletion of RNF157 did not affect 
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Fig 3.23 No deficits in motor functions of RNF157-/- mice. 
a) Shorter latency on rotarod showed by the homozygous 
mice only on the first day. (Bonferroni post-hoc test, **= p < 
0.01) 
b) Although a trend of improvement could be observed 
between trials, the time mice stayed on the rolling rotarod 
was the same for all genotypes in each trial in the 3-trial 
rotarod test. 
c) All test animals showed comparable grip force. 
 
3.4.1.4 Intact sensory and sensorimotor gating functions in RNF157-/- mice   
 Next, I went on to test the sensory functions including vision, hearing, olfaction as well as 
pain sensation since intact sensory functions are required for the following cognitive tests. First, 
I assessed the vision using the visual cliff test. The ground of the apparatus is divided into a 
ground and an air area. During the experiment, the apparatus is lifted up and the mice can see the 
floor through the transparent “air” area while the “ground” area is opaque. Mice tend to stay in 
the ground area if the depth perception is intact (Fox, 1965).  I found that all mice spent more 
time in the “ground” area than the “air” part (Fig 3.24a; p < 0.0001) and there was no significant 
difference between genotypes. This result indicates an intact depth perception of all mice.  
The hearing test examines the hearing ability by measuring animals’ startle responses to the 
sound at different dB level. The wild type and homozygous mice responded similarly to the 
sounds (Fig 3.24b). The startle amplitude of heterozygous mice however was significantly 
stronger than that of wild type (113 dB: p < 0.0001; 120 dB: p < 0.05) and homozygous mice 
(107 dB: p < 0.01; 110 dB: p < 0.01; 113 dB: p < 0.0001; 120 dB: p < 0.0001). These could be 
attributed to the trend that heterozygous mice were slight heavier as shown in Fig 3.20.   




find the hidden cookies. One piece of cookie was buried shallowly in the bedding in a cage as 
described in chapter 2.13.11. During the test, mice were released in the cage and allowed to 
search for the cookie. Three trials with an inter-trial interval of 50 min were conducted in each 
mouse. The cookie was visible in the 3rd trial as a control. Mice responded significantly faster in 
the subsequent sessions (Fig 3.24c, p < 0.0001), which implied a learning effect and I did not 
find a difference between genotypes. This indicates that the olfactory sensitivity is normal in all 
genotypes tested.  
Pain sensation was examined by the duration that animals can stay on the hot plate. Mice 
were placed on a 55°C hot metal plate and the duration from placement till animals respond to 
the heat was recorded. Similar to the wild type mice, the heterozygous and homozygous animals 
were able to tolerate the heat to the same extent (Fig 3.24d). The measurement revealed that all 
tested mice had comparable sensitivity to pain. 
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Fig 3.24 No deficits in sensory functions of RNF157-/- mice. 
a) The time mice spent in the “air” or “ground” part of the visual cliff test apparatus. Mice from all genotypes 
spent significantly more time in the “ground” area than “air” area (2-way ANOVA, ***= p<0.0001), indicating 
intact vision. 
b) The startle amplitude plotted against the sound intensities. All mice showed a similar hearing curve, the startle 
amplitude was clear from 95 dB onwards. 
c) The time that mice needed to find the hidden cookies. No difference was observed, indicating all animals had 
similar olfactory sensitivity. 
d) The time animals need to sense the heat. All animals responded as soon as each other in the hot plate test, 
indicating intact pain perception.  
e) The startle responses to the loud pulse as baseline for pre-pulse inhibition test. No difference in the startle 
amplitude could be seen between genotypes.  
f) Percentage of pre-pulse inhibition plotted against the pre-pulse intensities. Mice from all three genotypes 
exhibited similar pre-pulse inhibition. 
 
In addition, the sensorimotor-gating ability was examined using the pre-pulse inhibition test, 
in which the startle responses to auditory stimuli presented with or without a pre-pulse were 
recorded. Mice were placed into the metal chamber enclosed in a sound-attenuating isolation box. 
Various auditory stimuli were played and the startle responses of animals were recorded. Since I 
have already mentioned that the auditory function of all animals was undamaged, the result of 
pre-pulse inhibition test can indicate the integrity of the cortico-striato-pallido-pontine circuitry 
(Swerdlow et al., 2000). The similar startle responses to a loud stimulus demonstrated that all 
mice had an equal startle baseline (Fig 3.24e). Furthermore, all mice exhibited significantly 
stronger inhibition on the startle amplitude when the pre-pulse was louder (Fig 3.24f, p < 0.001). 
Nonetheless, no difference of the inhibition could be observed between genotypes, suggesting 
that the sensorimotor-gating function is unchanged upon deletion of RNF157.  
To sum up, loss of RNF157 did not induce any damage on the basic sensory function such as 
vision, hearing, olfaction and pain sensitivity. The more complex brain circuitry underlying 




3.4.1.5 Lack of RNF157 does not affect exploratory and impulsive behaviors  
 The exploratory activity was examined using the hole board test. The time mice need to 
make the first nose poke was recorded. Here, all mice spent approx. 100 sec to make the first 
nose poke (Fig 3.25a). The number of nose pokes was also compared. While the heterozygous 
mice showed reduced exploratory behavior (Fig 3.25b; p < 0.05) as compared to wild type 
animals, the RNF157-/- mice showed similar number of entries, indicating that loss of RNF157 
does not alter the exploratory behavior.  
Moreover, I investigated the impulsivity and the stereotypic digging behavior using the 
marble-burying test. The number of buried marbles in the periphery or center area was analyzed. 
All mice buried a similar amount of marbles in the periphery and in the center regardless of 
genotypes (Fig 3.25c). These data suggest that deletion of RNF157 does not affect the impulsive 
behaviors. 
 
             a      Hole board – time to the first entry                b        Hole board – numbers of entry  
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Fig 3.25 No difference in exploratory and impulsive 
behaviors of RNF157 knockout mice. 
a) The time mice spent until mice made the first nose 
poke (p > 0.05). 
b) Numbers of nose pokes of each genotype in the hole 
board test. Although the heterozygous animals poked less 
times then the other two genotypes, there was no 
difference between the wild type and the knockout 
groups. (Bonferroni post-hoc test, *= p < 0.05) 
c) The number of buried marbles was significantly 
different between the positions of marbles (p < 0.001), 
but not different between burying behavior of genotypes. 
 
Taken together, the abovementioned basic behavioral battery demonstrated that all animals 




3.4.2 Analyses of cognitive functions of RNF157 mice 
3.4.2.1 Deletion of RNF157 does not impair working memory  
 To assess the object recognition memory of RNF157-/- mice, I first performed the novel 
object recognition test. This test is based on the natural preference of rodents for the novel 
objects (Ennaceur and Delacour, 1988). Animals tend to spend more time with a new object as 
compared to familiar objects. Various studies demonstrated the involvement of hippocampus and 
adjacent cortical areas in the formation and retention of object memory (Broadbent et al., 2010; 
Goulart et al., 2010; Hammond et al., 2004). Since RNF157 is highly expressed in the 
hippocampus, I hypothesized that its deletion might lead to memory deficits.  
To test working memory, mice were allowed to explore the old objects for 5 sessions, 6 min 
per session. In the final session, a familiar object was replaced with a novel object. The time 
mice spent with objects was recorded. The analysis showed that all mice spent significantly more 
time with novel object as compared to the old ones (Fig 3.26, p < 0.001). However, mice from all 
genotypes showed similar preference to the novel object, indicating that loss of RNF157 did not 
induce working memory impairment. 
 





Fig 3.26 Working memory was undamaged in 
RNF157 transgenic mice 
The time mice spent with the novel object or the old 
objects. Animals explored the novel object significantly 




3.4.2.2 Loss of RNF157 does not affect spatial memory  
I also examined the role of RNF157 in spatial learning and memory using Morris water 
maze. In rodents, the formation and consolidation of spatial memory is tightly regulated by 
hippocampus as well as cortex (Kolb et al., 1983; Morris et al., 1986). Due to the robust 





On the first two days, mice were trained to escape onto a visible platform. This was followed 
by 8 days of acquisition phase, in which mice search for the hidden platform. A probe trial 
without the platform afterwards was carried out to examine their memory. Then, the hidden 
platform was positioned in the opposite quadrant and the mice had 4 days to learn the new 
position. After the learning phase, the second probe trial was performed. For data analysis, the 
water maze was divided into four quadrants as depicted in Fig 3.27a: target (T), target right (TR), 
target opposite (TO), and target left (TL). The platform is illustrated in red. The time mice 
needed to escape onto the platform and their swimming distance was recorded.  
The analysis showed a proper learning curve for all mice (Fig 3.27b). The escape latency 
was reduced over time during the first as well as the reversal training phases, indicating that all 
mice were able to acquire the position of the hidden platform even when the hidden platform was 
moved in the reversal phase.  In the probe trial 1 and 2, my data demonstrated that all animals 
stayed longer in the target area (T) than other zones (Fig 3.27c, d). Interestingly, when 
comparing the visits onto the target, the knockout animals visited the former location platform 
more often than the others (Fig 3.27e, f). Although there was no main effect of the genotype in 
the first trial, I further analyzed the data using Bonferroni post-hoc due to the observed trend. 
The post-hoc analysis revealed that the knockouts made more visits than the heterozygotes (p < 
0.001). Moreover, a main effect of genotype was observed when comparing the number of visits 
in the probe trial 2 (Fig 3.27f, p < 0.05), indicating deletion of RNF157 led to more visits of the 
target. This probably could be explained by higher speed of swimming behaviors of the 
knockouts in the second probe trial, although all animals swam at similar speed in the first probe 
trial (Fig 3.27g, h). This also indicated a higher activity in the second probe trial. However, taken 
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Fig 3.27 Spatial learning and memory of RNF157-/- mice is 
unaltered. 
a) Illustration of the position of the hidden platform and the division of 
four quadrants of the Morris water maze. 
b) Curves depict the escape latency onto the platform. All mice learned 
equally well in the acquisition as well as reverse phases.  
c), d) The time that mice swam in each quadrant during the first probe 
trial (c) and 2nd trial (d). The platform was removed during the trials. 
e), f) Number of visits to the target in the probe trials.  The knockout 
animals tended to visit the target more often than other mice.  
f) Average swimming velocity of mice was similar in the probe trial 1, 
but the RNF157-/- mice swam significantly faster in the trial 2, 
indicating a higher activity. 
 
 
3.4.2.3 RNF157 knockouts have impaired cued associative fear memory  
In addition, I investigated the impact of RNF157 on fear memory. The formation of fear 
memory is highly dependent on the amygdala, while the hippocampus mainly contributes to the 
memory retention concerning the context (Kim et al., 1993; Phillips and LeDoux, 1992). Here, I 
used the fear-conditioning paradigm in order to assess the role of RNF157 in fear memory.  




sec tone (conditioned stimulus, CS), followed by a 2-sec foot shock (unconditioned stimulus, 
US). Each mouse received two tone-shock pairing so that the association between CS and US 
was achieved. 24 hours after training, mice were placed in the same chamber to examine their 
freezing behavior as the readout for contextual fear memory. Three hours later, the cued fear 
memory was measured. Mice were placed a new chamber and the same tone as in the training 
phase was played. The freezing behavior during this period refers to as cued fear memory. All 
mice exhibited a similar baseline freezing level in both contextual as well as cued condition (Fig 
3.28a, b). Although there was no main effect of genotype on the freezing response to the same 
context (Fig 3.28a, p = 0.09), post-hoc test revealed that the RNF157-/- mice showed less freezing 
as compared to the RNF157+/- mice (p < 0.01). Interestingly, statistical analysis revealed a main 
effect of the genotype in the cued fear memory (p < 0.05, Fig 3.28b). Subsequent post-hoc tests 
demonstrated that the freezing level of RNF157-/- mice attenuated significantly compared to the 
wild type (p < 0.05) as well as the RNF157+/- mice (p < 0.01). In sum, impaired fear associative 
memory was found in the mice without RNF157. Although the deletion of RNF157 seemed to 
have a smaller impact on the hippocampus-based fear memory, my data suggest that RNF157 
could be essential for the formation of amygdala-dependent fear memory. 
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Fig 3.27 Loss-of-RNF157 leads to impairment of fear memory. 
a) Freezing response to the same context. Mice showed similar baseline freezing level. While no main effect of 
genotype was shown (p = 0.09), post-hoc test indicated a possible impaired fear memory in RNF157-/- mice as 
compared to RNF157+/- littermates (Bonferroni post-hoc test, ** = p < 0.01). 
b) Freezing response in the cued fear memory test. All mice had comparable baseline freezing level. RNF157-/- 
mice showed damaged fear memory compared to the wild type as well as heterozygous littermates (Bonferroni 
post-hoc test, ** = p < 0.01; * = p < 0.05). 
 
To sum up, the results from the aforementioned cognitive tests pointed out that loss-of-




hippocampal functions was not yet clear in adult mice, impairment in amygdala-mediated fear 
memory could already be observed. This indicates that RNF157 is essential for amygdaloid 





































The loss of neurons in the brain is often associated with an imbalance of the protein 
homeostasis. Emerging evidence signifies the direct role of E3 ubiquitin ligases in 
neurodegeneration. A previous study demonstrated that disrupted transcription of the Mgrn1 
gene induces progressive spongiform neurodegeneration (He et al., 2003). In our lab, the E3 
ligase RNF157, which is highly homologous to Mgrn1 (Jiao et al., 2009), has been found to 
regulate neuronal survival (Matz et al., in press). Furthermore, a novel interactor of RNF157, 
Fe65, was found to operate in the nucleus to promote apoptosis and to act downstream in the 
RNF157 survival pathway (Matz et al., in press). My study further elaborated on the role of 
RNF157 in regulation of neuronal survival. I uncovered that aside from cerebellar granule 
neurons, the RNF157/Fe65 survival pathway is also active in hippocampal neurons. Moreover, 
my results indicate that Fe65 is a substrate of RNF157 and that Fe65 is most likely targeted for 
proteasomal degradation. Furthermore, I identified an additional player, the RNA-binding 
protein Tip110, in this survival pathway. Tip110 is required for Fe65 to trigger apoptosis in the 
nucleus. In addition to the in vitro characterization of RNF157, I investigated the behavior of 
transgenic RNF157 mice. The RNF157-/- mice are apparently normal and exhibit intact motor 
and sensory functions. Notably, while all tested mice possess similar short-term and spatial 
working memory, mice lacking RNF157 have impaired fear-memory. To sum up, my study 
elucidated the RNF157/Fe65/Tip110 survival pathway in vitro. Together with the behavioral data, 
my work expands our understanding of the E3 ligase RNF157 in regulating neuronal survival. 
 
4.1 RNF157 is a brain-dominant protein involved in the Akt- and Erk-
mediated survival pathways 
My study revealed that RNF157 is expressed in cultured neuronal as well as non-neuronal 
cells in the brain. Interestingly, RNF157 is strongly expressed in the cortex as well as 
hippocampus of the adult mouse brain, indicating its potential role in cognitive functions. 
However, only a low expression level can be observed in the internal granule layer of the 
cerebellum, where the cerebellar granule neurons (CGNs) are, and in white matter, while 
RNF157 is robustly expressed in cultured CGNs, astrocytes as well as oligodendrocyte precursor 




speculated that RNF157 is essential for the early development of these cells rather than for the 
maintenance of the cells in the adult brain.   
Using subcellular fractionation analysis, I found that RNF157 is restricted to the cytoplasm. 
This subcellular localization is different from that of Mgrn1, which shows a nuclear and 
cytoplasmic expression (Kim et al., 2007a). Unlike the widespread distribution of its homologue 
Mgrn1, RNF157 exhibits a brain-dominant and cytoplasmic expression, indicating a distinct role 
of RNF157 in the brain, but a certain degree of functional redundancy provided by Mgrn1 cannot 
be excluded due to the spatially overlapping distribution of Mgrn1 and RNF157. 
Notably, the major survival pathways mediated by the kinases Akt and Erk in the RNF157-/- 
brains were altered due to loss of RNF157, suggesting a potential role of RNF157 in the 
regulation of neuronal health. To protect neurons from death after stroke, the activity of Akt has 
been shown to be transiently upregulated (Zhao et al., 2006). Transient activation of Erk to 
inhibit apoptosis can also be observed in cells responding to pro-apoptotic stimuli such as 
radiation, osmotic stress or growth factor withdrawal (Lu and Xu, 2006a). These indicate a 
neuroprotective function of Akt and Erk in response to cellular stress. While the total amount of 
Akt and Erk remains unchanged in the RNF157-/- brain, the activity of both kinases decreases. 
This downregulation of Akt and Erk activity, however, does not affect the viability of the mice. It 
can be speculated that the low kinase activity is sufficient for the basic physiological functions, 
but mice lacking RNF157 might be more susceptible to harmful stimuli or events that are 
associated with aging. To test this hypothesis, further experiments using cultured neurons 
exposed to different stress stimuli can be considered. Moreover, it remains unclear how RNF157 
regulates Akt or Erk. So far, the kinases phosphoinositide 3-kinase (PI3K) or 3-phosphoinositide-
dependent kinase (PDK) and the Ras/Raf/Mitogen-activated protein kinase kinase (MEK) 
cascade has been shown to phosphorylate Akt and Erk, respectively (Song et al., 2012). It would 
be worthwhile to investigate if their activity is modulated by RNF157. 
 
4.2 RNF157/Fe65 pathway regulates apoptosis in hippocampal neurons  
RNF157 has been shown to regulate neuronal survival in cerebellar granule neurons (Matz 
et al., in press). Owing to its robust expression in the hippocampus, I characterized this role of 
RNF157 in hippocampal neurons and found that knockdown of RNF157 triggers apoptosis in 




Furthermore, it has been demonstrated that Fe65 triggers cell death in cerebellar granule 
neurons (Matz et al., in press). My result showing that Fe65 also initiates apoptosis in 
hippocampal neurons is in line with the previous finding. In addition, it has been reported that 
only nuclear Fe65 contributes to cell death in the cerebellar granule neurons (Matz et al., in 
press). Interestingly, I found that in hippocampal neurons, both nuclear and cytoplasmic Fe65 
can induce apoptosis with the nuclear Fe65 being more potent. It can be postulated that 
hippocampal neurons are more sensitive to Fe65-induced cellular stress, and therefore even 
cytoplasmic Fe65 is sufficient to cause cell death. It could be that overexpression of cytoplasmic 
Fe65 leads to the translocation of endogenous Fe65 into nucleus and thus to an apoptotic 
response in hippocampus. Another possible explanation would be that the cytoplasmic Fe65 
triggers distinct apoptotic pathways. As an adaptor protein, Fe65 has been reported to bind to 
different transmembrane receptors such as LRP or ApoEr2 (Borquez and Gonzalez-Billault, 
2012), which have been implicated in apoptosis (Hashimoto et al., 2000; Kysenius et al., 2012). 
Hence, it would be interesting to investigate if Fe65 governs two distinct pro-apoptotic pathways 
in the different cell compartments. 
In addition, epitasis analysis demonstrated that Fe65 knockdown does not have an effect on 
neuronal apoptosis but, together with RNF157 knockdown, Fe65 knockdown rescues 
hippocampal neurons from cell death. Together with our previous study, regardless of neuronal 
cell types, RNF157 operates upstream of Fe65 in a linear pathway to control neuronal survival.  
 
4.3 RNF157 ubiquitinates Fe65 via K63 chains for progressive proteasomal 
degradation  
Since Fe65 acts downstream of the E3 ligase RNF157, I reasoned that RNF157 can 
ubiquitinate Fe65. My study revealed that Fe65 is ubiquitinated by RNF157 via K63-linked 
polyubiquitin chains. Generally, K48 polyubiquitin chains are considered as the primary signal 
for proteasomal targeting, while K63 chains are often associated with protein stabilization and 
transportation, DNA repair and lysosomal degradation (Komander and Rape, 2012). However, 
Saeki and colleagues have shown that K63 chains can also mediate proteasomal degradation 
(Saeki et al., 2009). Upon deletion of RNF157 in vivo, I found progressive accumulation of the 
Fe65 protein in the cortices as well as hippocampi of RNF157-/- mice, while the mRNA level was 
unaltered, indicating that post-translational modification mediated by RNF157 leads to 




Furthermore, I have verified that Fe65 is localized to the cytoplasm as well as the nucleus. 
Various studies have demonstrated that Fe65 can translocate into the nucleus together with AICD 
to mediate gene transcription (Bruni et al., 2002; Cao and Südhof, 2001; Kimberly et al., 2001) 
and K63-linked polyubiquitination has been shown to facilitate the nuclear translocation of 
substrates (Geetha et al., 2005). Since nuclear Fe65 is the main contributor in inducing neuronal 
apoptosis, I reasoned that the ubiquitination of Fe65 via RNF157 could lead to its accumulation 
in the nucleus to trigger apoptosis. The subcellular fractionation study, however, revealed that 
not only the nuclear Fe65 but also cytoplasmic Fe65 accumulate in the cortex of 10-week-old 
RNF157-/- mice, suggesting that RNF157 ubiquitinates Fe65 mainly for degradation, not for 
nuclear translocation.  
Next, I analyzed if Fe65 undergoes proteasomal or lysosomal protein turnover since it has 
been reported that K63-linked chains enhance endosomal trafficking of the substrate to the 
lysosome for degradation (Lauwers et al., 2009; Tofaris et al., 2011). I found that Fe65 is 
degraded by the proteasome rather than the lysosome. This is an interesting finding since 
previous studies on this matter show conflicting results. It has been shown that all ubiquitin 
chains except K63 chains can target substrates for proteasomal degradation (Bedford et al., 2011; 
Xu et al., 2009b). This was partial debated by Saeki and colleagues who showed that K63 chains 
do mediate proteasomal turnover (Saeki et al., 2009). More recently, a study reported that while 
K48 and K63 chains binds equally well to the proteasome, K63-chains-associated factors weaken 
its association with the proteasome (Nathan et al., 2013). Another possible scenario is that other 
E3 ligases are also involved in the ubiquitination and degradation of Fe65. Since Fe65 is an 
adaptor protein involved in numerous cellular signaling pathways, it can be speculated that 
RNF157 is not the only E3 ligase for Fe65. Notably, the homologue of RNF157, Mgrn1, has 
been found to interact with Fe65 (Matz et al., in press), it is very likely that Mgrn1 also 
ubiquitinates Fe65. In addition, Nedd4-2, a HECT-type E3 ligase belonging to Nedd4 family has 
been shown to ubiquitinate Fe65 (Lee et al., 2009a), although the functional implication of this is 
not yet known. Furthermore, it has been reported that Fe65 forms a trimeric complex with 
Notch1, a transmembrane receptor, and Itch, another HECT-type E3 ligase, to stimulate the 
ubiquitination of Notch1 by Itch probably for proteasomal degradation (Kim et al., 2012). 
However, it is unclear if Fe65 is turned over together with Notch1. Hence, it would be important 
to investigate the consequence of Mgrn1 or Nedd4-2-mediated ubiquitination of Fe65. 
To sum up, my study so far suggests that RNF157 interacts with Fe65 to ubiquitinate Fe65 





4.4 RNF157 competes with APP for the binding of Fe65  
Fe65 binds to APP via its PTB2 domain and mediated the trafficking and processing of APP 
(Borquez and Gonzalez-Billault, 2012; McLoughlin and Miller, 2008). Since one of the products 
of APP processing, Aβ, appears to be neurotoxic (Kriem et al., 2005; Morishima et al., 2001), I 
reasoned that APP might play a role in the RNF157/Fe65 survival pathway. Moreover, APP 
harboring Swedish mutation (swAPP) produces more Aβ as compared to the wild type human 
APP (hAPP) (Citron et al., 1992). Therefore, I included both hAPP and swAPP into my analysis 
and found that RNF157 can compete with both hAPP and swAPP for the binding to Fe65 via its 
PTB2 domain and thus interfere their interaction. This scenario resembles the one of the adaptor 
protein Dab1 that competes with Fe65 for the binding to APP, and in turn blocks the association 
between Fe65 and APP, leading to suppression of APP processing (Kwon et al., 2010). Hence, I 
hypothesized that RNF157 can influence the production of Aβ. My experiments suggest that in 
the presence of Fe65, more Aβ42 appears to be produced, which is the more toxic form among all 
Aβ species (Klein et al., 1999; Zhang et al., 2002). However, I did not find a consistent influence 
of RNF157 on Fe65-mediated Aβ secretion. My results also indicate that Fe65 could promote Aβ 
production, which is in line with previous report that overexpression of Fe65 upregulates Aβ 
levels in Madin-Darby canine kidney cells (Sabo et al., 1999). Further animal models also 
support the observation that deletion of Fe65 leads to reduced Aβ42 secretion in the brain 
(Guenette et al., 2006). Additionally, ablation of Fe65 in mice carrying human mutant APP also 
suppresses Aβ42 production (Wang et al., 2004). However, Ando and colleagues have shown that 
Fe65 inhibits Aβ42 production in HEK293T (Ando et al., 2001). This discrepancy can be 
attributed to the different cell types. Taken together, it is more likely that Fe65 promotes Aβ 
secretion, which in turn induces cell death. However, the link between RNF157 and Fe65-
mediated Aβ production needs to be established with further experiments.  
Moreover, APP has been shown to tether Fe65 to the membrane, where Fe65 can be 
liberated upon phosphorylation of APP at Thr668 or Thr682 (Barbagallo et al., 2010; Nakaya and 
Suzuki, 2006). This adds to my hypothesis that the binding between RNF157 and Fe65 could 
result in the dissociation of Fe65 from APP. The interaction between RNF157 and Fe65 then 
facilitates the ubiquitination of Fe65 governed by RNF157. This in turn degrades Fe65, 
decreases its nuclear translocation and thus hinders apoptosis. 
To complicate the story, a previous study revealed that tyrosine kinase c-Abl phosphorylates 




2004). The phosphorylation of Fe65 is necessary for APP/Fe65-mediated gene transcription. 
Phosphorylation of substrates has been shown to have an impact on ubiquitination. For instance, 
the phosphorylation of c-Myc mediated by the glycogen synthase kinase 3 (GSK3) is necessary 
for the binding of the F-box protein Fbw7 and c-Myc, which enables the ubiquitination of c-Myc 
governed by the E3 ligase SCF/Fbw7 complex (Welcker et al., 2004). Accordingly, I postulate 
that the phosphorylation of Fe65 might be needed for its binding to RNF157 and thus facilitates 
the RNF157-mediated ubiquitination of Fe65, which could further affect the Fe65’s turnover. To 
verify this assumption in RNF157/Fe65 pathway, more evidence concerning the interplay 
between phosphorylation and ubiquitination of Fe65 is required. 
 
4.5 The nuclear interactors of Fe65  
Having shown that nuclear Fe65 is as potent as the wild type Fe65 at inducing apoptsis, I 
reasoned that Fe65 could act with other nuclear proteins to inhibit neuronal survival. After 
analyzing two nuclear proteins, Tip60 and Tip110, I found that while Tip60 does not induce 
apoptosis, Tip110 promotes neuronal death in the RNF157/Fe65 survival pathway. 
 
4.5.1 Tip60 interacts with Fe65 but does not promote neuronal apoptosis 
The nuclear protein Tip60, a histone acetyltransferase (HAT), has been reported to form a 
complex with Fe65 and AICD, which triggers gene transcription in the nucleus (Cao and Südhof, 
2001; Yamamoto and Horikoshi, 1997). Tip60 is normally localized to the nucleus; however, a 
small fraction can be anchored to cytoplasmic membranes by APP. This facilitates 
phosphorylation of Tip60 by cyclin-dependent kinase (CDK) and in turn promotes the nuclear 
translocation of Tip60/Fe65 to activate gene transcription (Hass and Yankner, 2005).  
Much is known about the role of Tip60 in DNA damage responses and the resulting DNA 
repair or apoptosis (Squatrito et al., 2006). Tip60 lacking its HAT activity fails to repair double-
strand DNA breaks (Ikura et al., 2000). Upon DNA damage, the HAT coactivator TRRAP 
recruits Tip60 to form a complex at the DNA damage sites, which facilitates acetylation of ATM, 
the ataxia telangiectasia mutant kinase involved in the DNA damage response (Bakkenist and 
Kastan, 2003; Murr et al., 2006; Sun et al., 2005). ATM further phosphorylates p53 and triggers 
p53-dependent DNA repair or apoptotic pathways (Saito et al., 2002; Squatrito et al., 2006). 




mediated activation of p21, a cyclin-dependent kinase inhibitor, or the pro-apoptotic genes Puma 
and Noxa (Deng et al., 1995; Tang et al., 2006; Villunger et al., 2003). With these various options 
the cell can go into cell cycle arrest to attempt DNA repair, or, if not successful, initiate apoptosis. 
In short, these findings indicate a role of Tip60 in regulating transcription of diverse genes to 
regulate different events in the cell. 
Intriguingly, nuclear Fe65 is required for the recruitment of Tip60-TRRAP to the double 
strand breaks and the resulting DNA damage response (Stante et al., 2009). Therefore, I reasoned 
that Tip60 could be a player in the RNF157/Fe65 survival pathway. Due to its interesting dual 
role in the response to DNA damage, various studies attempted to elucidate the role of Tip60 in 
apoptosis. Given its importance in DNA damage response, it is not surprising that knockdown of 
Tip60 in U2OS cells suppresses apoptosis induced by irradiation (Tyteca et al., 2006), while 
overexpression of Tip60 slightly increases apoptotic rate in stressed cell (Xu et al., 2009a). 
Furthermore, overexpression of Tip60 in unstressed SH-SY5Y cells has no effect on survival 
(Kim et al., 2007b). Taken together, Tip60 appears to promote cell apoptosis in heterogeneous 
cell systems only after DNA damage. However, a direct link between Tip60 and apoptosis in 
neurons is not yet well understood. Owing to its interaction with Fe65, I hypothesized that Tip60 
could act together with Fe65 to regulate neuronal apoptosis. 
I first verified the interaction between Fe65 and Tip60. My result supports the previous 
report that they do interact (Cao and Südhof, 2001).  Surprisingly, my mapping analysis revealed 
that Tip60 interacts with the PTB2 domain of Fe65, rather than the suggested PTB1 domain (Cao 
and Südhof, 2001). Comparing the deletion mutants used in that study, no evidence was shown 
about the binding between Tip60 and the PTB2 domain. In addition, I attempted to narrow down 
the binding area by including further deletion mutants lacking PTB1, PTB2 or the sequence 
between 2 PTB domains. However, all these mutants interact with Tip60. Since mutations of a 
protein can alter its conformation and thus change its binding affinity with other proteins (Abrol 
et al., 2014), the folding structure of the PTB domains could be necessary for the interaction 
between Fe65 and Tip60. 
I further analyzed the function of Tip60 in cerebellar granule neurons. The survival assays 
revealed that Tip60 by itself does not promote neuronal apoptosis. Therefore, I went on to 
investigate if Tip60 potentiates or attenuates Fe65-induced apoptosis. I found that overexpression 
of Tip60 and Fe65 does not increase the extent of apoptosis mediated by Fe65 itself. This is in 
line with a previous finding that Tip60 alone or Tip60 and Fe65 do not induce cell death in SH-




study.  However, they found that while overexpression of AICD induces cell death, transfection 
of Tip60, Fe65 and AICD potentiates apoptosis up to 3-fold. Hence, it is worth considering to 
include AICD into further analysis. In addition, a recent study using Drosophila models 
demonstrated that pan-neuronal expression of mutant Tip60 that does not possess HAT activity 
leads to cell loss in the central nervous system, and overexpression of wild type Tip60 even 
worsens the apoptotic phenotype as compared to mutant Tip60 (Pirooznia et al., 2012). 
Interestingly, introduction of APP rescues the apoptosis induced by Tip60-overexpression in flies. 
This could be attributed to the observation that APP tethers Fe65 in the cytosol so that Fe65 
cannot enter the nucleus to trigger apoptosis either with or without Tip60 (Nakaya et al., 2008). 
However, how Tip60 operates in the mammalian central nervous system needs further 
examination. 
Furthermore, since I found that Tip60 overexpression does not worsen Fe65-triggered 
apoptosis, it would also be worthwhile to investigate if knockdown of Tip60 promotes or inhibits 
neuronal survival in the background of Fe65 overexpression. As Tip60 colocalizes with Fe65 in 
the nucleus (von Rotz et al., 2004), it is possible that they act as a complex to trigger apoptosis 
and thus the apoptotic effect of Fe65 can be alleviated upon loss of Tip60. Furthermore, Fe65 has 
been shown to stabilize AICD in the nucleus and form a complex with Tip60 to initiate gene 
transcription (Cao and Südhof, 2001; Kimberly et al., 2001; von Rotz et al., 2004). If loss of 
Tip60 alters the Fe65-triggered apoptotic phenotype, it can be speculated that the AICD-induced 
gene transcription would be blocked. Since AICD has been demonstrated to promote APP 
transcription as well as the accumulation of cellular APP (von Rotz et al., 2004), suppressed 
AICD-mediated gene expression can reduce cellular APP level. This in turn results in more 
nuclear translocation of Fe65 due to the lack of membrane anchoring mediated by APP, which 
ultimately triggers apoptosis. Another possible scenario could be that less AICD leads to a 
decrease of the formation of nuclear Fe65/Tip60/AICD, which in turn promotes cell survival. 
Furthermore, the target genes for AICD-mediated transcription are not fully identified. The 
verification of this model requires an extended understanding of the key molecules. 
Once it is clear how Tip60 regulates apoptosis, it would be intriguing to know if RNF157 
plays a role in concert with Fe65 and Tip60 to regulate neuronal survival. Since RNF157 
mediates the degradation of Fe65 and loss of Fe65 could result in the dissociation of this 
potential apoptotic Fe65/Tip60/AICD complex and hence promote survival. Therefore, it would 





4.5.2 Tip110, a novel interactor of Fe65, induces neuronal apoptosis 
In this study, I found that the RNA-binding protein Tip110 interacts with Fe65 and promotes 
neuronal apoptosis. Tip110 was first identified as a nuclear molecule that can bind RNA in vitro 
(Gu et al., 1998). It was later shown to directly interact with Tat, encoded by the HIV-1 
regulatory gene tat, and thus involved in regulating HIV-1 gene transcription (Liu et al., 2002; 
Zhao et al., 2014).  Tip110 is present in various human tissues with robust expression in kidney, 
skeletal muscle, heart and brain (Liu et al., 2002). Besides its function related to HIV-1, Tip110 
has also been implicated in pre-mRNA splicing (Liu et al., 2013; Song et al., 2010), thus 
mediating the pluripotency of human embryonic stem cells (Liu et al., 2013). Moreover, it is 
involved in androgen receptor-mediated transcription (Liu et al., 2004) and hematopoiesis (Liu et 
al., 2011). My study reveals a novel function of Tip110 in neurons in apoptosis.  
So far, no other studies propose a role for Tip110 in apoptosis. Although deletion of the 
Tip110 orthologue in zebrafish causes embryonic lethality (Trede et al., 2007), overexpression of 
human Tip110 in transgenic mice does not induce apparent developmental, behavioral or 
pathological alterations (Liu et al., 2011). This suggests an important role of Tip110 during early 
development rather than later in tissue maintenance, but interestingly, Tip110 has been shown to 
interact with the transcriptional factor c-Myc to operate its function in pre-mRNA processing 
(Liu et al., 2011; Liu et al., 2013). C-Myc is a oncoprotein, which is aberrantly upregulated in 
tumor cells, leading to uncontrolled cell proliferation (Pelengaris et al., 2002). Intriguingly, a 
transgenic model with c-Myc overexpression in the forebrain of mice supports these in vitro 
observations in vivo (Lee et al., 2009b). Mice with additional c-Myc develop neurodegeneration 
and astrocytosis in the hippocampus, which is associated with a deficit in working memory. 
These findings indicate the importance of c-Myc in regulating neuronal apoptosis. Since Tip110 
interacts with c-Myc, it is conceivable that Tip110 promotes neuronal cell death through the c-
Myc-mediated apoptotic pathway. Expression of c-Myc has been shown to facilitate the release 
of cytochrome c by cooperating with the Bax-mediated mitochondrial apoptotic cascade and thus 
triggers apoptosis (Juin et al., 2002). Furthermore, Liu and colleagues have previously shown 
that while overexpression of Tip110 promotes c-Myc expression and knockdown of Tip110 
reduces c-Myc level in different cell lines and human embryonic stem cells, c-Myc controls the 
expression of Tip110 in a similar manner (Liu et al., 2011; Liu et al., 2013). They are also shown 
to promote each other’s transcription (Liu et al., 2011). According to this evidence, it would be 
interesting to explore whether c-Myc is required for Tip110 to trigger apoptosis in neurons and in 





In addition, my epistasis analysis showing that Tip110 knockdown protects neurons from 
Fe65-mediated apoptosis suggests that Tip110 is required for Fe65 to trigger neuronal death in 
the nucleus. A subsequent experiment demonstrated that knockdown of Tip110 partially rescues 
the apoptosis induced by knockdown of RNF157, implying that other nuclear proteins could be 
involved in this pathway.  
Taken together, my findings characterize a novel RNF157/Fe65/Tip110 pathway in the 
control of neuronal apoptosis. Further analyses addressing the role of other possible interactors 
of Fe65 or Tip110 such as Tip60 or c-Myc, respectively, could expand our understanding of the 
E3 ligase RNF157-mediated neuronal survival.  
 
4.6 The role of RNF157 in cognitive function 
Unlike mice lacking Mgrn1, which exhibit change of coat color, curly whiskers and 
muscular weakness, RNF157-/- mice show no apparent alterations in the fur color and muscle 
function. This could be attributed to the brain-dominant expression of RNF157, in contrast to 
Mgrn1, which is present in various tissues (He et al., 2003). The behavioral analysis of RNF157 
knockout mice revealed that loss of RNF157 neither affects basic motor and sensory functions 
nor the mice’s anxious, exploratory or impulsive behaviors. Notably, intact basic functions are 
required for the accuracy of the memory tests. 
Converging evidence indicates a role of proteasome-mediated degradation in various brain 
areas to regulate memory function. Inhibition of proteasomal function in hippocampus, amygdala 
or prefrontal cortex impairs the formation or consolidation of memory (Artinian et al., 2008; 
Jarome et al., 2011; Lee et al., 2008b; Reis et al., 2013). Among the components of the ubiquitin 
proteasome system, E3 ligases have also been reported to regulate memory function. While lack 
of Cdh1, the coactivator of RING-type E3 ligase APC/C, is embryonic lethal, Cdh1+/- mice 
exhibit deficits in fear memory (Li et al., 2008a), which resembles the phenotype in 
heterozygous mice of SCRAPPER, an F-box protein in SCF E3 ligases (Yao et al., 2011). 
Furthermore, selective deletion of Cdh1 in the forebrain also showed fear memory impairment 
(Pick et al., 2013), whereas forebrain-specific knockout of APC2, another subunit of APC/C 
damages spatial memory as well as fear memory (Kuczera et al., 2011). These findings indicate 




4.6.1 RNF157 has no impact on hippocampus-mediated working and spatial 
memory 
Due to the intriguing hippocampal cell loss in the Mgrn1 null mouse and the robust 
expression of RNF157 in the hippocampus, I raised the question whether loss of RNF157 leads 
to deficits in cognitive functions. Therefore, I carried out the object recognition test and the 
Morris water maze test that are highly hippocampus-dependent (Broadbent et al., 2010; Garthe 
and Kempermann, 2013; Wang and Morris, 2010). To my surprise, I found that lack of RNF157 
neither alters the formation of working memory nor affects spatial learning or memory.  
Considering upregulated Fe65 levels in RNF157-/- hippocampi as well as in the brain of 
patients with Alzheimer’s disease (Delatour et al., 2001), it would be conceivable that deletion of 
RNF157 might lead to memory deficits. It was however not the case. This could also be 
attributed to the age when the test was performed. Since the accumulation of Fe65 became 
obvious only after 3 months of age in the RNF157-/- brain, it could be speculated that the 
behavioral consequence of Fe65 upregulation would appear much later, not at 4 or even at 9 
months of age when the working memory or spatial memory was assessed.  
Nonetheless, my result is in line with the finding that overexpression of Fe65 in mouse does 
not damage working memory at 8 months of age with no neuronal loss observed in the 
hippocampus of these mice over 18 months old (Ghosal et al., 2009). Moreover, mice with extra 
human Fe65 also fail to exhibit any obvious phenotype up to 13 months of age (Santiard-Baron 
et al., 2005), although no behavioral data concerning these mice has been shown. On the other 
hand, isoform-specific deletion of 97-KDa full-length Fe65 induces impairments in hidden-
platform acquisition in Morris water maze in both young (2-4 months old) and 14-month-old 
mice, while no difference in hippocampal morphology can be observed at 6 months (Wang et al., 
2004; Wang et al., 2009). These results suggest that Fe65 is required for hippocampal function.  
Another possible explanation would be that RNF157 or Fe65 might affect memory retention 
but not formation. To address this hypothesis, one can examine the memory in Morris water 
maze much later after training. For instance, a mouse model lacking the RING-type E3 ligase 
cbl-b showed normal learning but enhanced long-term memory when tested 45 days after 
acquisition (Tan et al., 2006). If reviewing my result carefully, there seems to be a trend that 
RNF157-/- mice stay longer in the target zone. It is possible that deletion of RNF157 facilitates 
memory retention, but this needs to be confirmed with further experiments.  




the pro-apoptotic function of Fe65 might not be favored in the normal physiological environment. 
Instead, redundant Fe65 might damage hippocampal neurons only under certain conditions. Fe65 
has been shown to induce age-dependent working memory deficits only together with AICD 
(Ghosal et al., 2009). The regulation of apoptosis by the Fe65 pathway in vivo might thus require 
other proteins that act together with Fe65 or modify its function. For instance, Fe65 also interacts 
with Notch1, which triggers apoptosis in neurons after ischemic stroke (Cheng et al., 2014; Kim 
et al., 2012). Interestingly, Fe65 has been shown to restrain Notch1 function by either facilitating 
its degradation or suppressing Notch1-mediated signaling (Kim et al., 2012), suggesting that 
Fe65 may counteract the pro-apoptotic impact of Notch1 in neurons and thus promote neuronal 
survival. In short, to comprehend the intact working and spatial memory in RNF157-/- mice, we 
would need to fully assess the role of Fe65 in hippocampal function. 
The other explanation for the intact hippocampal function in RNF157-/- mice could be that 
Mgrn1 and RNF157 may be interchangeable in the brain. Mgrn1 appears to play a crucial role in 
neuronal health and integrity in the mouse brain as mice with a mutant Mgrn1 gene develop a 
spongiform change in the hippocampus at 2 months of age (He et al., 2003), indicating that the 
presence of RNF157 cannot compensate for loss-of-Mgrn1-induced neurodegeneration. On the 
contrary, loss-of-RNF157 seems not to have similar outcome, hinting that Mgrn1 may have more 
prominent impacts and thus take over most of RNF157’s functions in the RNF157-/- brain. 
Therefore, it is important to establish if loss-of-RNF157 can lead to spongiform degeneration in 
vivo as seen in Mgrn1 null mice by further histological analyses of the aged RNF157-/- mouse. 
Taken together, it could be speculated that RNF157 is essential for the neuronal integrity at the 
cellular level, but Mgrn1 and RNF157 could have a large degree of functional redundancy in 
vivo in the early phase of brain development and during young adulthood but not in the aging 
brain. 
 
4.6.2 RNF157 is required for associated fear memory 
In addition to aforementioned memory, two forms of fear memory were examined in the 
RNF157 transgenic mice. While the contextual fear memory requires both hippocampus and 
amygdala, the cued fear memory relies mainly on amygdala (Kim et al., 1993; Phillips and 
LeDoux, 1992). My results indicate that while RNF157-/- mice seemed to have only a subtle 
deficit in contextual memory, deletion of RNF157 impaired the amygdala-dependent fear 




slight tendency in contextual condition could be attributed to the involvement of amygdala in 
this type of fear memory. This supports the notion that E3 ligases are essential in regulating fear 
memory.  
Notably, patients with Alzheimer’s disease exhibited deficits in fear conditioning (Hamann 
et al., 2002) and symptom-related amygdala as well as hippocampal atrophy (Poulin et al., 2011). 
This is not yet in agreement with the observations from the animal model of Alzheimer’s disease. 
Although the APP/PS1 transgenic mice also showed impaired memory, only altered dendritic 
morphology but no neuronal loss in amygdala was observed (Knafo et al., 2009). The 
explanation could be that the dendritic phenotype contributes to the fear memory deficits and a 
general imbalance in the central nervous system. On the contrary, an imbalanced central nervous 
system could be the cause for the change in dendrites. In both scenarios, the final consequence of 
a disturbed cell signaling could be the cell death seen in patients. Since it has been shown that 
RNF157 can also promote dendrite growth independent of its ligase activity (Matz et al., in 
press), it could be the reason for the impaired memory when RNF157 is absent in amygdala. The 
molecular pathway underlying RNF157-mediated dendrite development however needs further 
research.  
The possibility that loss of RNF157 can lead to neuronal apoptosis in amygdala can still not 
be excluded. Therefore, it is worthwhile to examine, first of all, the expression pattern of 
RNF157 and Fe65 in the amygdala. Secondly, if neurons in amygdala develop shorter dendrites 
or are more prone to apoptosis in RNF157-/- mice should be addressed. If the RNF157/Fe65 
survival pathway is also active in the amygdala, I speculate that Fe65 could mediate the 
expression of genes that govern fear memory formation during fear conditioning since Fe65 is 
involved in the transcription of various genes (Minopoli et al., 2012). Hence, it would be 
interesting to identify the target genes of Fe65 during fear conditioning and if Tip60, Tip110 or 
other proteins operate together with Fe65 to regulate these genes. 
Additionally, the study using Fe65-/- mice demonstrated that deletion of Fe65 impaired both 
hippocampal-dependent contextual fear memory and the induction of associated long-term 
potentiation (LTP) in the hippocampus (Wang et al., 2009). However, no data concerning 
amygdala function has been shown in this mouse model. Owing to its strong association with 
cued fear memory, the long-term potentiation (LTP) in amygdala is worth being examined 
(Rogan et al., 1997). I would expect defective LTP in the RNF157-/- amygdala. Furthermore, it 
would be interesting to examine LTP in hippocampus since a trend of impaired contextual 




in hippocampus and amygdala or if RNF157 acts in distinct ways in various brain regions. Lastly, 
due to its ability to bind to Fe65 (Matz et al., in press), the function of Mgrn1 in these brain areas 
should be taken into consideration. Whether Mgrn1 compensates the function of RNF157 in 
these parts of the brain would induce different outcome of RNF157 knockdown. If Mgrn1 is the 
functionally redundant homologue of RNF157 in neurons, a Mgrn1/RNF157 double knockout 
mouse model would help to elaborate the real impact of RNF157 in the central nervous system. 
 
4.7 Conclusion 
My study extends our understanding of the brain-dominant E3 ligase RNF157 in the control 
of neuronal survival. Here I show that the novel interactor of RNF157, the adaptor protein Fe65 
is pro-apoptotic and operates downstream of RNF157 in the control of neuronal apoptosis. 
Importantly, RNF157 counteracts Fe65’s pro-apoptotic function by attaching the K63-linked 
polyubiquitin chain on Fe65, which atypically targets Fe65 for proteasomal degradation and thus 
protects neurons from cell death. In hippocampal neurons, Fe65 acts mainly in the nucleus to 
trigger apoptosis. I further elucidated this pathway and identified a novel interactor of nuclear 
Fe65, the nuclear RNA-binding protein Tip110. Like Fe65, Tip110 induces neuronal apoptosis. 
Further epistasis analysis demonstrated that Tip110 is required for Fe65 to trigger cell death. In 
short, my in vitro work uncovers a novel RNF157/Fe65/Tip110 pathway in the control of 
neuronal survival. Based on these and other findings, I propose a working model depicted in Fig 
4.1. 
In addition, the behavioral analyses of RNF157-/- mice indicate that loss of RNF157 does not 
induce a severe pathological outcome in mouse behavior at young age. Notably, I found that 
deletion of rnf157 impairs the amygdala-mediated fear memory. My study elaborates on the role 
of RNF157 in neuronal survival as well as in fear memory.  
In conclusion, my work provides further insight into the pro-survival function of the E3 
ligase RNF157 and its role in cognitive function. Further research is necessary to establish a link 
between RNF157 and neurodegeneration in vivo that could ultimately contribute to deeper 









Fig 4.1 Current working model of the E3 ligase RNF157 in neuronal survival.  
The adaptor protein Fe65, can be tethered by APP to the membrane upon their interaction (Nakaya and Suzuki, 
2006). (1) When APP is phosphorylated, Fe65 is liberated from APP into the cytoplasm (Nakaya and Suzuki, 2006). 
RNF157 can therefore bind to Fe65 and ubiquitinate it. (2) Alternatively, RNF157 can directly compete with APP 
for the binding to Fe65. In both scenarios, Fe65 is targeted for proteasomal degradation. (3) In the absence of 
RNF157, cytoplasmic Fe65 can translocate into the nucleus and act together with Tip110 to trigger the transcription 
of its target genes resulting in apoptosis. (4) Fe65 can also translocate into the nucleus together with AICD to 
trigger gene transcription, which may lead to cell death (Cao and Südhof, 2001; Perkinton et al., 2004; von Rotz et 
al., 2004) or (5) initiate the putative apoptotic pathway mediated by AICD, Fe65 and Tip60. Briefly, cyclin-
dependent kinase (CDK) activates Tip60 by phosphorylation (Hass and Yankner, 2005). Together with activated 
Tip60, Fe65 and AICD can form a trimeric complex, which translocates either together or separately in the nucleus 
to stimulate gene transcription (Cao and Sudhof, 2004; Cao and Südhof, 2001). However, several questions remains 
unsolved in the RNF157-mediated survival mechanism: i) can RNF157 also compete with AICD for the binding to 
Fe65 to inhibit the pathway (4), ii) is Tip60 required for Fe65 to induce apoptosis, and iii) which are the target 
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